

Please type a plus (+) inside this box - ☒

10-03-00

A/Box Sec

PTO/SB/29 (12/97)

Approved for use through 09/30/00. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

10/02/00
10/03/00

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 7969-087 Total Pages 146

First Named Inventor or Application Identifier

W. James Jackson

Express Mail Label No. EL 501 634 175 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing
2. ☒ Specification [Total Pages 89]
(preferred arrangement set forth below)
 - Table of Contents
 - Descriptive title of the Invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description of the Invention *(including drawings, if filed)*
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) *(35 USC 113)* [Total Sheets 14]
4. ☒ Oath or Declaration [Total Sheets 2]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
 - i. ☐ **DELETION OF INVENTORS(S)**
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).
 - ☐ Incorporation By Reference *(useable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program *(Appendix)*
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☒ Small Entity ☐ Statement filed in prior application, Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:
☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No: filed .

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 20583
(Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME				
ADDRESS				
CITY	STATE	ZIP CODE		
COUNTRY	TELEPHONE	FAX		

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW
1155 Avenue of the Americas
New York, N.Y. 10036-2711
(212) 790-9090

ATTORNEY DOCKET NO. 7969-087Date: October 2, 2000

Assistant Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): W. James Jackson

Executed on: October 2, 2000

Title of Invention: CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

PATENT APPLICATION FEE VALUE

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	104	-20	84	\$18.00 each	\$ 1,512.00
Independent	8	-3	5	\$80.00 each	\$ 400.00
Minimum Fee					\$ 690.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 270.00
Total					\$ 2,872.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					- \$ 1,453.00
Total Filing Fee					\$ 1,419.00

- ☐ Priority of application no. filed on in is claimed under 35 U.S.C. § 119.
- ☐ The certified copy of the priority application has been filed in application no. filed
- ☐ Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed .

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Respectfully submitted,

Geraldine F. Baldwin 31,232
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP

by Margaret B. Boisard

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

Reg No.
40,922.

Express Mail No.: EL 501 634 175 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: W. James Jackson

Application No.: To Be Assigned

Group Art Unit:

Filed: Concurrently Herewith

Examiner:

For: CHLAMYDIA PROTEIN, GENE
SEQUENCE AND USES THEREOF

Attorney Docket No.: 7969-087

**REQUEST TO ESTABLISH SMALL ENTITY STATUS
AND TRANSMITTAL OF VERIFIED STATEMENT CLAIMING
SMALL ENTITY STATUS UNDER 37 C.F.R. § 1.9(f) AND 1.27(c)(d)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Attorneys for Applicant request that Small Entity Status be established for the above-identified application and submit herewith an original executed Verified Statement Claiming Small Entity Status - Small Business Concern from Antex Biologics, Inc., assignee of the above-identified application by virtue of assignment from the inventor W. James Jackson filed herewith. It is requested that this document be made of record in the file of the above-identified application.

Respectfully submitted,

Date October 2, 2000

Geraldine F. Baldwin^{31,232}
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

by Margaret B. Brindley
Reg. No. 40,922

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: ☒ Application of: W. James Jackson
☐ Patent of:

☒ Application No.: To Be Assigned
☐ Patent No.:

Group Art Unit:

☒ Filed: Concurrently Herewith
☐ Issued:

Examiner:

For: CHLAMYDIA PROTEIN, GENE
SEQUENCE AND USES THEREOF

Attorney Docket No.: 7969-087

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
[37 CFR 1.9(f) and 1.27(c)] - Small Business Concern

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby declare that I am

- ☐ the owner of the small business concern identified below:
- ☒ an official of the small business concern empowered to act in behalf of the concern identified below:

Name of organization Antex Biologics, Inc.Address of organization 300 Professional DriveGaithersburg, Maryland 20879

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the person employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern and/or there is an obligation under contract or law by the inventor(s) to convey rights to the small business concern with regard to the invention entitled CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF by inventor(s) W. James Jackson described in

- ☒ the specification filed herewith
- ☐ application no. filed
- ☐ patent no. issued

NY2 - 1126269.1

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

FULL NAME _____
ADDRESS _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28 (b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, and patent issuing thereon, or any patent to which this verified statement is directed.

Send correspondence to:

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711

Direct Telephone calls to:

PENNIE & EDMONDS LLP
(212) 790-9090

Name of person signing V. M. ESPASITO

Title of person other than owner CEO and Chairman

Address of person signing 300 Professional Drive

Gaithersburg, Maryland 20879

Signature [Signature] Date 9-29-00

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities.
(37 CFR 1.27)

NY2 - 1126269.1

CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF**TABLE OF CONTENTS**

Page

JC930 U.S. PRO

09/677752



5	1.	FIELD OF THE INVENTION	1
	2.	BACKGROUND OF THE INVENTION	1
10	3.	SUMMARY OF THE INVENTION	3
	3.1	ABBREVIATIONS	8
	4.	BRIEF DESCRIPTION OF DRAWINGS	10
15	5.	DETAILED DESCRIPTION OF THE INVENTION	11
	5.1.	<i>CHLAMYDIA</i> PMP POLYPEPTIDES	11
	5.2	<i>CHLAMYDIA</i> PMP DERIVED POLYPEPTIDES	15
	5.3	ISOLATION AND PURIFICATION OF PMP POLYPEPTIDES AND PMP-DERIVED POLYPEPTIDES	23
20	5.4.	PMP IMMUNOGENS AND ANTI-PMP ANTIBODIES	26
	5.5	NUCLEIC ACIDS ENCODING THE PMP POLYPEPTIDE AND PMP DERIVED POLYPEPTIDES	30
	5.6	RECOMBINANT PRODUCTION OF PMP POLYPEPTIDE AND PMP- DERIVED POLYPEPTIDES	39
25	5.7	COMPOSITIONS	43
	5.8	IMMUNOASSAYS AND DIAGNOSTIC REAGENTS	53
	5.9	APPLICATIONS	57
	5.10.	BIOLOGICAL DEPOSITS	57
30	6.	EXAMPLES	58
	6.1	EXTRACTION OF ENVELOPE PROTEINS	58
	6.2	AMINO TERMINAL SEQUENCING OF PMP POLYPEPTIDE	59
	6.3.	DETERMINATION OF POST-TRANSLATIONAL MODIFICATIONS	59
35	6.4	ANTI-PMPE or Anti-PMPI ANTISERUM	60
	6.5	ELISA	61

		<u>Page</u>
	6.6 WESTERN BLOTS	61
	6.7 CELLULAR ENVELOPE LOCATION OF PMPE AND PMPI	62
	6.8 PROPERTIES OF PMPE and PMPI POLYPEPTIDES	63
	6.9 VACCINE EFFICACY	63
5	6.9.1 <i>IN VITRO</i> NEUTRALIZATION MODEL	63
	6.9.2 VACCINE EFFICACY (MOUSE MODEL OF SALPINGITIS AND FERTILITY)	64
	IMMUNIZATION AND CHALLENGE	64
	HISTOPATHOLOGY	65
10	DETERMINATION OF rPMPE or rPMPI SPECIFIC HUMORAL RESPONSES	66
	DETERMINATION OF rPMPE or rPMPI SPECIFIC CELLULAR RESPONSES	66
	6.10 ISOLATION OF <i>C. TRACHOMATIS</i> CHROMOSOMAL DNA	67
15	6.11 PCR CLONING OF THE PMPE ORF	68
	6.12 PCR CLONING OF THE PMPI ORF	69
	6.13 EXPRESSION OF RECOMBINANT PMPE	71
	6.14 EXPRESSION OF RECOMBINANT PMPI	73
20	6.15 AFFINITY CHROMATOGRAPHY PURIFICATION OF RECOMBINANT PROTEIN	75
	6.16 GENERATION OF A RADIOLABELLED SCREENING PROBE	76
	6.17 HYBRIDIZATION OF PLAQUE-LIFT FILTERS AND SOUTHERN BLOTS WITH RADIOLABELLED PROBE	76
	6.18 CONSTRUCTION OF A <i>Chlamydia</i> GENOMIC DNA LIBRARY	76
25	6.19 DETERMINATION OF INSERT SIZE AND MAPPING OF DNA FRAGMENTS	77
	6.20 SEQUENCING OF THE PMPE and PMPI GENE	77

30

35

CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

1. FIELD OF THE INVENTION

The present invention generally relates to PMP polypeptides of *Chlamydia*, amino acid and nucleotide sequences thereof, antibodies specific for such *Chlamydia* PMP polypeptides, prophylactic and therapeutic compositions, including vaccines, and to methods of preventing, treating or ameliorating disorders in mammals and birds related to *Chlamydia* infections and for inducing immune responses in animals to *Chlamydia*.

2. BACKGROUND OF THE INVENTION

Chlamydiae are obligate intracellular bacteria that infect animals, including mammals and birds, particularly at the epithelial lining of the lung, conjunctivae or genital tract. The most common species of *Chlamydia* include *Chlamydia trachomatis*, *Chlamydia psittaci*, *Chlamydia pecorum* and *Chlamydia pneumoniae*. Recently, the newly designated species of *Chlamydia*, *C. pneumoniae* (formerly *C. trachomatis* TWAR), has been implicated as a major cause of epidemic human pneumonitis and perhaps may play a role in atherosclerosis.

There are currently 18 recognized *C. trachomatis* serovars, causing trachoma and a broad spectrum of sexually transmitted diseases, with the A, B and C serovars being most frequently associated with trachoma, while the D-K serovars are the most common cause of genital infections.

Chlamydia are prevalent human pathogens causing disorders such as sexually transmitted diseases, respiratory diseases, including pneumonia, neonatal conjunctivitis, and blindness. Reactive inflammatory arthritis is a common sequel to sexually acquired non-gonococcal genital tract infection. Approximately 50% of reactive inflammatory arthritis cases are associated with *Chlamydia trachomatis* infection of the genital tract.

C. trachomatis is the major cause of sexually transmitted disease in many industrialized countries, including the United States. While the exact incidence of *C. trachomatis* infection in the United States is not known, current epidemiological studies indicate that more than 4 million chlamydial infections occur each year, compared to an estimated 2 million gonococcal infections. While all racial, ethnic and socioeconomic groups are affected, the greatest number of chlamydial infections occurs among young, 12 to 20 year-old, sexually active individuals. Most genitourinary chlamydial infections are clinically asymptomatic. Prolonged carriage in both men and women is common. As many as 25% of men and 75% of women diagnosed as having chlamydial infections have no overt

signs of infection. As a consequence, these asymptomatic individuals constitute a large reservoir that can sustain transmission of the agent within the community.

Far from being benign, serious disease can develop from these infections including: urethritis, lymphogranuloma venereum (LGV), cervicitis, and epididymitis in males. Ascending infections from the endocervix commonly gives rise to endometritis, pelvic inflammatory disease (PID) and salpingitis which can cause tubal occlusion and lead ultimately to infertility in females.

C. trachomatis infection of neonates results from perinatal exposure to the mother's infected cervix. Nearly 70% of neonates born vaginally to mothers with chlamydial cervicitis become infected during delivery. The mucus membranes of the eye, oropharynx, urogenital tract and rectum are the primary sites of infection. Chlamydial conjunctivitis has become the most common form of ophthalmia neonatorum. Approximately 20-30% of exposed infants develop inclusion conjunctivitis within 14 days of delivery even after receiving prophylaxis with either silver nitrate or antibiotic ointment. *C. trachomatis* is also the leading cause of infant pneumonia in the United States. Nearly 10-20% of neonates delivered through an infected cervix will develop chlamydial pneumonia and require some type of medical intervention.

In developing countries, ocular infections of *C. trachomatis* cause trachoma, a chronic follicular conjunctivitis where repeated scar formation leads to distortion of the eyelids and eventual loss of sight. Trachoma is the world's leading cause of preventable blindness. The World Health Organization estimates that over 500 million people worldwide, including about 150 million children, currently suffer from active trachoma and over 6 million people have been blinded by this disease.

In industrialized countries, the costs associated with treating chlamydial infections are enormous. In the United States, the annual cost of treating these diseases was estimated at \$2.5-3 billion in 1992 and has been projected to exceed \$8 billion by the year 2000.

One potential solution to this health crisis would be an effective chlamydial vaccine. Several lines of evidence suggest that developing an effective vaccine is feasible.

Studies in both humans and primates have shown that short-term protective immunity to *C. trachomatis* can be produced by vaccinating with whole *Chlamydia*. However, protection was characterized as short lived, serovar specific, and due to mucosal antibody production. Additionally, in some vaccinees disease was exacerbated when these individuals became naturally infected with a serovar different from that used for immunization. This adverse reaction was ultimately demonstrated to be due to a delayed-

type hypersensitivity response. Thus, the need exists to develop a subunit-based chlamydial vaccine capable of producing an efficacious but nonsensitizing immune response. Such a subunit vaccine may need to elicit both mucosal neutralizing secretory IgA antibody and/or cellular immune response to be efficacious.

5 Subunit vaccine development efforts to date have focused almost exclusively on the major outer membrane protein (MOMP). MOMP is an integral membrane protein of approximately 40 kDa in size and comprises up to about 60% of the infectious elementary body (EB) membrane protein (Caldwell et al. 1981. Infect. Immun., 31:1161-1176). MOMP imparts structural integrity to the extracellular EB and is thought to function as a porin-like molecule when the organism is growing intracellularly and is metabolically active. With the exception of four surface exposed variable domains (VDI-VDIV), MOMP is highly conserved among all 18 serovars. MOMP is highly immunogenic and can elicit a local neutralizing anti-*Chlamydia* antibody. However, problems exist with this approach.

To date, most MOMP-specific neutralizing epitopes that have been mapped are located within the VD regions and thus give rise only to serovar-specific antibody. Attempts to combine serovar-specific epitopes in various vaccine vectors (e.g., poliovirus) to generate broadly cross-reactive neutralizing antibodies have been only marginally successful (Murdin et al. 1993. Infect. Immun., 61:4406-4414; Murdin et al. 1995. Infect. Immun., 63:1116-1121).

20 Two other major outer membrane proteins in *C. trachomatis*, the 60 kDa and 12 kDa cysteine-rich proteins, as well as the surface-exposed lipopolysaccharide, are highly immunogenic but, unlike MOMP, have not been shown to induce a neutralizing antibody (Cerrone et al., 1991, Infect. Immun., 59:79-90). Therefore, there remains a need for a novel subunit-based chlamydial vaccine.

25 Citation or identification of any reference in this section or any other section of this application shall not be construed as an indication that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

30 This invention is directed to PMP (putative membrane proteins) proteins (referred to hereafter and in the claims as PMP polypeptides or PMP proteins) from *Chlamydia* spp. More particularly, the present invention encompasses the family of PMPE and PMPI polypeptides of *Chlamydia trachomatis* and other *Chlamydia* spp., including but not limited to, *Chlamydia pneumonia*, *Chlamydia pecorum*, and *Chlamydia psittaci*, having a molecular weight of 90 to 115 kD, and an amino acid sequence of or homologous to SEQ

5 ID NO.:2 (PMPE) or SEQ ID NO.:4 (PMPI), in isolated or recombinantly produced form. SEQ ID NOs.:2 and 4 represent the amino acid sequences of the *Chlamydia trachomatis* L2 serovar PMPE and PMPI proteins, respectively, encoded by the *pmpE* and *pmpI* genes. The nucleotide sequences for the *pmpE* and *pmpI* *Chlamydia trachomatis* L2 serovar coding regions are SEQ ID NOs.:1 and 3, respectively. The present invention encompasses all *Chlamydia* PMPE and PMPI polypeptides, particularly those of the *Chlamydia trachomatis* L2 serovar, and also including PMPI and PMPE polypeptides from other *Chlamydia trachomatis* serovars and other *Chlamydia* species. Identification of these homologs and analogs can be accomplished by methods well known in the art, for example, but not limited to, nucleic acid hybridization and PCR based techniques. The present invention encompasses a purified PMPE or PMPI polypeptide, polypeptides derived therefrom ("PMP-derived polypeptides", e.g., derivatives, fragments and analogs thereof), preferably, that elicit an immune reaction against whole *Chlamydia* cells and/or are bound by anti-PMPE or anti-PMPI antibodies, and methods for making said polypeptides and PMP-derived polypeptides.

Preferably the PMP protein has the amino acid sequence of SEQ IN NO.:2 or 4 or is substantially homologous to any of SEQ ID NO.:2, 4 or 5-34. Preferred fragments of the protein comprise an amino acid sequence of any of SEQ ID NOs.:5-34.

20 Preferably, the PMP protein is an outer membrane protein. More preferably, the PMP protein is surface localized. Preferably, the PMP protein has at least one GGAI (Gly Gly Ala Ile) domain. It is intended that PMP proteins from all species of *Chlamydia* are included in this invention; however, preferred species include *Chlamydia trachomatis*, *Chlamydia psittaci*, *Chlamydia pecorum* and *Chlamydia pneumoniae*.

25 The invention also provides PMP fusion peptides having B and/or T-cell stimulating activity, preferably comprising at least two T or B cell epitopes derived from the same or from different *Chlamydia* PMP proteins which proteins, or portions thereof, are arranged in a contiguous polypeptide in a configuration different from a naturally occurring configuration of the regions of a *Chlamydia* PMP protein.

30 A preferred polypeptide of the invention is a fusion polypeptide comprising at least two peptides, said at least two peptides consisting of amino acid sequences selected from the group consisting of SEQ ID NOs.:5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, and 34, with the proviso that the peptides of the polypeptide are arranged in a contiguous polypeptide configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide (e.g., is not a naturally occurring PMPE or PMPI polypeptide).

Other preferred PMP-derived polypeptides of the invention are isolated fusion polypeptides wherein the polypeptide comprises an amino acid sequence of SEQ ID NO.:5, 6, 7, 8, 9, 10 or 11 or an isolated fusion polypeptide wherein the polypeptide comprises an amino acid sequence of SEQ ID NO.:23, 24, 25, 26, 27, 28, or 29, with the proviso that the peptides of the polypeptide are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide. A preferred PMP-derived polypeptide is an isolated fusion polypeptide, wherein the polypeptide comprises an amino acid sequence of SEQ ID NO.:5, 6, 7, 8, 9, 10, 11, 23, 24, 25, 26, 27, 28 or 29, with the proviso that the peptides are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide.

Preferably, the PMP-derived polypeptides of the invention are immunologically cross-reactive with the PMP protein from which they are derived and are capable of eliciting in an animal an immune response to *Chlamydia*. A preferred PMP polypeptide or PMP-derived polypeptide of the invention induces IgM, IgG, IgA, and/or IgE antibodies, delayed hypersensitivity T-cell responses and/or cytotoxic T-cell responses to cells expressing Chlamydial antigens (including but not limited to cells infected with *Chlamydia* and antigen presenting cells such as macrophages, dendritic cells, B cells, or synthetic antigen presenting cells which display Chlamydial antigens), native PMP protein from which the polypeptide is derived, *Chlamydia* cells, or *Chlamydia* elemental bodies (EB). In a more preferred embodiment, the PMP polypeptide or PMP-derived polypeptide is capable of eliciting an immune response against other *Chlamydia* serovars and, more preferably, other *Chlamydia* species along with the *Chlamydia* serovar or species in which the PMP polypeptide occurs naturally.

The invention also encompasses antisera and antibodies, including but not limited to, cytotoxic or bactericidal polyclonal and monoclonal antibodies, which bind to and are specific for the PMP polypeptide, PMP-derived polypeptides and/or fragments thereof.

Preferably the antibodies bind a PMP protein having the amino acid sequence of SEQ ID NOs.:2 or 4 or an amino acid sequence substantially homologous thereto. Also included are monoclonal antibodies that specifically bind a PMP or PMP-derived polypeptide, including but not limited to monoclonal antibodies that specifically bind a polypeptide consisting of an amino acid sequence of any of SEQ ID NOs.:2, 4 or 5-34. Also included are antigen binding fragments of polyclonal or monoclonal antibodies, e.g., Fv, Fab, Fab' and F(ab')₂ fragments. A further aspect of the invention are chimerized or humanized antibodies in which one or more of the antigen binding regions of the anti-

PMP antibody is introduced into the framework region of a heterologous (*e.g.*, human) antibody. In a preferred aspect, the antibodies are human antibodies.

Another aspect of the invention is directed to T-cells raised against an antigenic or immunogenic composition of the invention or T-cells specific for antigenic or immunogenic polypeptides of the invention or specific for cells expressing Chlamydial antigens (including but not limited to cells infected with *Chlamydia* or antigen presenting cells presenting PMP polypeptides such as dendritic cells, B cells, or synthetic antigen presenting cells), *Chlamydia* cells, or *Chlamydia* elemental bodies (EB).

The invention further provides isolated nucleic acid molecules (DNA or RNA) encoding the PMPE polypeptides, PMPI polypeptides, PMPE-derived polypeptides, PMPI-derived polypeptides, vectors having said sequences, host cells containing said vectors or having the sequences operably linked to a heterologous promoter, recombinant polypeptides produced therefrom, and pharmaceutical compositions comprising the nucleic acid molecules, vectors, and cells.

A preferred aspect of the invention is a nucleotide sequence encoding a PMP protein comprising the amino acid sequence of any of SEQ ID NOs.:2, 4 or 5-34 or an amino acid sequence substantially homologous thereto. Also included is an isolated nucleic acid molecule comprising a DNA sequence of SEQ ID NOs.:1 or 3 or a complementary sequence thereof; a fragment of the DNA molecule having the nucleotide sequence of SEQ ID NOs.:1 or 3, or the complimentary sequence thereof; or a nucleic acid molecule which hybridizes under stringent conditions to any one of the sequences described above. The nucleic acid molecule that hybridizes under stringent conditions preferably has a sequence homology of about 70%, 80%, 90%, 95%, or 99% with any of the sequences identified above, more preferably about 90%.

The invention further encompasses pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions, including vaccines, comprising one or more of the PMP polypeptides of the invention, optionally in combination with, fused to, or conjugated to one or more other component(s), including a lipid, phospholipid, a carbohydrate, including a lipopolysaccharide, any proteins either novel or known to those skilled in the art, inactivated whole or attenuated organisms, including but not limited to viruses, yeasts, fungi and bacteria. Particularly preferred bacteria include, but are not limited to *Neisseria*, *Chlamydia*, *Moraxella*, *Pseudomonas*, *Streptococcus* or *Haemophilus* bacteria.

In a specific embodiment, the invention encompasses pharmaceutical compositions, including prophylactic or therapeutic compositions, which may be

immunogenic compositions including vaccines, comprising one or more of the PMP polypeptides and/or PMP-derived polypeptides and an attenuated or inactivated *Chlamydia* cultivar or an attenuated or inactivated *Chlamydia* cultivar expressing PMP polypeptide in a greater amount when compared to wild-type *Chlamydia*.

5 The invention further encompasses pharmaceutical compositions comprising isolated nucleic acid molecules encoding PMP polypeptides and PMP-derived polypeptides of the present invention which can be used in methods to detect *Chlamydia* infection or to prevent, treat or reduce the severity of a disease or disorder related to infection with *Chlamydia*. Such compositions include but are not limited to vectors or recombinant host
10 cells comprising such nucleic acid molecules or having a nucleotide sequence of the invention operably linked to a heterologous promoter.

 The invention also includes diagnostic reagents, that may include any one or more of the above mentioned aspects, such as native PMP proteins, recombinant PMP proteins, PMP-derived polypeptides, nucleic acid molecules, immunogenic compositions,
15 antigenic compositions, antisera, T-cells, antibodies, vectors comprising the nucleic acids, and transformed cells comprising the vectors.

 A further aspect of the present invention provides methods for determining the presence of nucleic acids encoding a PMP protein or a PMP-derived polypeptide in a test sample, and diagnostic kits and reagents therefor, for determining the presence of a
20 nucleic acid encoding a PMP polypeptide or PMP-derived polypeptide.

 Also included in this invention are methods of inducing an immune response to *Chlamydia spp.* and methods of preventing, treating or ameliorating disorders or diseases related to *Chlamydia* in an animal, including mammals and birds and, preferably, in humans, in need of such treatment comprising administering an effective amount of the
25 pharmaceutical or vaccine composition of the invention. Preferred disorders or diseases include a *Chlamydia* bacterial infection, trachoma, conjunctivitis, urethritis, lymphogranuloma venereum (LGV), cervicitis, epididymitis, or endometritis, pelvic inflammatory disease (PID), salpingitis, tubal occlusion, infertility, cervical cancer, reactive arthritis, and atherosclerosis.

30 A further aspect of the invention relates to antagonists or agonists which inhibit or enhance the activity or expression of the polypeptides or nucleic acid molecules of the invention. Preferred are bacteriostatic or bacteriocidal agonists or antagonists.

 A further aspect of the invention is a method for identifying compounds which interact with and inhibit or activate an activity of the polypeptides or nucleic acid
35 molecules of the invention comprising contacting a composition comprising the polypeptide

or the nucleic acid molecule with the compound to be screened under conditions that permit interaction between the compound and the polypeptide or nucleic acid molecule to assess the interaction of a compound and to detect interaction of the compound with the polypeptide of nucleic acid. The interaction of the compound with the polypeptide or
5 nucleic acid molecule is determined by the association of a second component (*e.g.*, an antibody) capable of providing a detectable signal in response to the interaction of the polypeptide or nucleic acid molecule with the compound; and determining the presence or absence of a signal generated from the interaction of the compound with the polypeptide or nucleic acid molecule. Alternatively, the interaction of the compound with the polypeptide
10 or nucleic acid molecule is determined by the ability of the compound to inhibit the activity of the polypeptide or the nucleic acid molecule.

3.1 ABBREVIATIONS

	anti-PMP	= PMP polypeptide antibody or antiserum
15	ATCC	= American Type Culture Collection
	immuno-reactive	= capable of provoking a cellular or humoral immune response
	kD or kDa	= kilodaltons
	OG	= n-octyl-D-glucopyranoside or octyl glucoside
20	OMP	= outer membrane protein
	OMPs	= outer membrane proteins
	PBS	= phosphate buffered saline
	PAGE	= polyacrylamide gel electrophoresis amino acid residues
	polypeptide	= a peptide of any length, preferably having eight or more amino acid residues
25	SDS	= sodium dodecylsulfate
	SDS-PAGE	= sodium dodecylsulfate polyacrylamide gel electrophoresis

Nucleotide sequences defined herein are represented by one-letter symbols
30 for the bases as follows:

- A (adenine)
- C (cytosine)
- G (guanine)
- T (thymine)
- 35 U (uracil)

- M (A or C)
- R (A or G)
- W (A or T/U)
- S (C or G)
- 5 Y (C or T/U)
- K (G or T/U)
- V (A or C or G; not T/U)
- H (A or C or T/U; not G)
- D (A or G or T/U; not C)
- 10 B (C or G or T/U; not A)
- N (A or C or G or T/U) or (unknown)

Peptide and polypeptide sequences defined herein are represented by one-letter symbols for amino acid residues as follows:

- 15 A (alanine)
- R (arginine)
- N (asparagine)
- D (aspartic acid)
- C (cysteine)
- 20 Q (glutamine)
- E (glutamic acid)
- G (glycine)
- H (histidine)
- I (isoleucine)
- 25 L (leucine)
- K (lysine)
- M (methionine)
- F (phenylalanine)
- P (proline)
- 30 S (serine)
- T (threonine)
- W (tryptophan)
- Y (tyrosine)
- V (valine)
- 35 X (unknown)

The present invention may be more fully understood by reference to the following detailed description of the invention, non-limiting examples of specific embodiments of the invention and the appended figures.

5 **4. BRIEF DESCRIPTION OF DRAWINGS**

Figure 1. Schematic map of the *C. trachomatis* PMPE expression plasmid M15 pREP (pQE-PmpE-Ct#37). The mature form of the *C. trachomatis* PMPE protein is expressed in *E. coli* as a fusion protein carrying the MRGS-(H)₆ domain encoded by the vector plasmid pQE-30 at the N-terminus.

10 Figure 2. Schematic map of the *C. trachomatis* PMPI expression plasmid TOP10 (pBAD-pmpI-Ct-Uni#7). The *C. trachomatis* PMPI protein is expressed in *E. coli* as a fusion protein carrying the HP-Thio domain encoded by the vector plasmid pBAD/Thio-E at the N-terminus.

Figure 3. A Coomassie blue-stained SDS-PAGE gel of the gel-purified *C. trachomatis* PMPE protein expressed from the pQE-pmpE-Ct #37 plasmid. The PMPE protein migrates as an ~100 kDa protein. Pre-stained molecular weight markers (Lane 1) are Myosin (~250 kDa), Phosphorylase B (~148 kDa), BSA (~98 kDa), GDH (~64 kDa), ADH (~50 kDa), CAH (~36 kDa), Myoglobin (30 kDa), Lysozyme (16 kDa), Aprotinin (~6 kDa), Insulin B chain (~4 kDa) (SeeBlue prestained standard Novex LC5625).

15 Figure 4. A Coomassie blue-stained SDS-PAGE gel of *E. coli* Top10 cell extracts carrying the *C. trachomatis* PMPI expression plasmid pBAD-pmpI-ct-Uni#7. Lane 1, pre-stained molecular weight markers (Novex MultiMark LC5725); lane 2, non-induced cells; lane 3, arabinose induced cells. The *C. trachomatis* PMPI protein in the arabinose-induced lane is indicated by an arrow. Molecular weight markers (Lane 1) are Myosin (~250 kDa), Phosphorylase B (~148 kDa), GDH (~60 kDa), CAH (~42 kDa), Myoglobin-Blue (~30 kDa), Myoglobin-Red (~22 kDa), Lysozyme (~17 kDa).

Figure 5. Full length nucleotide sequence and corresponding deduced amino acid sequence of the PMPE polypeptide of *Chlamydia trachomatis* L2.

Figure 6. Full length nucleotide sequence and corresponding deduced amino acid sequence of the PMPI polypeptide of *Chlamydia trachomatis* L2.

Figure 7. In vitro antigen-specific spleen cell proliferative response in animals immunized with recombinant PMPE and an adjuvant. Spleens were harvested from immunized C3H HeOuJ female mice approximately 14 days after a three dose immunization regimen. Single cell suspensions were prepared and the cells from two animals were pooled for analysis. Aliquots of the pooled cell samples were incubated for

72-96 hours in the presence of a test stimulant and pulsed with ³H-thymidine for the last 18-24 hours. Pooled samples incubated and pulsed labeled in parallel but in the absence of any stimulant served as the baseline ³H-thymidine uptake control. Represented is the stimulation index of cells stimulated with ConA (concanavalin A) (positive stipulation control); adjuvant (adjuvant employed in immunizations); PMPE (recombinant pmpE protein); EB (UV-inactivated *C. trachomatis* elementary bodies). 1 µg/ml (open bars), 4 µg/ml (solid bars) and 8 µg/ml (hatched bars) denote the three concentrations of *in vitro* stimulant used in the experiment. Stimulation index (SI) denotes the difference in ³H-thymidine incorporation of stimulated cells minus the background incorporation of the unstimulated controls. Bars denote the mean ± standard deviation in SI.

5. DETAILED DESCRIPTION OF THE INVENTION

5.1. CHLAMYDIA PMP POLYPEPTIDES

The present invention is generally directed to compositions and methods for the diagnosis, prevention, and treatment of Chlamydial infection. In one aspect, the composition of the subject invention provides pure native (wildtype) or recombinantly produced PMP polypeptides that comprise at least one immunogenic portion of a *Chlamydia* antigen.

The terms “treatment” or “therapy” as used herein and in the claims encompasses elimination as well as reduction in the severity or amelioration of disease symptoms caused directly or indirectly by the organism or numbers of organisms present.

In particular embodiments, the term “*Chlamydia*” refers to any Chlamydial species (spp.) including but not limited to *Chlamydia trachomatis*, *Chlamydia pneumonia*, *Chlamydia psittaci* and *Chlamydia pecorum*.

Strains from any of these organism may be obtained worldwide from any biologicals depository, particularly strains of *Chlamydia* ATCC VR-346, VR-347, VR-348B, VR-571B, VR-572, VR-573, VR-577, VR-578, VR-878, VF-879, VR-880, VR-885, VR-886, VR-887, VR-901B, VR-902B, VR-903, VR-1355, VR-1474, VR-1477, VR-2282, which may be obtained from the ATCC.

In a particular embodiment, the *Chlamydia* PMP protein is a PMPE polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO.:2.

In another particular embodiment, the PMPE polypeptide is encoded by the nucleotide sequence of SEQ ID NO.:1. In another embodiment, the *Chlamydia* PMPE polypeptide comprises or consists of an amino acid sequence which is substantially

homologous to SEQ ID NO.:2 or a portion thereof or is encoded by a nucleotide sequence substantially homologous to (or hybridizes under low, moderate or high stringency conditions to) the nucleotide sequence of SEQ ID NO.:1, or a portion thereof.

In another particular embodiment the *Chlamydia* PMP protein is a PMPI protein comprising or consisting of the amino acid sequence of SEQ ID NO.:4. In another embodiment, the *Chlamydia* polypeptide is a PMPI polypeptide encoded by the nucleotide sequence of SEQ ID NO.:3. In another embodiment, the *Chlamydia* polypeptide comprises or consists of an amino acid sequence which is substantially homologous to SEQ ID NO.:4, or a portion thereof, or is encoded by a nucleotide sequence substantially homologous to (or hybridizes under low, moderate or high stringency conditions to) the nucleotide sequence of SEQ ID NO.:3, or a portion thereof.

The present invention provides the family of *Chlamydia* PMPE and PMPI proteins. The amino acid sequences of SEQ ID NOs.:2 and 4 and the nucleotide sequences of SEQ ID NOs.:1 and 3 represent the amino acid and nucleotide sequences, respectively, of the PMPE and PMPI polypeptides, respectively, of the *Chlamydia trachomatis* L2 serovar. The invention also relates to PMPE and PMPI polypeptide homologs from other *Chlamydia trachomatis* serovars and other *Chlamydia* species, as well as other derivatives, analogs, and fragments thereof (*i.e.*, PMPE- and PMPI-derived polypeptides). In a preferred embodiment, immunization with the polypeptide of the invention elicits antibodies that specifically bind to PMPE or PMPI polypeptides from other *Chlamydia* serovars and, preferably, species (preferably all species, but may be a subset of species) besides the serovar and species from which the polypeptide was isolated or derived.

As used herein a "substantially homologous" sequence is at least 70%, preferably greater than 80%, more preferably greater than 90% identical to a reference amino acid or nucleotide sequence of identical size or when compared to a reference sequence when the alignment or comparison is conducted by a computer homology program or search algorithm known in the art. By way of example and not limitation, useful computer homology programs include the following: Basic Local Alignment Search Tool (BLAST) (www.ncbi.nlm.nih.gov) (Altschul et al., 1990, J. of Molec. Biol., 215:403-410, "The BLAST Algorithm"; Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402) a heuristic search algorithm tailored to searching for sequence similarity which ascribes significance using the statistical methods of Karlin and Altschul 1990, Proc. Nat'l Acad. Sci. USA, 87:2264-68; 1993, Proc. Nat'l Acad. Sci. USA 90:5873-77. Five specific BLAST programs perform the following tasks:

35

- 1) The BLASTP program compares an amino acid query sequence against a protein sequence database.
- 2) The BLASTN program compares a nucleotide query sequence against a nucleotide sequence database.
- 5 3) The BLASTX program compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database.
- 4) The TBLASTN program compares a protein query sequence against a nucleotide sequence database translated in all six reading frames (both strands).
- 5) The TBLASTX program compares the six-frame translations of a nucleotide
10 query sequence against the six-frame translations of a nucleotide sequence database.

Smith-Waterman (database: European Bioinformatics Institute wwwz.ebi.ac.uk/bic_sw/) (Smith-Waterman, 1981, J. of Molec. Biol., 147:195-197) is a mathematically rigorous algorithm for sequence alignments.

- FASTA (see Pearson et al., 1988, Proc. Nat'l Acad. Sci. USA, 85:2444-2448)
15 is a heuristic approximation to the Smith-Waterman algorithm. For a general discussion of the procedure and benefits of the BLAST, Smith-Waterman and FASTA algorithms see Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.

- By further way of example and not limitation, useful computer homology
20 algorithms and parameters for determining percent identity include the following:

- To determine the percent identity of two amino acid sequences or of two nucleotide sequences, *e.g.*, between PMP sequences and other known sequences, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second
25 amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical
30 positions shared by the sequences (*i.e.*, % identity = # of identical positions/total # of positions (*e.g.*, overlapping positions) x 100). In one embodiment, the two sequences are the same length.

- The determination of percent identity between two sequences can be accomplished using a mathematical algorithm, a preferred, non-limiting example of a
35 mathematical algorithm utilized for the comparison of two sequences is the algorithm of

Karlin and Altschul, 1990, Proc. Nat'l Acad. Sci. USA, 87:2264-68; as modified by 1993, Proc. Nat'l Acad. Sci. USA 90:5873-77. Such algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, 1990, J. of Molec. Biol., 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches can be performed with the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecule of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul, 1997, Nuc. Acids Res. 25:3389-3402. Alternatively, PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules (*Id.*). When utilizing BLAST, Gapped BLAST, and PSI-BLAST programs, the default parameters of the respective programs can be used. Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, CABIOS (1989). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the CGC sequence alignment software package. When using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art and include ADVANCE and ADAM as described in Torellis and Robotti (1994) Comput. Appl. Biosc., 10:3-5; and FASTA described in Pearson and Lipman, 1988, Proc. Nat'l Acad. Sci. USA, 85:2444-2448. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search. If ktup = 2, similar regions in the two sequences being compared are found by looking at pairs of aligned residues; if ktup = 1, single aligned amino acids are examined. Ktup can be set to 2 or 1 for protein sequences, or from 1 to 6 for nucleotide sequences. The default, if ktup is not specified, is 2 for proteins and 6 for nucleotides. For a further description of FASTA parameters, see <http://bioweb.pasteur.fr/docs/man/man/fasta.1.html#sect2>, the contents of which are incorporated herein by reference. Alternatively, protein sequence alignment may be carried out using the CLUSTAL W algorithm as described by Higgins et al., 1996, Methods Enzymol., 266:383-402.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, only exact matches are counted.

According to various aspects of the invention, the polypeptides of the invention are characterized by their apparent molecular weights based on the polypeptides'

migration in SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) relative to the migration of known molecular weight markers. While any molecular weight standards known in the art may be used with the SDS-PAGE, preferred molecular weight markers comprise pre-stained Myosin (250 kDa), Phosphorylase B (148 kDa), BSA (98 kDa) and GDH (64 kDa). One skilled in the art will appreciate that the polypeptides of the invention may migrate differently in different types of gel systems (e.g., different buffers; different types and concentrations of gel, crosslinkers or SDS, etc.). One skilled in the art will also appreciate that the polypeptides may have different apparent molecular weights due to different molecular weight markers used with the SDS-PAGE. Hence, the molecular weight characterization of the polypeptides of the invention is intended to be directed to cover the same polypeptides on any SDS-PAGE system and with any set of molecular weight markers which might indicate slightly different apparent molecular weights for the polypeptides than those disclosed herein.

In specific embodiments, the subject invention discloses PMP polypeptides comprising an immunogenic portion of a *Chlamydia* antigen, wherein the *Chlamydia* antigen comprises an amino acid sequence encoded by a nucleic acid molecule comprising a sequence selected from the group consisting of (a) nucleotide sequences of SEQ ID NO.:1 or SEQ ID NO.:3, (b) the complements of said nucleotide sequences; and (c) variants of such sequences.

Nucleic acid molecules encoding the precursor and mature forms of *Chlamydia* polypeptides are provided by the invention.

5.2 CHLAMYDIA PMP DERIVED POLYPEPTIDES

The term "antigens" and its related term "antigenic" as used herein and in the claims refers to a substance to which an antibody or T-cell receptor specifically binds. As used herein, antisera, antibodies and T-cells are "antigen-specific" if they specifically bind to or react with an antigen and do not react detectably with unrelated proteins other than by non-specific interaction. Preferably said antigens are immunogenic.

The term "immunogenic" as used herein and in the claims refers to the ability to induce an immune response, e.g., an antibody and/or a cellular immune response in an animal, preferably a mammal or a bird.

In a specific embodiment of the invention, proteins consisting of or comprising a fragment of a PMPE protein consisting of at least 8 (continuous) amino acids of the protein are provided. In other embodiments, the fragment consists of at least 10, 20, 40, 50, 60, 80, 100, 150, 200, 300, 400 or 500 amino acids of SEQ ID NO.:2. In specific

embodiments, such fragments are not larger than 10, 11, 12, 15, 20, 25, 35, 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675 or 700 amino acids. In preferred embodiments, the PMPE-derived polypeptide contains a sequence forming an outer-surface epitope.

5 In a particular embodiment, the PMPE-derived polypeptide is a fragment of a PMPE polypeptide which fragment comprises or consists of an amino acid sequence of any of SEQ ID NOs.:5-22. In another particular embodiment, the PMPE-derived polypeptide is a fragment of a PMPE polypeptide, which fragment comprises or consists of an amino acid sequence of any of SEQ ID NOs.:5-22, but also comprises additional C-terminal or N-
10 terminal PMPE sequences.

In a specific embodiment of the invention, proteins are provided that consist of or comprise a fragment of a PMPI protein consisting of at least 8 (continuous) amino acids of SEQ ID NO.:4. In other embodiments, the fragment consists of at least 10, 15, 20, 25, 50, 75, 100, 150 or 200 amino acids of SEQ ID NO.:4. In specific embodiments, such
15 fragments are not longer than 10, 11, 12, 15, 20, 25, 35, 50, 75, 80, 90, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675 or 700 amino acids. In preferred embodiments, PMPI-derived polypeptide contains a sequence forming an outer-surface epitope.

In a particular embodiment, the PMPI-derived polypeptide is a fragment of a
20 PMPI peptide which comprises the amino acid sequence of any of SEQ ID NOs.:23-34.

In another particular embodiment, the PMPE-derived polypeptide is a fragment of a PMPE polypeptide which comprises the amino acid sequence of any of SEQ ID NOs.:23-34, but also comprises additional C-terminal or N-terminal PMPI sequences.

Preferably, the PMPE-derived polypeptides of the invention are
25 immunologically cross-reactive with the PMPE polypeptide, and are capable of eliciting in an animal an immune response to *Chlamydia*, *Chlamydia* elemental bodies (EB), *Chlamydia* reticulate bodies (RBs), *Chlamydia* infected cells or antigen presenting cells expressing Chlamydial antigens and/or are able to be bound by anti-PMPE antibodies.

Preferably, the PMPI-derived polypeptides of the invention are
30 immunologically cross-reactive with the PMPI polypeptide, and are capable of eliciting in an animal an immune response to *Chlamydia*, *Chlamydia* elemental bodies (EB), reticulocyte bodies (RBs), *Chlamydia* infected cells or antigen presenting cells expressing Chlamydial antigens and/or are able to be bound by anti-PMPI antibodies. More preferably, the PMP-derived polypeptides of the invention comprise sequences forming one or more
35 epitopes of the native PMPE or PMPI polypeptide of *Chlamydia* (*i.e.*, the epitopes of PMPE

or PMPI polypeptide as they exist in intact *Chlamydia* cells). Such preferred PMPE-derived or PMPI-derived polypeptides can be identified by their ability to specifically bind polyclonal or monoclonal antibodies raised to intact *Chlamydia* cells (*e.g.*, antibodies elicited by formaldehyde or glutaraldehyde fixed *Chlamydia* cells; such antibodies are referred to herein as “anti-whole cell” antibodies). For example, peptides from a limited or complete protease digestion of the PMPE or PMPI polypeptide are fractionated using standard methods and tested for their ability to bind anti-whole cell antibodies. Reactive polypeptides are isolated and their amino acid sequence determined by methods known in the art. In a preferred embodiment, the PMPE and/or PMPI- derived polypeptide comprises one or more portions of a PMPE or PMPI protein, or derivative thereof, that is a T-cell epitope.

Polypeptide derivatives can also be constructed by deletions that remove a part of the parent polypeptide, while retaining the desired specific antigenicity. Deletions can also remove regions of high variability among strains.

Also preferably, the *Chlamydia* derived polypeptides of the invention comprise sequences that form one or more epitopes of a native *Chlamydia* polypeptide that elicit bactericidal or opsonizing antibodies. Such preferred *Chlamydia*-derived polypeptides may be identified by their ability to generate antibodies that kill *Chlamydia* spp., particularly, *Chlamydia trachomatis* cells. For example, polypeptides from a limited or complete protease digestion or chemical cleavage of a *Chlamydia* polypeptide are fractionated using standard methods, (*e.g.*, by limited proteolytic digestion using enzymes such as trypsin, papain, or related proteolytic enzymes or by chemical cleavage using agents such as cyanogen bromide and followed by fractionation of the digestion or cleavage products), injected into animals and the antibodies produced therefrom are tested for the ability to interfere with or kill *Chlamydia* cells and/or *Chlamydia* infected cells. Once identified and isolated, the amino acid sequences of such preferred *Chlamydia*-derived polypeptides are determined using standard sequencing methods. The determined sequence may be used to enable production of such polypeptides by synthetic chemical and/or genetic engineering means.

These preferred *Chlamydia*-derived polypeptides also can be identified by using anti-whole cell antibodies to screen bacterial libraries expressing random fragments of *Chlamydia* genomic DNA or cloned nucleotide sequences encoding a PMPE or PMPI polypeptide or fragments thereof. See, *e.g.*, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Press, Cold Spring Harbor, New York, Vol. 1, Chapter 12. The reactive clones are identified and their inserts are isolated and

sequenced to determine the amino acid sequences of such preferred *Chlamydia*-derived polypeptides.

Examples of immunogenic portions of antigens contemplated by the present invention include polypeptides comprising or consisting of the fragments set forth in Tables 1 and 2, where the numbers following the PMPE (table 1, column 1) or PMPI (table 2, column 1) designation refer to the amino acid residues in SEQ ID NOs. 2 or 4, respectively. Polypeptides comprising at least an immunogenic portion of one or more *Chlamydia* antigens or immunogenic portions as described herein may generally be used, alone or in combination, to detect, prevent, treat or reduce the severity of Chlamydial infection.

TABLE 1: PREFERRED FRAGMENTS OF PMPE

	<u>FRAGMENT</u>	<u>SEQ ID NO.:</u>
15	PMPE15-56	5
	PMPE15-121	6
	PMPE45-125	7
	PMPE125-190	8
	PMPE195-261	9
20	PMPE275-366	10
	PMPE375-440	11
	PMPE440-490	12
	PMPE525-590	13
	PMPE590-625	14
25	PMPE615-650	15
	PMPE625-700	16
	PMPE725-800	17
	PMPE755-775	18
	PMPE785-845	19
30	PMPE815-865	20
	PMPE1-31	21
	PMPE1-500	22

TABLE 2: PREFERRED FRAGMENTS OF PMPI

	<u>FRAGMENT</u>	<u>SEQ ID NO.:</u>
5	PMPI 13-40	23
	PMPI 70-110	24
	PMPI 150-225	25
	PMPI 250-290	26
	PMPI 370-455	27
	PMPI 400-455	28
	PMPI 470-520	29
10	PMPI 615-670	30
	PMPI 710-775	31
	PMPI 765-825	32
	PMPI 830-860	33
	PMP 1-500	34

Polypeptides having a sequence homologous to one of the PMP polypeptides of the invention, including naturally-occurring allelic variants, as well as mutants, variants or any other non-naturally occurring variants that are analogous to, *e.g.*, cross-reacting with antibodies against, a PMP polypeptide of the present invention, are encompassed by the present invention.

Allelic variants are very common in nature. For example, a bacterial species *e.g.*, *C. trachomatis*, is usually represented by a variety of strains or serovars that differ from each other by minor allelic variations. Indeed, a polypeptide that fulfills the same biological function in different strains can have an amino acid sequence that is not identical in each of the strains. Such an allelic variation may be equally reflected at the nucleic acid molecule level.

An allelic variant is an alternate form of a polypeptide that is characterized as having a substitution, deletion, or addition of one or more amino acids that does not substantially alter the biological function of the polypeptide. By “biological function” is meant the function of the polypeptide in the cells in which it naturally occurs, even if the function is not necessary for the growth or survival of the cells.

Nucleic acid molecules, *e.g.*, DNA molecules, encoding allelic variants can easily be retrieved by the polymerase chain reaction (PCR) amplification of genomic bacterial DNA extracted by conventional methods. This involves the use of synthetic oligonucleotide primers matching upstream and downstream sequences of the 5’ and 3’ ends of the encoding domains. Typically, a primer can consist of 10 to 40, preferably 15 to 25 nucleotides. It may be also advantageous to select primers containing C and G

nucleotides in a proportion sufficient to ensure efficient hybridization; *e.g.*, an amount of C and G nucleotides of at least 40%, preferably 50% of the total number of nucleotides in the primer.

5 Variants of *Chlamydia trachomatis* PMP proteins, such as PMP proteins from the A, B, Ba, C, D, Da, E, F, G, H, I, Ia, J, K, MoPN, L1, L2, and L3 serovars, which share sequence homology to the PMP polypeptides and nucleic acid molecules described herein are also provided.

10 Homology is defined as being at least 70, 80, 85, 90, 95 or 99% identical to a reference sequence of identical size or when the alignment or comparison is by a computer homology program or search algorithm known in the art (see Section 5.1 *supra*).

Preferably, the serovar homologues show 70, 80, 85, 90, 95 or 99% homology to the corresponding polypeptide sequence(s) described herein. Most preferably, the serovar homologues show 95-99% homology to the corresponding polypeptide sequence(s) described herein.

15 A *Chlamydia*-derived PMP polypeptide of the invention may also be a modified PMPE or PMPI polypeptide or fragment thereof (*i.e.*, a *Chlamydia* polypeptide or fragment having one or more amino acid substitutions, insertions and/or deletions of the wild-type *Chlamydia* sequence or amino acids chemically modified *in vivo* or *in vitro*). Such modifications may enhance the immunogenicity of the resultant *Chlamydia*-derived
20 polypeptide product or have no effect on such activity.

As used herein, the term "enhance the immunogenicity" refers to an increased antibody titer or increased cellular immune response elicited by exposure to the modified polypeptide as compared to the immune response elicited by unmodified polypeptides or formalin or glutaraldehyde fixed *Chlamydia*. Modification techniques that
25 may be used include, but are not limited to, those disclosed in U.S. Patent No. 4,526,716.

As an illustrative, non-limiting example, one or more amino acid residues within the PMP-derived polypeptide sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting, for example, in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other
30 members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic)
35 amino acids include aspartic acid and glutamic acid.

Included within the scope of the invention are PMP-derived polypeptides which are *Chlamydia* PMP polypeptide fragments or other derivatives or analogs which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, lipidation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the *Chlamydia* polypeptide sequence. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, α -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ -Abu, ϵ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β -alanine, fluoro-amino acids, designer amino acids such as β -methyl amino acids, C α -methyl amino acids, N α -methyl amino acids, PNA's and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

A *Chlamydia* PMP-derived polypeptide may further be a chimeric polypeptide comprising one or more heterologous polypeptides, lipids, phospholipids or lipopolysaccharides of *Chlamydia* origin or of another bacterial or viral origin, fused (*e.g.*, covalently bound) to the amino-terminus or carboxyl-terminus or is within a complete PMPE or PMPI polypeptide or PMP-derived polypeptide. Useful heterologous polypeptides to be included within such a chimeric polypeptide include, but are not limited to, a) pre- and/or pro- sequences that facilitate the transport, translocation and/or processing of the PMP-derived polypeptide in a host cell, b) affinity purification sequences, and c) any useful immunogenic sequences (*e.g.*, sequences encoding one or more epitopes of a surface-exposed protein of a microbial pathogen). One preferred heterologous protein of the chimeric polypeptide includes Hin47 (see U.S. Patents 5,679,547 and 5,721,115 which are hereby incorporated by reference in their entirety). Another preferred chimeric polypeptide includes an HMWP protein of *Chlamydia* or fragments thereof (see United States patent application Serial No. 08/942,596, filed October 2, 1997, entitled "Chlamydia Protein, Gene Sequence and Uses Thereof", which is incorporated by reference herein in its entirety) or

Chlamydia MOMP protein or fragments thereof (see U.S. Patent No. 5,869,608, which is incorporated herein by reference in its entirety).

PMP-derived polypeptides also include but are not limited to fusion polypeptides comprising at least two regions derived from one or more *Chlamydia* proteins, each having T-cell or antibody stimulating activity. The regions may be derived from the same *Chlamydia* protein or may comprise one or more regions from more than one *Chlamydia* protein. The polypeptides are arranged in a nonsequential order or noncontiguous order (*e.g.*, in an order different from the order of the amino acids of the native protein). A preferred polypeptide of the invention is a fusion polypeptide comprising at least two peptides, each of which peptides consists of an amino acid sequence selected from the group consisting of SEQ ID NOs.:5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, and 34, with the proviso that the peptides are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide.

Other preferred PMP-derived polypeptides of the invention are an isolated fusion polypeptide wherein the polypeptide comprises all the peptides consisting of the amino acid sequences of SEQ ID NOs.:5, 6, 7, 8, 9, 10 and 11, or an isolated fusion polypeptide wherein the polypeptide comprises all the peptides consisting of the amino acid sequences of SEQ ID NOs.:23, 24, 25, 26, 27, 28, and 29, with the proviso that the peptides are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide. A preferred PMP-derived polypeptide is an isolated fusion polypeptide comprising a peptide consisting of an amino acid sequence of any of SEQ ID NOs.:5, 6, 7, 8, 9, 10, 11, 23, 24, 25, 26, 27, 28 or 29, with the proviso that the peptides are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide.

If desired, the amino acid sequences of the regions can be produced and joined by a linker.

Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their ability to adopt a secondary structure that could interact with functional epitopes of the first and second polypeptides; (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes; (4) the ability to increase solubility; and (5) the ability to increase sensitivity to processing by antigen-presenting cells. Such linkers can be any amino acid sequence or other appropriate link or joining agent.

Linkers useful in the invention include linkers comprising a charged amino acid pair such as KK or RR, linkers sensitive to cathepsin and/or other trypsin-like enzymes, thrombin or Factor X_a, or linkers which result in an increase in solubility of the polypeptide.

Preferred peptide linker sequences contain Gly, Asn and Ser residues.

- 5 Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea et al. Gene 40:39-46 (1985); Murphy et al., Proc. Nat. Acad Sci USA 83:8258-8562 (1986); U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length.

- Another particular example of fusion polypeptides of the invention includes
10 a polypeptide or polypeptide derivative of the invention fused to a polypeptide having adjuvant activity, such as the subunit B of either cholera toxin or *E. coli* heat labile toxin. Another particular example of a fusion polypeptide encompassed by the invention includes a polypeptide or polypeptide derivative of the invention fused to a cytokine (such as, but not limited to, IL-2, IL-4, IL-10, IL-12, or interferon). A polypeptide of the invention can be
15 fused to the N- or C-terminal end of the polypeptide having adjuvant activity.

Alternatively, a polypeptide of the invention can be fused within the amino acid sequence of the polypeptide having adjuvant activity.

- Also preferably, the *Chlamydia* derived fusion polypeptides of the invention comprise sequences that form one or more epitopes of a native *Chlamydia* polypeptide that
20 elicit bactericidal or opsonizing antibodies and/or T-cells. Such preferred *Chlamydia*-derived polypeptides may be identified by their ability to generate antibodies and/or T-cells that kill cells infected with *Chlamydia* spp. cells particularly, *Chlamydia trachomatis* cells.

25 5.3 ISOLATION AND PURIFICATION OF PMP POLYPEPTIDES AND PMP-DERIVED POLYPEPTIDES

- The invention provides isolated PMPE and PMPI polypeptides, PMPE-derived and PMPI-derived polypeptides. As used herein, the term "isolated" means that the product is significantly free of other biological materials with which it is naturally associated, or free from other biological materials derived, for example, from a recombinant
30 host cell that has been genetically engineered to express the polypeptide of the invention. That is, for example, an isolated PMP polypeptide composition that is between about 70% and 99% pure PMP polypeptide by weight. As used herein, the term "purified" means that the product is substantially free of other biological material with which it is naturally associated, or free from other biological materials derived, for example, from a recombinant
35 host cell that has been genetically engineered to express the polypeptide of the invention.

That is, a purified PMP polypeptide composition is at least 70-95% pure PMP polypeptide by weight, preferably at least 98% pure PMP polypeptide by weight, and most preferably at least 99% pure PMP polypeptide by weight.

The PMP polypeptide of the invention may be isolated from a protein
5 extract, including a whole cell extract of any *Chlamydia spp.*, including, but not limited to, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Chlamydia pecorum*, and *Chlamydia psittaci*. Strains from any of these organisms may be obtained worldwide from any biologicals depository, for example, strains of ATCC VR-346, VR-347, VR-348B, VR-571B, VR-572, VR-573, VR-577, VR-578, VR-878, VR-879, VR-880, VR-885, VR-886,
10 VR-887, VR-901B, VR-902B, VR-903, VR-1355, VR-1474, VR-1477, or VR-2282 may be obtained from the American Type Culture Collection.

Another source of the PMP polypeptide is a protein preparation from a gene expression system (such as *E. coli*) engineered to express a cloned sequence encoding a PMP polypeptide or PMP-derived polypeptide (see Section 5.5, *infra*).

15 The PMP polypeptide can be isolated and purified from the source material using any biochemical technique and approach well known to those skilled in the art. In one approach, *Chlamydia* cellular envelope is obtained by standard techniques and inner membrane, periplasmic and outer membrane proteins are solubilized using a solubilizing compound such as a detergent or hypotonic solution. A preferred detergent solution is one
20 containing octyl glucopyranoside (OG), sarkosyl or TRITON X100™. A preferred solubilizing hypotonic solution is one containing LiCl. The PMP polypeptide is in the solubilized fraction. Cellular debris and insoluble material in the extract are separated and removed preferably by centrifugation. The polypeptides in the extract are concentrated, incubated in SDS-containing Laemmli gel sample buffer at 100°C for 5 minutes and then
25 fractionated by electrophoresis in a denaturing sodium dodecylsulfate (SDS) polyacrylamide gel from about 6% to about 12%, with or without a reducing agent. See Laemmli, 1970, Nature 227:680-685. The band or fraction identified as a PMP polypeptide, having an apparent molecular weight of about 90-115 kDa, as described above, may then be isolated directly from the fraction or gel slice containing the PMP polypeptide. In a preferred
30 embodiment, the PMP polypeptide has an apparent molecular weight of about 90-115 kDa which can be determined by comparing its migration distance or rate in denaturing SDS-PAGE relative to the migration of known molecular weight markers such as of myosin (250 kDa), Phosphorylase B (148 kDa), BSA (98 kDa) and GDH (64 kDa) (weights for pre-stained markers).

35

Another method of purifying PMP polypeptide is by affinity chromatography using anti-PMP antibodies (see Section 5.4). The affinity chromatography may be carried out using either polyclonal or monoclonal anti-PMP antibodies, preferably, monoclonal antibodies. The antibodies are covalently linked to agarose gels activated by cyanogen
5 bromide or succinamide esters (Affi-Gel, BioRad, Inc.) or by other methods known to those skilled in the art. The protein extract is loaded on the top of the gel and is left in contact with the gel for a period of time and under standard reaction conditions sufficient for PMP polypeptide to bind to the antibody. Preferably, the solid support is a material used in a chromatographic column. The affinity gel is washed to remove other proteins and cell
10 materials not bound by the anti-PMP antibody. The PMP polypeptide is then removed from the antibody to recover the PMP polypeptide in isolated, or preferably, in purified form.

A PMP-derived polypeptide of the invention can be produced by chemical and/or enzymatic cleavage or degradation of an isolated or purified PMP polypeptide. A PMP-derived polypeptide can also be chemically synthesized based on the known amino
15 acid sequence of the PMP polypeptide and, in the case of a chimeric polypeptide, the amino acid sequence of the heterologous polypeptide, by methods well known in the art. See, for example, Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman and Co., NY.

A PMP-derived polypeptide can also be produced in a gene expression
20 system expressing a recombinant nucleic acid construct comprising a sequence encoding a PMP-derived polypeptide. The nucleotide sequences encoding polypeptides of the invention may be synthesized, and/or cloned, and expressed according to techniques well known to those skilled in the art. See, for example, Sambrook, et al., 1989, Molecular Cloning, A Laboratory Manual, Vols. 1-3, Cold Spring Harbor Press, NY, Chapter 9.

PMP-derived polypeptides of the invention can be fractionated and purified
25 by the application of standard protein purification techniques, modified and applied in accordance with the discoveries and teachings described herein. In particular, preferred PMP polypeptides of the invention, those that form an outer-surface or exposed epitope of the native PMP polypeptide, may be isolated and purified according to the affinity
30 procedures disclosed above for the isolation and purification of a PMP polypeptide (e.g., affinity purification using anti-PMP antibodies).

If desirable, the polypeptides of the invention may be further purified using standard protein or peptide purification techniques including but not limited to, electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography
35 (including ion exchange chromatography, affinity chromatography, immunoadsorbent

affinity chromatography, dye-binding chromatography, size exclusion chromatography, hydroxyappitite chromatography, reverse-phase high performance liquid chromatography, and gel permeation high performance liquid chromatography), isoelectric focusing, and variations and combinations thereof.

5 One or more of these techniques may be employed sequentially in a procedure designed to isolate and/or purify the PMP polypeptide or the PMP-derived polypeptides of the invention according to its/their physical or chemical characteristics. These characteristics include the hydrophobicity, charge, binding capability, and molecular weight of the protein. The various fractions of materials obtained after each technique are
10 tested for binding to the PMP receptor or ligand or to anti-PMP antibodies or for functional activity ("test" activities). Those fractions showing such test activity are then pooled and subjected to the next technique in the sequential procedure, and the new fractions are tested again. The process is repeated until fractions are obtained that have one or more of the above described "test" activities and that contain only a single band (or a very predominant
15 band) or entity when subjected to polyacrylamide gel electrophoresis or chromatography.

5.4. PMP IMMUNOGENS AND ANTI-PMP ANTIBODIES

The present invention provides antibodies that specifically bind a PMP polypeptide and/or PMP-derived polypeptide. For the production of such antibodies,
20 isolated or, preferably, purified preparations of a PMP polypeptide or PMP-derived polypeptide are used as immunogens in an immunogenic composition.

In one embodiment, the PMP polypeptide is separated from other outer membrane or periplasmic proteins present in the extracts of *Chlamydia* cells using SDS-PAGE (see Section 5.3 above) and the gel slice containing the PMP polypeptide is used as
25 an immunogen and injected into a rabbit to produce antisera containing polyclonal PMP antibodies. The same immunogen can be used to immunize mice for the production of hybridoma lines that produce monoclonal anti-PMP antibodies. In particular embodiments, the immunogen is an SDS-PAGE gel slice containing isolated or purified PMP from any *Chlamydia* strain, including, but not limited to, *Chlamydia trachomatis*, *Chlamydia*
30 *pneumoniae*, *Chlamydia pecorum*, and *Chlamydia psittaci*. Particularly preferred are the strains of *Chlamydia trachomatis* ATCC: VR-346, VR-347, VR-348B, VR-571B, VR-572, VR-573, VR-577, VR-578, VR-878, VF-879, VR-880, VR-885, VR-886, VR-887, VR-901B, VR-902B, VR-903, VR-1355, VR-1474, VR-1477, VR-2282.

In other embodiments, peptide fragments of a PMP polypeptide are used as
35 immunogens. Preferably, peptide fragments of purified PMP polypeptide are used. The

peptides may be produced by protease digestion, chemical cleavage of isolated or purified PMP polypeptide, chemical synthesis or by recombinant expression, after which they are then isolated or purified. Such isolated or purified peptides can be used directly as immunogens. In particular embodiments, useful peptide fragments are 8 or more amino acids in length.

Useful immunogens may also comprise such peptides or peptide fragments conjugated to a carrier molecule, preferably a carrier protein. Carrier proteins may be any commonly used in immunology, include, but are not limited to, bovine serum albumin (BSA), chicken albumin, keyhole limpet hemocyanin (KLH), tetanus toxoid and the like.

For a discussion of hapten protein conjugates, see, for example, Harlow and Lane Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988, or a standard immunology textbook such as Roitt, et al., IMMUNOLOGY, C.V. Mosby Co., St. Louis, MO (1985) or Klein, IMMUNOLOGY, Blackwell Scientific Publications, Inc., Cambridge, MA (1990).

In yet another embodiment, for the production of antibodies that specifically bind one or more epitopes of a native PMP polypeptide, intact *Chlamydia* cells or elemental bodies (EBs) or reticulate bodies (RBs) prepared therefrom, or cells infected with *Chlamydia* are used as immunogen. The cells, EBs, RBs or cells infected with *Chlamydia* may be fixed with agents such as formaldehyde or glutaraldehyde before immunization.

See Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988, Chapter 15. It is preferred that such anti-whole cell antibodies be monoclonal antibodies. Hybridoma lines producing the desired monoclonal antibodies can be identified by using purified PMP polypeptide, intact *Chlamydia* cells, EBs, RBs or cells infected with *Chlamydia* as the screening ligand. The immunogen for inducing these antibodies may be whole *Chlamydia* cells, EBs, RBs, extracts or lysates of any *Chlamydia*, including, but not limited to, *Chlamydia trachomatis*, *Chlamydia pneumoniae*, *Chlamydia pecorum*, and *Chlamydia psittaci*. Particularly preferred are strains of *Chlamydia* strains ATCC VR-346, VR-347, VR-348B, VR-571B, VR-572, VR-573, VR-577, VR-578, VR-878, VF-879, VR-880, VR-885, VR-886, VR-887, VR-901B, VR-902B, VR-903, VR-1355, VR-1474, VR-1477, VR-2282.

Polyclonal antisera produced by immunization with cells infected with *Chlamydia*, whole cells, EBs or RBs contain antibodies that bind other *Chlamydia* proteins ("non-anti-PMP antibodies") and thus are more cumbersome to use when it is known or suspected that the sample contains other *Chlamydia* proteins or materials that are cross-reactive with these other proteins. Under such circumstances, any binding by the anti-whole

cell antibodies of a given sample or band must be verified by coincidental binding of the same sample or band by antibodies that specifically bind the PMP polypeptide (e.g., anti-PMPE antibodies) and/or a PMP-derived polypeptide, or by competition tests using anti-PMP antibodies, PMP polypeptides or PMP-derived polypeptides as the competitor (i.e.,
5 addition of anti-PMP antibodies, PMP polypeptide or PMP-derived polypeptide to the reaction mix lowers or abolishes sample binding by anti-whole cell antibodies).
Alternatively, such polyclonal antisera containing "non-anti-PMP" antibodies, may be cleared of such non-anti-PMP antibodies by standard approaches and methods. For example, the non-anti-PMP antibodies may be removed by precipitation with cells having a
10 deletion of the PMP coding sequence or *Chlamydia* strains known not to have the PMP polypeptide; or by absorption to columns comprising such cells or outer membrane proteins of such cells.

In further embodiments, useful immunogens for eliciting antibodies of the invention comprise mixtures of two or more of any of the above-mentioned individual
15 immunogens.

Immunization of animals with the immunogens described herein, preferably of humans, rabbits, rats, ferrets, mice, sheep, goats, cows or horses, is performed following procedures well known to those skilled in the art, for purposes of obtaining antisera containing polyclonal antibodies or hybridoma lines secreting monoclonal antibodies.

20 Monoclonal antibodies can be prepared by standard techniques, given the teachings contained herein. Such techniques are disclosed, for example, in U.S. Patent No. 4,271,145 and U.S. Patent No. 4,196,265. Briefly, an animal is immunized with the immunogen. Hybridomas are prepared by fusing spleen cells from the immunized animal with myeloma cells. The fusion products are screened for those producing antibodies that
25 bind to the immunogen. The positive hybridomas clones are isolated, and the monoclonal antibodies are recovered from those clones.

Immunization regimens for production of both polyclonal and monoclonal antibodies are well known in the art. The immunogen may be injected by any of a number of routes, including subcutaneous, intravenous, intraperitoneal, intradermal, intramuscular,
30 mucosal, or a combination of these. The immunogen may be injected in soluble form, aggregate form, attached to a physical carrier, as a gel slice, or mixed with an adjuvant, using methods and materials well known in the art. The antisera and antibodies may be purified using column chromatography methods well known to those of skill in the art.

The antibodies may also be used as probes for identifying clones in
35 expression libraries that have or may have inserts encoding one or more PMP polypeptides

or fragments thereof. The antibodies, PMP polypeptides or PMP-derived polypeptides may also be used in immunoassays (e.g., ELISA, RIA, Western Blots) to specifically detect and/or quantitate *Chlamydia* or anti-*Chlamydia* antibody in biological specimens. Anti-PMP antibodies of the invention specifically bind PMP polypeptide from *Chlamydia*
5 *trachomatis*, *Chlamydia pneumoniae*, *Chlamydia pecorum*, and/or *Chlamydia psittaci*. Thus anti-PMP antibodies can be used to diagnose *Chlamydia* infections.

The antibodies of the invention, including but not limited to those that are cytotoxic, cytostatic, or neutralizing, may also be used in passive immunization to prevent or attenuate *Chlamydia* infections of animals, including humans. As used herein, a
10 cytotoxic antibody is one that enhances opsonization and/or complement killing of the bacterium bound by the antibody. As used herein, neutralizing antibody is one that reduces the infectivity of the *Chlamydia* and/or blocks binding of *Chlamydia* to a target cell. An effective concentration of polyclonal or monoclonal antibodies raised against the immunogens of the invention may be administered to a host to achieve such effects. The
15 exact concentration of the antibodies administered will vary according to each specific antibody preparation, but may be determined using standard techniques well known to those of ordinary skill in the art. Administration of the antibodies may be accomplished using a variety of techniques, including, but not limited to those described in Section 5.7 for the delivery of vaccines.

20 Another aspect of the invention is directed to antisera raised against an antigenic or immunogenic composition of the invention, and antibodies present in the antisera that specifically bind a PMP protein or a fragment or analogue thereof.

Preferably, the antibodies bind a PMP polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs.:2 and 4-34 or a PMP-derived
25 polypeptide. Also included are monoclonal antibodies that specifically bind a PMP polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NOs.:2 and 4-34 or a PMP-derived polypeptide. The term "antibodies" is intended to include all forms, such as but not limited to polyclonal, monoclonal, purified IgG, IgM, or IgA antibodies and fragments thereof, including but not limited to antigen binding
30 fragments such as Fv, single chain Fv (scFv), F(ab)₂, Fab, and F(ab)' fragments (Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press); single chain antibodies (U.S. Patent No. 4,946,778) and complementary determining regions (CDR), (see Verhoeven and Winter, in Molecular Immunology 2ed., by B.D. Hames and D.M. Glover, IRL Press, Oxford University Press, 1996, at pp. 283-325), etc.

35

A further aspect of the invention are chimeric or humanized antibodies (Morrison et al., 1984, Proc. Nat'l Acad. Sci. USA 81:6851; Reichmann *et al.* Nature 332:323; U.S. Patent Nos. 5,225,539; 5,585,089; and 5,530,101; Neuberger et al., 1984, Nature 81:6851; Riechmann *et al.*, 1988, Nature 332:323; U.S. Patent Nos. 5,225,539; 5,585,089; and 5,530,101) in which one or more of the antigen binding regions of the anti-PMP antibody is introduced into the framework region of a heterologous (*e.g.*, human) antibody. The chimeric or humanized antibodies of the invention are less antigenic in humans than non-human antibodies but have the desired antigen binding and other activities, including but not limited to neutralizing activity, cytotoxic activity, opsonizing activity or protective activity.

In a preferred embodiment, the antibodies of the invention are human antibodies. Human antibodies may be isolated, for example, from human immunoglobulin libraries (see, *e.g.*, PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16054, WO 96/34096, WO 96/33735, and WO 91/10741) by, preferably, phage display techniques (see, *e.g.*, Brinkman *et al.*, *J. Immunol. Methods* 182:41-50 (1995); Ames *et al.*, *J. Immunol. Methods* 184:177-186 (1995); Kettleborough *et al.*, *Eur. J. Immunol.* 24:952-958 (1994); Persic *et al.*, *Gene* 187 9-18 (1997); Burton *et al.*, *Advances in Immunology* 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety. Human antibodies may also be generated from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, see, *e.g.*, U.S. Patent No. 5,939,598 by Kucherlapati *et al.*

A further aspect of the invention is T-cells specific for *Chlamydia*, Chlamydial EB, RBs, *Chlamydia* infected cells or antigen presenting cells displaying Chlamydial antigens. T-cell preparations enriched for T-cells specific for PMP or PMP-derived polypeptides can be produced or isolated by methods known in the art (See section 5.8).

5.5 NUCLEIC ACIDS ENCODING THE PMP POLYPEPTIDE AND PMP DERIVED POLYPEPTIDES

The isolated nucleic acids of the present invention, including DNA and RNA, comprising a sequence encoding the PMP protein or PMP-derived polypeptide

thereof, may be synthesized using methods known in the art, such as using conventional chemical approaches or polymerase chain reaction (PCR) amplification using convenient pairs of oligonucleotide primers and ligase chain reaction using a battery of contiguous oligonucleotides. The sequences also allow for the identification and cloning of the PMP
5 protein gene from any species or serovar of *Chlamydia*, for instance for screening Chlamydial genomic libraries or expression libraries as described below.

In a particular embodiment, the PMP polypeptide comprises an amino acid sequence of either SEQ ID NO.:2 or 4 and the nucleic acids comprise nucleotide sequences encoding said amino acid sequences. Particularly preferred fragments of PMP have 8 or
10 more amino acids of the amino acid sequences of SEQ ID NOs.:2 or 4, or sequences substantially homologous thereto, and the invention encompasses nucleic acids comprising nucleotide sequences encoding said amino acid sequences. In another particular embodiment, the PMP polypeptide is encoded by the nucleotide sequence of SEQ ID NOs.:1 or 3, with particularly preferred fragments having a nucleotide sequence of SEQ ID
15 NOs.:36-65, or sequences substantially homologous thereto.

The term "isolated nucleic acid" or "isolated nucleic acid molecule" is defined as a nucleic acid molecule or removed from the environment in which it naturally occurs. For example, a naturally-occurring DNA molecule present in the genome of a living bacteria or as part of gene bank is not isolated, but the same molecule separated from the
20 remaining part of the bacterial genome, as a result of, *e.g.*, a cloning event (amplification) is isolated. Typically, an isolated DNA molecule is free from DNA regions (*e.g.*, coding regions) with which it is immediately contiguous at the 5' or 3' end, in the naturally occurring genome. Such isolated nucleic acids or nucleic acid molecules could be part of a vector or a composition and still be isolated in that such a vector or composition is not part
25 of its natural environment. However, "isolated nucleic acid" or "isolated nucleic acid molecule" does not include a nucleic acid that is part of a recombinant library.

Nucleic acids of the present invention can be single or double stranded. The invention also provides nucleic acids hybridizable to or complementary to SEQ ID NO.:1 or 3 or fragments thereof, as well as polypeptides encoded by these nucleic acids. In specific
30 aspects, nucleic acids are provided which comprise a sequence fully complementary to or complementary to at least 10, 15, 25, 50, 100, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400 or 1500 contiguous nucleotides of a nucleic acid encoding a PMP polypeptide or an PMP-derived polypeptide. In a specific embodiment, a nucleic acid which is hybridizable to a nucleic acid encoding a
35 PMP polypeptide (*e.g.*, having a nucleotide sequence of SEQ ID NO.:1 or 3), or to a nucleic

acid encoding a PMP-derived polypeptide, under conditions of low, moderate or high stringency is provided.

By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations).

In another specific embodiment, a nucleic acid which is hybridizable to a nucleic acid encoding a PMP polypeptide or a PMP-derived polypeptide under conditions of high stringency is provided. By way of example and not limitation, procedures using such conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art.

In another specific embodiment, a nucleic acid which is hybridizable to a nucleic acid encoding a PMP polypeptide or a PMP-derived polypeptide under conditions of moderate stringency is provided.

Various other stringency conditions which promote nucleic acid hybridization can be used. For example, hybridization in 6X SSC at about 45°C, followed by washing in 2X SSC at 50°C may be used. Alternatively, the salt concentration in the wash step can range from low stringency of about 5X SSC at 50°C, to moderate stringency

of about 2X SSC at 50°C, to high stringency of about 0.2X SSC at 50°C. In addition, the temperature of the wash step can be increased from low stringency conditions at room temperature, to moderately stringent conditions at about 42°C, to high stringency conditions at about 65°C. Other conditions include, but are not limited to, hybridizing at 68°C in
5 0.5M NaHPO₄ (pH7.2)/ 1 mM EDTA/ 7% SDS, or hybridization in 50% formamide/0.25M NaHPO₄ (pH 7.2)/.25 M NaCl/1 mM EDTA/7% SDS; followed by washing in 40 mM NaHPO₄ (pH 7.2)/1 mM EDTA/5% SDS at 42°C or in 40 mM NaHPO₄ (pH7.2) 1 mM EDTA/1% SDS at 50°C. Both temperature and salt may be varied, or alternatively, one or the other variable may remain constant while the other is changed.

10 Low, moderate and high stringency conditions are well known to those of skill in the art, and will vary predictably depending on the base composition of the particular nucleic acid sequence and on the specific organism from which the nucleic acid sequence is derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Press, N.Y.,
15 pp. 9.47-9.57; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

In the preparation of genomic libraries, DNA fragments are generated, some of which will encode parts or the whole of a *Chlamydia* PMPE or PMPI protein. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may
20 use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis, column chromatography and sucrose gradient centrifugation. The DNA fragments can then be inserted into suitable vectors, including but
25 not limited to plasmids, cosmids, bacteriophages lambda or T₄, bacmids and yeast artificial chromosome (YAC). (See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) The genomic library may be screened by nucleic acid
30 hybridization to labeled probe (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A., 72:3961).

The genomic libraries may be screened with labeled degenerate oligonucleotide probes corresponding to the amino acid sequence of any peptide of PMP protein using optimal approaches well known in the art. Any probe used preferably is 15
35 nucleotides or longer.

5 The term "probe" as used herein refers to DNA (preferably single stranded) or RNA molecules that hybridize under stringent conditions as defined above, to nucleic acids having sequences homologous to SEQ ID NO.:1 or SEQ ID NO.:3 or to a complementary or anti-sense sequence thereof. Generally, probes are significantly shorter than full-length sequences shown in SEQ ID NO.:1 or 3.

10 For example, they can contain from about 5 to about 100 nucleotides preferably from about 10 to about 80 nucleotides. In particular, probes have sequences that are at least 75% preferably at least 85%, and more preferably 95%, homologous to a portion of a sequence of SEQ ID NO.:1 or 3, or complementary to such sequences. Probes can contain modified bases such as inosine, methyl-5-deoxycytidine, deoxyuridine, dimethylamino-5-deoxyuridine, or diamino-2,6 purine.

15 Clones in libraries with insert DNA encoding a PMP protein or a PMP-derived polypeptides will hybridize to one or more of the degenerate oligonucleotide probes. Hybridization of such oligonucleotide probes to genomic libraries is carried out using methods known in the art. For example, hybridization with the two above-mentioned oligonucleotide probes may be carried out in 2X SSC, 1.0% SDS at 50°C and washed using the same conditions.

20 In yet another aspect, clones of nucleotide sequences encoding a part or the entire PMP protein or PMP-derived polypeptide may also be obtained by screening *Chlamydia* expression libraries. For example, *Chlamydia* DNA or *Chlamydia* cDNA generated from RNA is isolated and random fragments are prepared and ligated into an expression vector (*e.g.*, a bacteriophage, plasmid, phagemid or cosmid) such that the inserted sequence in the vector is capable of being expressed by the host cell into which the vector is then introduced. Various screening assays can then be used to select for the expressed PMP-protein or PMP-derived polypeptides. In one embodiment, the various anti-PMP antibodies of the invention can be used to identify the desired clones using methods known in the art. See, for example, Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Appendix IV. Clones or plaques from the library are brought into contact with the antibodies to identify those clones that bind.

30 In an embodiment, colonies or plaques containing DNA that encodes a PMP protein or PMP-derived polypeptide could be detected using DYNA Beads according to Olsvick et al., 29th ICAAC, Houston, Tex. 1989, incorporated herein by reference. Anti-PMP antibodies are crosslinked to DYNA Beads M280, and these antibody-containing beads are used to adsorb to colonies or plaques expressing a PMP protein or a PMP derived

polypeptide. Colonies or plaques expressing a PMP protein or a PMP derived polypeptide are identified as any of those that bind the beads.

Alternatively, the anti-PMP antibodies can be nonspecifically immobilized to a suitable support, such as silica or Celite™ resin. This material is used to adsorb to
5 bacterial colonies expressing a PMP protein or a PMP derived polypeptide as described in the preceding paragraph.

In another aspect, PCR amplification may be used to produce substantially pure DNA encoding a part of or the whole of a PMP protein from *Chlamydia* genomic DNA. Oligonucleotide primers, degenerate or otherwise, corresponding to known PMP
10 protein sequences can be used as primers.

In particular embodiments, an oligonucleotide encoding a portion of SEQ ID NO.:2 or 4 may be used as the 5' primer. For fragment examples, a 5' primer may be made from any one of the nucleotide sequences of SEQ ID NO.:66 or 69 or any portion thereof. For 3' primers, a nucleotide sequence of SEQ ID NO.:67 or 70 or any portion thereof may
15 be used.

As examples, an oligonucleotide encoding the N-terminal primer, and together with a 3' reverse PCR oligonucleotide complementary to an internal, downstream protein coding sequence may be used to amplify an N-terminal-specific PMP DNA fragment. Alternatively, an oligonucleotide encoding an internal PMP coding sequence may
20 be used as the 5' forward PCR primer together with a 3' reverse PCR oligonucleotide complementary to downstream, internal PMP protein coding sequences may be used to PCR amplify an internal PMP specific DNA fragment. Alternatively, the forward primer can be combined together with an oligonucleotide complementary to the C-terminal PMP coding region to PCR amplify the PMP ORF. These PMP specific PCR products can be cloned
25 into appropriate expression vectors to direct the synthesis of all or part of the PMP polypeptide as distinct proteins or fusion proteins. Alternatively, these PMP specific PCR products can be appropriately labeled and used as hybridization probes to identify all or part of the PMP gene from genomic DNA libraries.

PCR can be carried out, *e.g.*, by use of a Perkin-Elmer thermal cyclor and
30 Taq polymerase (Gene Amp™). One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the degenerate primers and the corresponding sequences in *Chlamydia* DNA. After successful amplification of a segment
35 of the sequence encoding a PMP protein, that segment may be molecularly cloned and

sequenced, and utilized as a probe to isolate a complete genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described *infra*.

5 Once a PMP polypeptide coding sequence has been isolated from one *Chlamydia* species, strain, or cultivar, it is possible to use the same approach to isolate PMP polypeptide coding sequences from other *Chlamydia* species, strains and cultivars. It will be recognized by those skilled in the art that the DNA or RNA sequence encoding PMP polypeptide (or fragments thereof) of the invention can be used to obtain other DNA or
10 RNA sequences that hybridize with it under conditions of moderate to high stringency, using general techniques known in the art (see *supra*). Hybridization with PMP sequence from one *Chlamydia* strain or cultivar under high stringency conditions will identify the corresponding sequence from other strains and cultivars. High stringency conditions vary with probe length and base composition. The formulae for determining such conditions are
15 well known in the art. See Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, NY, Chapter 11. As an example, high stringency hybridization conditions as applied to probes of greater than 300 bases in length involve a final wash in 0.1X SSC/0.1% SDS at 68°C for at least 1 hour (Ausubel, et al., Eds., 1989, Current Protocols in Molecular Biology, Vol. I, Greene Publishing Associates, Inc and John
20 Wiley & Sons, Inc. New York, at page 2.10.2). See also, the description of high stringency conditions, *supra*.

One skilled in the art would be able to identify complete clones of a PMP polypeptide coding sequence using approaches well known in the art. The extent of the PMP polypeptide coding sequence contained in an isolated clone may be ascertained by
25 sequencing the cloned insert and comparing the deduced size of the polypeptide encoded by the open reading frames (ORFs) with that of the PMP polypeptide and/or by comparing the deduced amino acid sequence with that of known amino acid sequence of the purified PMP polypeptide. Where a partial clone of the PMP polypeptide coding sequence has been isolated, complete clones may be isolated by using the insert of the partial clone as a
30 hybridization probe. Alternatively, a complete PMP polypeptide coding sequence can be reconstructed from overlapping partial clones by splicing their cloned PMP inserts together.

Complete clones may be any that an ORF with a deduced amino acid sequence matching or substantially homologous to that of the PMP polypeptide or, where the complete amino acid sequence of the latter is not available, matching or substantially
35 homologous to that of a peptide fragment of a PMP polypeptide and having a molecular

weight corresponding to that of the PMP polypeptide. Further, complete clones may be identified by the ability of their inserts, when placed in an expression vector, to produce a polypeptide that binds antibodies specific to the amino-terminus of the PMP polypeptide and antibodies specific to the carboxyl-terminus of the PMP polypeptide.

5 Nucleic acids encoding PMP-derived polypeptides and PMP fusion proteins may be produced by methods well known in the art. In one aspect, nucleic acids encoding PMP-derived polypeptides can be derived from PMP polypeptide coding sequences by recombinant DNA methods in view of the teachings disclosed herein. For example, the coding sequence of a PMP polypeptide may be altered creating amino acid substitutions that
10 will not affect the immunogenicity of the PMP polypeptide or which may improve its immunogenicity, such as conservative or semi-conservative substitutions as described above. Various methods may be used, including but not limited to, oligonucleotide directed, site specific mutagenesis. This and other techniques known in the art may be used to create single or multiple mutations, such as replacements, insertions, deletions, and
15 transpositions, for example, as described in Botstein and Shortle, 1985, Science 229:1193-1210.

Further, nucleic acids containing PMP polypeptide coding sequences may be truncated by restriction enzyme or exonuclease digestions. Heterologous coding sequences may be added to the PMP polypeptide coding sequence by ligation or PCR amplification.
20 Moreover, DNA encoding the whole or a part of PMP-derived polypeptide may be synthesized chemically or using PCR amplification based on the known or deduced amino acid sequence of the PMP polypeptide and any desired alterations to that sequence.

The identified and isolated DNA containing the PMP polypeptide or PMP-derived polypeptide coding sequence can be inserted into an appropriate cloning vector. A
25 large number of vector-host systems known in the art may be used. The term "host" as used herein and in the claims refers to either *in vivo* in an animal or *in vitro* in mammalian cell cultures.

Possible vectors include, but are not limited to, plasmids and modified viruses, but the vector system must be compatible with the host cell used. Such vectors
30 include, but are not limited to, bacteriophage such as lambda derivatives, or plasmids such as pET, pBAD, pTrcHis, pBR322 or pUC plasmid derivatives. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of
35 the DNA molecules may be enzymatically modified. Alternatively, any site desired may be

produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved DNA may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host
5 cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired DNA containing a PMP polypeptide or PMP-derived polypeptide coding sequence may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired
10 sequence, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that contain a PMP polypeptide or PMP-derived polypeptide coding sequence enables generation of multiple copies of such coding sequence. Thus, the coding sequence
15 may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted coding sequence from the isolated recombinant DNA.

The nucleotide sequences encoding the PMP polypeptides of the present invention are useful for their ability to selectively form duplex molecules with
20 complementary stretches of other protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve hybridization with varying sequence identities. In specific aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 15, 25, 50, 100, 200 or 250 nucleotides of the PMP protein coding nucleic acid molecule. In specific embodiments, nucleic acids which hybridize to a
25 PMP protein nucleic acid (*e.g.*, having a nucleotide sequence of SEQ ID NO.:1 or 3) under annealing conditions are provided.

For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as, by way of example and not limitation, low salt and/or high temperature conditions, such as provided by 0.02 M to 0.15 M NaCl at temperatures of
30 between about 50°C to 70°C. For some applications, less stringent hybridization conditions are required, by way of example and not limitation, such as 0.15 M to 0.9 M salt, at temperatures ranging from between about 20°C to 55°C. Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily
35 manipulated, and will generally be a method of choice depending on the desired results.

5.6 RECOMBINANT PRODUCTION OF PMP POLYPEPTIDE AND PMP-DERIVED POLYPEPTIDES

In accordance with this invention, it is preferred to make the *Chlamydia* protein of the present invention by recombinant methods, particularly when the naturally occurring protein as isolated from a culture of a species of *Chlamydia* may include trace amounts of toxic materials or other contaminants. This problem can be avoided by using protein recombinantly produced in heterologous systems which can be isolated from the host in a manner to minimize contaminants in the isolated material. In this case, the PMP proteins are produced by an appropriate host cell that has been transformed by a DNA molecule that codes for the polypeptide.

The nucleic acids encoding the PMP polypeptides or PMP-derived polypeptides of the invention can be inserted into an appropriate expression vector, *i.e.*, a vector that contains the necessary elements for the transcription and translation of the inserted polypeptide-coding sequence. The nucleotide sequences encoding the PMP polypeptides or PMP-derived polypeptides are inserted into the vectors in a manner such that they will be expressed under appropriate conditions (*e.g.*, in proper orientation and correct reading frame). The recombinant expression vector also comprises an "expression means". The term "expression means" refers to elements of a vector which are necessary for transcription and translation of the nucleic acid encoding the protein, including but not limited to promoter/enhancer elements, a replication site, an RNA polymerase binding sequence, a ribosomal binding sequence, sequences which are capable of providing phenotype selection (*e.g.*, ampicillin or tetracycline resistance) and replicon and control sequences that can be used to transform host cells. The expression means is operatively coupled to the nucleic acid molecule encoding the PMP protein by linking the inserted nucleic acid molecule into the expression vector.

Promoter/enhancer elements which may be used to control expression of inserted sequences include, but are not limited to the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42) for expression in animal cells; the promoters of lactamase (Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), *tac* (DeBoer et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25), or *trc* for expression in bacterial cells (see also "Useful

proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94); the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter (Gardner et al., 1981, Nucl. Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120) for expression
5 in plant cells; Gal4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter for expression in yeast or other fungi.

Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In a preferred embodiment, a
10 chimeric protein comprising a PMP protein or PMP-derived polypeptide sequence and a pre and/or pro sequence of the host cell is expressed. In other preferred embodiments, a chimeric protein comprising a PMP protein or PMP derived polypeptide sequence fused with, for example, an affinity purification peptide, including but not limited to, maltose binding protein, glutathione-S-transferase, thioredoxin or histidine tag, is expressed. In
15 further preferred embodiments, a chimeric protein comprising a PMP protein or PMP-derived polypeptide sequence and a useful immunogenic peptide or protein is expressed.

Any method known in the art for inserting DNA fragments into a vector may be used to construct expression vectors containing a PMP or PMP-derived polypeptide encoding nucleic acid molecule consisting of appropriate transcriptional/translational
20 control signals and the polypeptide coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombination (genetic recombination).

Methods of introducing exogenous DNA into yeast hosts include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations.
25 Transformation procedures usually vary with the yeast species to be transformed. See *e.g.*, Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141; for *Candida*, Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; for *Hansenula*; Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983) J. Bacteriol. 154:1165; Van den Berg et al. (1990)
30 Bio/Technology 8:135; for *Kluyveromyces*; Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. Patent No. 4,837,148 and U.S. Patent No. 4,929,555; for *Pichia*; Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163; for *Saccharomyces*; Beach et al. (1981) Nature 300:706; for *Schizosaccharomyces*; Davidow et al. (1985) Curr. Genet. 10:39.

35

Expression vectors containing PMP polypeptide or PMP-derived polypeptide coding sequences can be identified by three general approaches: (a) nucleic acid hybridization; (b) presence or absence of "marker" gene functions; and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted into an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to the inserted PMP polypeptide or PMP-derived polypeptide coding sequence. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes into the vector.

For example, *E. coli* may be transformed using pBR322 which contains genes for ampicillin and tetracycline resistance. If the PMP polypeptide or PMP-derived polypeptide coding sequence is inserted within the marker gene sequence of the vector, recombinants containing the insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of PMP polypeptide or PMP-derived polypeptide in *vitro* assay systems, e.g., binding of a His tag to a column, binding to a PMP ligand or receptor or binding with anti-PMP antibodies of the invention.

Commercially available vectors for expressing heterologous proteins in bacterial hosts include but are not limited to pZERO, pTrc99A, pUC19, pUC18, pKK223-3, pEX1, pCAL, pET, pSPUTK, pTrxFus, pFastBac, pThioHis, pTrcHis, pTrcHis2, and pLEx. For example, the phage in lambda GEM™-11 may be utilized in making recombinant phage vectors which can be used to transform host cells, such as *E. coli* LE392. In a preferred embodiment, the vector is pQE30 or pBAD/ThioE, which can be used transform host cells, such as *E. coli*.

Expression and transformation vectors for transformation into many yeast strains are available. For example, expression vectors have been developed for, the following yeasts: *Candida albicans*, Kurtz, et al. (1986) Mol. Cell. Biol. 6:142; *Candida maltosa*, Kunze, et al. (1985) J. Basic Microbiol. 25:141; *Hansenula polymorpha*, Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; *Kluyveromyces fragilis*, Das, et al. (1984) J. Bacteriol. 158:1165; *Kluyveromyces lactis*, De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg, et al. (1990) Bio/Technology 8:135; *Pichia quillerimondii*, Kunze et al. (1985) J. Basic Microbiol.

25:141; *Pichia pastoris*, Cregg, et al. (1985) Mol. Cell. Biol. 5:3376, U.S. Patent No. 4,837,148 and U.S. Patent No. 4,929,555; *Saccharomyces cerevisiae*, Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929, Ito et al. (1983) J. Bacteriol. 153:163; *Schizosaccharomyces pombe*, Beach et al. (1981) Nature 300:706; and *Yarrowia lipolytica*,
5 Davidow, et al. (1985) Curr. Genet. 10:380-471, Gaillardin, et al. (1985) Curr. Genet. 10:49.

A variety of host-vector systems may be utilized to express the polypeptide-coding sequence. These include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus
10 (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA, plant cells or transgenic plants.

Hosts that are appropriate for expression of nucleic acid molecules of the present invention, fragments, analogues or variants thereof, may include *E. coli*, *Bacillus*
15 species, *Haemophilus*, fungi, yeast, such as *Saccharomyces*, *Pichia*, *Bordetella*, or *Candida*, or the baculovirus expression system may be used. Preferably, the host cell is a yeast or bacterium.

Particularly desirable hosts for expression in this regard include Gram positive bacteria which do not have LPS and are, therefore endotoxin free. Most preferably
20 the bacterium is *E. coli*, *B. subtilis* or *Salmonella*.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered PMP polypeptide or PMP-derived
25 polypeptide may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed.

Once a suitable host system and growth conditions are established,
30 recombinant expression vectors can be propagated and prepared in quantity. Upon expression, a recombinant polypeptide of the invention is produced and can be recovered in a substantially purified from the cell paste, the cell extract or from the supernatant after centrifugation of the recombinant cell culture using techniques well known in the art.

35

For instance, the recombinant polypeptide can be purified by antibody-based affinity purification, preparative gel electrophoresis, or affinity purification using tags (*e.g.*, 6X histidine tag) included in the recombinant polypeptide. (See, Section 5.3 *supra*).

5 5.7 COMPOSITIONS

The present invention also provides therapeutic and prophylactic compositions, which may be antigenic compositions, and preferably immunogenic compositions, including vaccines, for use in the treatment or prevention of *Chlamydia* infections of animals, including mammals and birds, and more specifically rodents and primates, including humans. Preferred immunogenic compositions include vaccines for use in humans. The antigenic, preferably immunogenic, compositions of the present invention can be prepared by techniques known to those skilled in the art and comprise, for example, an immunologically effective amount of any of the PMP immunogens disclosed in Sections 5.1. or 5.2, optionally in combination with or fused to or conjugated to one or more other immunogens, including lipids, phospholipids, carbohydrates, lipopolysaccharides, inactivated or attenuated whole organisms and other proteins, of *Chlamydia* origin or other bacterial origin, a pharmaceutically acceptable carrier, optionally an appropriate adjuvant, and optionally other materials traditionally found in vaccines. In one embodiment, the invention provides a cocktail vaccine comprising several immunogens, which has the advantage that immunity against one or several strains of a single pathogen or one or several pathogens can be obtained by a single administration. Examples of other immunogens include, but are not limited to, those used in the known DPT vaccines, HMWP of *C. trachomatis*, MOMP of *C. trachomatis*, entire organisms or subunits therefrom of *Chlamydia*, *Neisseria*, HIV, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Human papilloma virus*, *Herpes simplex virus*, *Haemophilus ducreyi*, *Treponema pallidum*, *Candida albicans* and *Streptococcus pneumoniae*, etc.

The term "immunogenic amount" is used herein to mean an amount sufficient to induce an immune response to produce antibodies, T-cells, and/or cytokines and other cellular immune response components. Preferably, the immunogenic composition is one that elicits an immune response sufficient to prevent *Chlamydia* infections or to attenuate the severity of any preexisting or subsequent *Chlamydia* infection. An immunogenic amount of the immunogen to be used in the vaccine is determined by means known in the art in view of the teachings herein. The exact concentration will depend upon the specific immunogen to be administered, but can be determined by using standard

35

techniques well known to those skilled in the art for assaying the development of an immune response.

The vaccine compositions of the invention elicit an immune response in a subject. Compositions which induce antibodies, including anti-PMP protein antibodies and antibodies that are opsonizing or bactericidal are one aspect of the invention. In preferred non-limiting, embodiments of the invention, an effective amount of a composition of the invention produces an elevation of antibody titer to at least three times the antibody titer prior to administration. In a preferred, specific, non-limiting embodiment of the invention, approximately 0.01 to 2000 μg and, preferably, 0.1 to 500 μg , of the PMP protein or PMP-derived protein is administered to a host. Compositions which induce T-cell responses which are bactericidal or reactive with host cells infected with *Chlamydia* are also an aspect of the invention. Preferred are compositions additionally comprising an adjuvant.

The combined immunogen and carrier or diluent may be an aqueous solution, emulsion or suspension or may be a dried preparation. Appropriate carriers are known to those skilled in the art and include stabilizers, diluents, and buffers. Suitable stabilizers include carbohydrates, such as sorbitol, lactose, mannitol, starch, sucrose, dextran, and glucose, and proteins, such as albumin or casein. Suitable diluents include saline, Hanks Balanced Salts, and Ringers solution. Suitable buffers include an alkali metal phosphate, an alkali metal carbonate, or an alkaline earth metal carbonate. In preferred embodiments, the composition of the invention is formulated for administration to humans.

The immunogenic compositions, including vaccines, of the invention are prepared by techniques known to those skilled in the art, given the teachings contained herein. Generally, an immunogen is mixed with the carrier to form a solution, suspension, or emulsion. One or more of the additives discussed herein may be added in the carrier or may be added subsequently. The vaccine preparations may be desiccated or lyophilized, for example, by freeze drying or spray drying for storage or formulations purposes. They may be subsequently reconstituted into liquid vaccines by the addition of an appropriate liquid carrier or administered in dry formulation using methods known to those skilled in the art, particularly in capsules or tablet forms.

An effective amount of the antigenic, immunogenic, pharmaceutical, including, but not limited to vaccine, composition of the invention should be administered, in which "effective amount" is defined as an amount that is sufficient to produce a desired prophylactic, therapeutic or ameliorative response in a subject, including but not limited to an immune response. The amount needed will vary depending upon the immunogenicity of

the PMP protein, PMP-derived polypeptide or nucleic acid used, and the species and weight of the subject to be administered, but may be ascertained using standard techniques.

Immunogenic, antigenic, pharmaceutical and vaccine compositions may further contain one or more auxiliary substance, such as wetting or emulsifying agents, pH buffering agents, or adjuvants to enhance the effectiveness thereof. Immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered to birds, humans or other mammals, including ruminants, rodents or primates, by a variety of administration routes, including parenterally, intradermally, intraperitoneally, subcutaneously or intramuscularly.

Alternatively, the immunogenic, antigenic, pharmaceutical and vaccine compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic, antigenic, pharmaceutical and vaccine compositions may be administered to mucosal surfaces by, for example, the nasal, oral (intra-gastric), ocular, bronchiolar, intravaginal or intrarectal routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example, polyalkylene glycols or triglycerides. Oral formulations may include normally employed excipients such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate. These compositions can take the form of microspheres, solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders and contain about 0.001 to 95% of the PMP protein. The immunogenic, antigenic, pharmaceutical and vaccine compositions are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective or immunogenic. Preferred are compositions additionally comprising an adjuvant.

Further, the immunogenic, antigenic, pharmaceutical and vaccine compositions may be used in combination with or conjugated to one or more targeting molecules for delivery to specific cells of the immune system and/or mucosal surfaces. Some examples include but are not limited to vitamin B12, bacterial toxins or fragments thereof, monoclonal antibodies and other specific targeting lipids, proteins, nucleic acids or carbohydrates.

Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dose may also depend on the route(s) of administration and will vary according to the size of the host. The concentration of the PMP protein or PMP-derived polypeptide in an

antigenic, immunogenic or pharmaceutical composition according to the invention is in general about 0.001 to 95%.

The antigenic, immunogenic or pharmaceutical preparations, including vaccines, may comprise as the immunostimulating material a nucleic acid vector comprising at least a portion of the nucleic acid molecule encoding the PMP protein or PMP-derived polypeptide.

A vaccine comprising nucleic acid molecules encoding one or more PMP polypeptides, PMP-derived polypeptides or fusion proteins as described herein, such that the polypeptide is generated *in situ* is provided. In such vaccines, the nucleic acid molecules may be present within any of a variety of delivery systems known to those skilled in the art, including nucleic acid expression systems, bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary nucleotide sequences for expression in the patient such as suitable promoter and terminating signals. In a preferred embodiment, the nucleic acid molecules may be introduced using a viral expression system (e.g., vaccinia or other pox virus, alphavirus retrovirus or adenovirus) which may involve the use of non-pathogenic (defective) virus. Techniques for incorporating nucleic acid molecules into such expression systems are well known to those of ordinary skill in the art. The nucleic acid molecules may also be administered as "naked" plasmid vectors as described, for example, in Ulmer et al. Science 259:1745-1749 (1992) and reviewed by Cohen, Science 259:1691-1692 (1993). Techniques for incorporating DNA into such vectors are well known to those of ordinary skill in the art. A retroviral vector may additionally transfer or incorporate a gene for a selectable marker (to aid in the identification or selection of transduced cells) and/or a targeting moiety, such as a gene that encodes a ligand for a receptor on a specific target cell, to render the vector target specific. Targeting may also be accomplished using an antibody, by methods known to those skilled in the art.

Nucleic acid molecules (DNA or RNA) of the invention can be administered as vaccines for therapeutic or prophylactic purpose. Typically a DNA molecule is placed under the control of a promoter suitable for expression in a mammalian cell. The promoter can function ubiquitously or tissue-specifically. Examples of non-tissue specific promoters include the early cytomegalovirus (CMV) promoter (described in U.S. Patent No. 4,168,062) and Rous Sarcoma virus promoter (described in Norton and Coffin, Molec. Cell Biol. 5:281 (1985)). The desmin promoter (Li et al. Gene 78:243 (1989); Li & Paulin, J. Biol Chem 266:6562 (1991); and Li & Paulin, J. Biol Chem 268:10401 (1993)) is tissue

specific and drives expression in muscle cells. More generally, useful vectors are described in, *e.g.*, WO 94/21797 and Hartikka et al., Human Gene Therapy 7:1205 (1996).

A composition of the invention can contain one or several nucleic acid molecules of the invention. It can also contain at least one additional nucleic acid molecule encoding another antigen or fragment derivative, including but not limited to, DPT
5 vaccines, HMWP of *C. trachomatis*, MOMP of *C. trachomatis*, entire organisms or subunits therefrom of Chlamydia, Neisseria, HIV, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Human papilloma virus*, *Herpes simplex virus*, *Haemophilus ducreyi*, *Treponema pallidum*, *Candida albicans* and *Streptococcus pneumoniae*, etc. A nucleic acid molecule encoding a
10 cytokine, such as interleukin-1 or interleukin-12 can also be added to the composition so that the immune response is enhanced. DNA molecules of the invention and/or additional DNA molecules may be on different plasmids or vectors in the same composition or can be carried in the same plasmid or vector.

Other formulations of nucleic acid molecules for therapeutic and
15 prophylactic purposes include sterile saline or sterile buffered saline colloidal dispersion systems, such as macromolecule complexes, nanocapsules, silica microparticles, tungsten microparticles, gold microparticles, microspheres, beads and lipid based systems including oil-in-water emulsions, micelles, mixed micelles and liposomes. A preferred colloidal system for use as a delivery vehicle *in vitro* and *in vivo* is a liposome (*i.e.*, an artificial
20 vesicle). The uptake of naked nucleic acid molecules may be increased by incorporating the nucleic acid molecules into and/or onto biodegradable beads, which are efficiently transported into the cells. The preparation and use of such systems is well known in the art.

A nucleic acid molecule can be associated with agents that assist in cellular uptake. It can be formulated with a chemical agent that modifies the cellular permeability,
25 such as bupivacaine (see, *e.g.*, WO 94/16737).

Cationic lipids are also known in the art and are commonly used for DNA delivery. Such lipids include Lipofectin™, also known as DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (1,2-bis(oleyloxy)-3-(trimethylammonio)propane, DDAB (dimethyldioctadecylammonium bromide), DOGS
30 (dioctadecylamidoglycy spermine) and cholesterol derivatives such as DC-Chol (3 beta-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol. A description of these cationic lipids can be found in EP 187,702, WO 90/11092, U.S. Patent No. 5,283,185, WO 91/15501, WO 95/26356, and U.S. Patent No. 5,527,928. Cationic lipids for DNA delivery are preferably used in association with a neutral lipid such as DOPE (dioleyl
35 phosphatidylethanolamine) as described in, *e.g.*, WO 90/11092.

Other transfection facilitation compounds can be added to a formulation containing cationic liposomes. They include, *e.g.*, spermine derivatives useful for facilitating the transport of DNA through the nuclear membrane (see, for example, WO 93/18759) and membrane-permeabilizing compounds such as GALA, Gramicidine S and cationic bile salts (see, for example, WO 93/19768).

The amount of nucleic acid molecule to be used in a vaccine recipient depends, *e.g.*, on the strength of the promoter used in the DNA construct, the immunogenicity of the expressed gene product, the mode of administration and type of formulation. In general, a therapeutically or prophylactically effective dose from about 1 µg to about 1 mg, preferably from about 10 µg to about 800 µg and more preferably from about 25 µg to about 250 µg can be administered to human adults. The administration can be achieved in a single dose or repeated at intervals.

The route of administration can be any conventional route used in the vaccine field. As general guidance, a nucleic acid molecule of the invention can be administered via a mucosal surface, *e.g.*, an ocular, intranasal, pulmonary, oral, intestinal, rectal, vaginal, and urinary tract surface; or via a parenteral route, *e.g.*, by an intravenous, subcutaneous, intraperitoneal, intradermal, intra-epidermal or intramuscular route. The choice of administration will depend on the formulation that is selected. For instance a nucleic acid molecule formulated in association with bupivacaine is advantageously administered into muscles.

Recombinant bacterial vaccines genetically engineered for recombinant expression of nucleic acid molecules encoding PMP or PMP-derived polypeptides include *Shigella*, *Salmonella*, *Vibrio cholerae*, and *Lactobacillus*. Recombinant BCG and *Streptococcus* expressing PMP or PMP-derived polypeptides can also be used for prevention or treatment of *Chlamydia* infections.

Non-toxicogenic *Vibrio cholerae* mutant strains that are useful as a live oral vaccine are described in Mekalanos et al. Nature 306:551 (1983) and U.S. Patent No. 4,882,278. An effective vaccine dose of a *Vibrio cholerae* strain capable of expressing a polypeptide or polypeptide derivative encoded by a DNA molecule of the invention can be administered. Preferred routes of administration include all mucosal routes, most preferably intranasally or orally.

Attenuated *Salmonella typhimurium* strains, genetically engineered for recombinant expression of heterologous antigens or not and their use as oral vaccines are described in Nakayama et al. Bio/Technology 6:693 (1988) and WO 92/11361. Preferred routes of administration include all mucosal routes, most preferably intranasally or orally.

Other bacterial strains useful as vaccine vectors are described in High et al., EMBO 11:1991(1992); Sizemore et al., Science 270:299 (1995) (*Shigella flexneri*); Medaglini et al., Proc Natl. Acad. Sci. US 92:6868 (1995) (*Streptococcus gordonii*); and Flynn, Cell Mol. Biol. 40:31 (1994); WO 88/6626; WO 90/0594; WO 91/13157; WO 5 92/1796; and WO 02/21376 (*Bacille Calmette Guerin*).

In genetically engineered recombinant bacterial vectors, nucleic acid molecule(s) of the invention can be inserted into the bacterial genome, carried on a plasmid, or can remain in a free state.

When used as vaccine agents, recombinant bacterial vaccines, nucleic acid 10 molecules and polypeptides of the invention can be used sequentially or concomitantly as part of a multistep immunization process. For example, a mammal or bird can be initially primed with a vaccine vector of the invention such as pox virus, *e.g.*, via the parenteral route and then boosted several time with the a polypeptide *e.g.*, via the mucosal route. In another example, a mammal can be vaccinated with polypeptide via the mucosal route and 15 at the same time or shortly thereafter, with a nucleic acid molecule via intramuscular route.

An adjuvant can also be added to a composition containing a vaccine recombinant bacteria. To efficiently induce humoral immune responses (HIR) and cell-mediated immunity (CMI), immunogens are typically emulsified in adjuvants. Immunogenicity can be significantly improved if the immunogen is co-administered with an 20 adjuvant. Adjuvants may act by retaining the immunogen locally near the site of administration to produce a depot effect facilitating a slow, sustained release of antigen to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen depot and stimulate such cells to elicit immune responses.

Many adjuvants are toxic, inducing granulomas, acute and chronic 25 inflammations (Freund's complete adjuvant, FCA), cytolysis (saponins and Pluronic polymers) and pyrogenicity, arthritis and anterior uveitis (LPS and MDP). Although FCA is an excellent adjuvant and widely used in research, it is not licensed for use in human or veterinary vaccines because of its toxicity.

Immunostimulatory agents or adjuvants have been used for many years to 30 improve the host immune responses to, for example, vaccines. Intrinsic adjuvants, such as lipopolysaccharides, normally are the components of the killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Thus, adjuvants have been identified that enhance the immune response to antigens delivered 35 parenterally. Aluminum hydroxide, aluminum oxide, and aluminum phosphate (collectively

commonly referred to as alum) are routinely used as adjuvants in human and veterinary vaccines. The efficacy of alum in increasing antibody responses to diphtheria and tetanus toxoids is well established and a HBsAg vaccine has been adjuvanted with alum.

Other extrinsic adjuvants may include chemokines, cytokines (e.g., IL-2),
5 saponins complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria in mineral oil, Freund's complete adjuvant, bacterial products, such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

International Patent Application PCT/US95/09005, incorporated herein by
10 reference, describes mutated forms of heat labile toxin of enterotoxigenic *E. coli* ("mLT"). U.S. Patent No. 5,057,540, incorporated herein by reference, describes the adjuvant, QS21, an HPLC purified non-toxic fraction of a saponin from the bark of the South American tree *Quilaja saponaria molina*. 3D-MPL is described in Great Britain Patent 2,220,211, which is incorporated herein by reference.

15 U.S. Patent No. 4,855,283 granted to Lockhoff et al. on August 8, 1989, which is incorporated herein by reference, teaches glycolipid analogues including N-glycosylamides, N-glycosylureas and N-glycosylcarbamates, each of which is substituted in the sugar residue by an amino acid, as immuno-modulators or adjuvants. Lockhoff reported that N-glycosphospholipids and glycoglycerolipids are capable of eliciting strong immune
20 responses in both herpes simplex virus vaccine and pseudorabies virus vaccine. Some glycolipids have been synthesized from long chain-alkylamines and fatty acids that are linked directly with the sugars through the anomeric carbon atom, to mimic the functions of the naturally occurring lipid residues.

U.S. Patent No. 4,258,029 granted to Moloney, incorporated herein by
25 reference, teaches that octadecyl tyrosine hydrochloride (OTH) functions as an adjuvant when complexed with tetanus toxoid and formalin inactivated type I, II and III poliomyelitis virus vaccine. Lipidation of synthetic peptides has also been used to increase their immunogenicity.

Therefore, according to the invention, the immunogenic, antigenic,
30 pharmaceutical, including vaccine, compositions comprising a PMP protein, or a PMP derived polypeptide or a PMP encoding nucleic acid or fragment thereof, vector or cell expressing the same, may further comprise an adjuvant, such as, but not limited to alum, mLT, QS21, MMPL, CpG DNA, MF59, calcium phosphate, PLG and all those listed above. Preferably, the adjuvant is selected from one or more of the following: alum, QS21, CpG
35 DNA, PLG, LT, 3D-mPL, or Bacille Calmette-Guerine (BCG) and mutated or modified

forms of the above, particularly mLT and LTR192G. The compositions of the present invention may also further comprise a suitable pharmaceutical carrier, including but not limited to saline, bicarbonate, dextrose or other aqueous solution. Other suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, which is incorporated herein by reference in its entirety.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may be administered in a suitable, nontoxic pharmaceutical carrier, may be comprised in microcapsules, and/or may be comprised in a sustained release implant.

Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may desirably be administered at several intervals in order to sustain antibody levels and/or T-cell levels. Immunogenic, antigenic and pharmaceutical, including vaccine, compositions may be used in conjunction with other bacteriocidal or bacteriostatic methods.

Another embodiment of the vaccines of the present is a vaccine comprising one or more isolated PMPE or PMPI polypeptides of *Chlamydia spp.*, having a molecular weight between 90 and 115 kDa as determined in SDS polyacrylamide gel electrophoresis; or isolated nucleic acids encoding an isolated PMPE or PMPI polypeptide of *Chlamydia spp.*, having a molecular weight between 90 and 115 kDa as determined in SDS polyacrylamide gel electrophoresis, and further comprising one or more components selected from the group consisting of alum, MLT, QS21, MF59, CpG DNA, MPL, calcium phosphate and PLG.

Also included in the invention is a method of producing an immune response in an animal comprising immunizing the animal with an effective amount of one or more of the PMP polypeptides or nucleic acid molecules encoding the PMP polypeptides of the invention, compositions comprising the same and vaccines comprising the same. The PMP polypeptides, nucleic acids, compositions and vaccines comprising the PMP polypeptides of the invention may be administered simultaneously or sequentially. Examples of simultaneous administration include cases in which two or more polypeptides, nucleic acids, compositions, or vaccines, which may be the same or different, are administered in the same or different formulation or are administered separately, *e.g.*, in a different or the same formulation but within a short time (such as minutes or hours) of each other. Examples of sequential administration include cases in which two or more polypeptides, nucleic acids, compositions or vaccines, which may be the same or different, are not administered together or within a short time of each other, but may be administered separately at intervals of, for example, days, weeks, months or years.

5 The polypeptides, nucleic acid molecules or recombinant bacterial vaccines
of the present invention are also useful in the generation of antibodies, as described *supra*,
or T-cells. For T-cells, animals, including humans, are immunized as described above.
Following immunization, PBL (peripheral blood lymphocytes), spleen cells or lymph node
10 cells are harvested and stimulated *in vitro* by placing large numbers of lymphocytes in
flasks with media containing human serum. A polypeptide of the present invention is added
to the flasks, and T-cells are harvested and placed in new flasks with X-irradiated peripheral
blood mononuclear cells. The polypeptide is added directly to these flasks, and cells are
grown in the presence of IL-2. As soon as the cells are shown to be *Chlamydia* specific T-
15 cells, they are changed to a stimulation cycle with higher IL-2 concentrations (20 units) to
expand them.

Alternatively, one or more T-cells that proliferate in the presence of a
polypeptide of the present invention can be expanded in number by cloning.
Methods for cloning cells are well known in the art. For example, T-cell lines may be
15 established *in vitro* and cloned by limiting dilution. Responder T-cells are purified from the
peripheral blood established in culture by stimulating with the nominal antigen in the
presence of irradiated autologous filler cells. In order to generate CD4⁺ T-cell lines, the
Chlamydia polypeptide is used as the antigenic stimulus and autologous PBL or
lymphoblastoid cell lines (LCL) immortalized by infection with Epstein Barr virus are used
20 as antigen presenting cells. In order to generate CD8⁺ T-cell lines, autologous antigen-
presenting cells transfected with an expression vector which produces the relevant
Chlamydia polypeptide may be used as stimulator cells. T-cell lines are established
following antigen stimulation by plating stimulated T-cells in 96-well flat-bottom plates
with PBL or LCL cells and recombinant interleukin-2 (rIL2) (50 U/ml). Wells with
25 established clonal growth are identified at approximately 2-3 weeks after initial plating and
restimulated with appropriate antigen in the presence of autologous antigen-presenting cells,
then subsequently expanded by the addition of low doses of IL2. T-cell clones are
maintained in 24-well plates by periodic restimulation with antigen and IL2 approximately
every two weeks.

30 T-cell preparations may be further enriched by isolating T-cells specific for
antigen reactivity using the methods disclosed by Kendricks et al. in U.S. Patent No.
5,595,881.

The vaccine compositions of the present inventions are useful in preventing,
treating or ameliorating disease symptoms in an animal with a disease or disorder associated
35 with *Chlamydia* infection. Such diseases or disorders include, but are not limited to,

Chlamydia bacterial infection, conjunctivitis, urethritis, lymphogranuloma venereum (LGV), cervicitis, epididymitis, salpingitis, tubal occlusion, infertility, cervical cancer, reactive arthritis, arteriosclerosis and atherosclerosis.

5 5.8 IMMUNOASSAYS AND DIAGNOSTIC REAGENTS

The PMP protein, PMP-derived polypeptide or nucleic acid encoding same, and fragments thereof, are useful as diagnostic reagents. Use of the proteins and nucleic acids of the invention as an antigen or immunogen for the generation of anti-PMP protein antibodies or as an antigen in immunoassays including enzyme-linked immunosorbent
10 assays (ELISA), radioimmunoassays (RIA) and other non-enzyme linked antibody binding assays or procedures known in the art for the detection of anti-bacterial, anti-*Chlamydia*, and anti-PMP protein antibodies are encompassed by the invention.

ELISA is well-known and routine in the art. Generally, in ELISA, the PMP protein is immobilized onto a selected surface, for example, a surface capable of binding
15 proteins such as the wells of a polystyrene microtiter plate. After washing to remove incompletely absorbed PMP protein, a nonspecific protein solution that is known to be antigenically neutral with regard to the test sample may be bound to the selected surface. This allows for blocking of nonspecific absorption sites on the immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex
20 (antigen/antibody) formation. This may include diluting the sample with diluents, such as solutions of bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from 2 to 4 hours, at temperatures on the order
25 of about 20°C to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound PMP protein, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be
30 determined by subjecting the immunocomplex to a second antibody having specificity for the first antibody. If the test sample is of human origin, the second antibody is an antibody having specificity for human immunoglobulins and in general IgG.

To provide detecting means, the second antibody may have an associated activity such as an enzymatic activity that will generate, for example, a color development
35 upon incubating with an appropriate chromogenic substrate. Detection may then be

achieved by detecting color generation. Quantification may then be achieved by measuring the degree of color generation using, for example, a visible spectrophotometer and comparing to an appropriate standard. Any other detecting means known to those skilled in the art are included.

5 In Western blot assays, the polypeptide, either as a purified preparation or a cell extract, is subjected to SDS-PAGE electrophoresis, for example, as described by Laemmli, Nature 227:690 (1970) or any other method known in the art. After transfer to a nitrocellulose membrane, the material is further incubated with the serum sample, polyclonal antibody preparation, or monoclonal antibody diluted in the range of from about
10 1:5 to 1:5000, preferably from about 1:100 to about 1:500, depending upon the titer and specification of the antibodies. Appropriate dilutions can be readily determined by methods known in the art. The reaction is revealed according to standard procedures. For example, when human antibody is used, the membrane is incubated in a goat anti-human peroxidase conjugate for an appropriate length of time. The membrane is washed. The reaction is
15 developed with the appropriate substrate and stopped. The reaction is measured visually by the appearance of a colored band *e.g.*, by colorimetry.

In a dot blot assay, the purified or partially purified polypeptide or cell extract can be used. Briefly, a solution of the antigen at about 100 µg/ml is serially two-fold diluted in 50m M Tris-HCl (pH 7.5). 100 µl of each dilution is applied to a 0.45 µm
20 nitrocellulose membrane set in a 96-well dot blot apparatus. The buffer is removed by applying vacuum to the system. Wells are washed by addition of 50µM Tris-HCl (pH 7.5) and the membrane is air-dried. The membrane is saturated in block buffer (50m M Tris-HCl (pH 7.5), 0.15 M NaCl and 10 g/L skim milk) and incubated with an antiserum dilution from about 1:50 to about 1:500. The reaction is revealed according to standard procedures.
25 For example, a goat anti-rabbit peroxidase conjugate is added to the well when rabbit antibodies are used. Incubation is carried out 90 minutes at 37°C and the blot is washed. The reaction is developed with the appropriate substrate and stopped. The reaction is measured visually by the appearance of a colored spot, *e.g.*, by colorimetry.

The PMP proteins, PMP-derived polypeptides or nucleic acids encoding
30 same, and fragments thereof, are also useful as antigens or immunogens for the generation of anti-PMP protein T-cell response or as an antigen in immunoassays, including T-cell proliferation assays, cytokine production, delayed hypersensitivity reactions or cytotoxic T-cells (CTL) reactions.

For analysis of *Chlamydia* peptide specific T-cell proliferative responses,
35 fresh peripheral blood, spleen or lymph node cells are harvested. Cells are plated into 96-

well round bottom microtiter plates and are incubated with peptides. Data is expressed as a stimulation index (SI) which is defined as the mean of the number of cells in experimental wells divided by the mean of the number of cells in control wells (no antigen).

For analysis of cytokine release of T-cells in response to *Chlamydia* polypeptides, responder cells are mixed with polypeptides. Supernatants are collected and added to an ELISA coated with antibody to the cytokine (e.g., anti-IFN- α or anti-IL-2 antibody). After washing, rabbit anti-cytokine polyclonal antibody (e.g., anti-IFN- α or anti-IL-2) is added. Labeled goat anti-rabbit IgG polyclonal is added. Substrate is added and the amount of cytokine released into the supernatant is determined based upon the amount of color developed in the ELISA.

Another embodiment includes diagnostic kits comprising all of the essential reagents required to perform a desired immunoassay according to the present invention. The diagnostic kit may be presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents. Such a kit may comprise PMP protein, PMP-derived polypeptide or nucleic acid encoding same, or a monoclonal or polyclonal antibody of the present invention, in combination with several conventional kit components. Conventional kit components will be readily apparent to those skilled in the art and are disclosed in numerous publications, including, for example, Harlow and Lane, Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1988) which is incorporated herein by reference in its entirety. Conventional kit components may include such items as, for example, microtiter plates, buffers to maintain the pH of the assay mixture (such as, but not limited to Tris, HEPES, etc.), conjugated second antibodies, such as peroxidase conjugated anti-mouse IgG (or any anti-IgG to the animal from which the first antibody was derived) and the like, and other standard reagents.

The nucleic acid molecules containing the PMP encoding sequences of the present invention may be used in combination with an appropriate indicator means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin and digoxigenin-labeling, which are capable of providing a detectable signal. In some diagnostic embodiments, an enzyme tag, such as urease, alkaline phosphatase or peroxidase, instead of a radioactive tag, may be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with samples containing PMP protein gene sequences.

Probes of the invention can be used in diagnostic tests, as capture or detection probes. Such capture probes can be conventionally immobilized on a solid support directly or indirectly, by covalent means or by passive adsorption. A detection probe can be labeled by a detection marker selected from radioactive isotopes, enzymes, such as peroxidase, alkaline phosphatase, and enzymes able to hydrolyze a chromogenic, fluorogenic or luminescent substrate; compounds that are chromogenic, fluorogenic or luminescent; nucleotide base analogs; and biotin.

Probes of the invention can be used in any conventional hybridization techniques, such as dot blot (Maniatis et al., Molecular Cloning: A Laboratory Manual (1982) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 1982), Southern blot (Southern, J. Mol. Biol. 98:503 1975), northern blot (identical to Southern blot to the exception that RNA is used as a target), or sandwich techniques (Dunn et al., Cell 12:23 1977).

In embodiments involving solid-phase procedures, the test DNA (or RNA) from samples, such as clinical samples, including exudates, body fluids (*e.g.*, serum, amniotic fluid, middle ear effusion, sputum, semen, urine, tears, mucus, bronchoalveolar lavage fluid) or even tissues, is absorbed or otherwise affixed to a selected matrix or surface. The fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes comprising the nucleotide sequences encoding a PMP protein, or fragments or analogues thereof, under desired conditions. The selected conditions will depend on the particular criteria required and on, for example, the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc. Following washing of the hybridization surface so as to remove non-specifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label. It is preferred to select nucleotide acid sequence portions that are conserved among species of *Chlamydia*. The selected probe may be at least 15 bp and may be in the range of about 30 to 90 bp.

The invention also relates to methods for identifying compounds which interact with and inhibit or activate an activity of the polypeptides or nucleic acid molecules of the invention comprising contacting a composition comprising the polypeptide or the nucleic acid molecule with the compound to be screened under conditions that permit interaction between the compound and the polypeptide or nucleic acid molecule to assess the interaction of a compound and to detect interaction of the compound with the polypeptide or nucleic acid. The interaction of the compound with the polypeptide or nucleic acid molecule is determined by the association of a second component (*e.g.*, an

antibody) capable of providing a detectable signal in response to the interaction of the polypeptide or nucleic acid molecule with the compound; and determining the presence or absence of a signal generated from the interaction of the compound with the polypeptide or nucleic acid molecule. Alternatively, the interaction of the compound with the polypeptide or nucleic acid molecule is determined by the ability of the compound to inhibit the activity of the polypeptide or the nucleic acid molecule.

5.9 APPLICATIONS

The proteins, polypeptides, peptides, antibodies, T-cells and nucleic acids of the invention are useful as reagents for clinical or medical diagnosis of *Chlamydia* infections and for scientific research on the properties of pathogenicity, virulence, and infectivity of *Chlamydia*, as well as host defense mechanisms. For example, DNA and RNA of the invention can be used as probes to identify the presence of *Chlamydia* in biological specimens by hybridization or PCR amplification. The DNA and RNA can also be used to identify other bacteria that might encode a polypeptide related to the *Chlamydia* PMP protein. The proteins of the invention may be used to prepare polyclonal and monoclonal antibodies that can be used to further purify compositions containing the proteins of the invention by affinity chromatography or for use as diagnostic or as prophylactic or therapeutic agents. The proteins can also be used in standard immunoassays to screen for the presence of antibodies or T-cells to *Chlamydia* in a biological sample.

5.10. BIOLOGICAL DEPOSITS

Certain plasmids that contain portions of the gene having the open reading frame of the PMP genes encoding the PMP proteins of the present invention have been inserted into *E. coli* and deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., pursuant to the Budapest Treaty and pursuant to 37 CFR 1.808 and prior to the filing of this application. The identifications of the respective portions of the genes present in these plasmids are shown below.

Samples of the deposited materials will become available to the public upon grant of a patent based upon this United States patent application. The invention described and claimed herein is not to be limited by the scope of the plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent

or similar plasmids that encode similar or equivalent proteins or fragments or analogues thereof as described in this application are within the scope of the invention.

	<u>Plasmid</u>	<u>ATCC Accession No.</u>	<u>Date Deposited</u>
5	M15 pREP (pQE-pmpE)#37	ATCC PTA-2462	Sept. 12, 2000
	TOP10(pBAD-pmpI-Ct-Uni)#7	ATCC PTA-2461	Sept. 12, 2000

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples.

10 These examples are described solely for purposes of illustration and not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein such terms are intended in a descriptive sense and not for purposes of limitation.

15

6. EXAMPLES

The above disclosure generally describes the present invention. The examples are described solely for the purpose of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as
20 circumstances suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in the disclosure and examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

25

6.1 EXTRACTION OF ENVELOPE PROTEINS

McCoy cells are cultured either in standard 225 cm² tissue culture flasks or in Belco spinner flasks (Cytodex microcarrier, Pharmacia) at 37°C in 5% CO₂ using DMEM media supplemented with 10% *Chlamydia*-antibody-free fetal bovine serum,
30 glucose and nonessential amino acids. *C. trachomatis*, including but not limited to the L2 serovar (ATCC VR-902B), elementary bodies (EBs) are prepared from lysates of infected McCoy cells. Basically, McCoy cells infected with *C. trachomatis* are sonicated and cellular debris is removed by centrifugation. The supernatant containing Chlamydial EBs is then centrifuged and the pellet containing the EBs is resuspended in Hanks' balanced salts
35 solution (HBSS). RNAase/DNAase solution is added and incubated at 37°C for 1 hour

with occasional mixing. The EB containing solution is layered onto a discontinuous density gradient (40%, 44% and 54%) of Renogratin-60 (mixture of diatrizoate melgumine and diatrizoate sodium, Bracco Diagnostics, Princeton, NJ) and ultracentrifuged for separation of the EBs on the gradient. After centrifugation, the EBs are harvested from the gradient
5 between the interface of the 44% and 54% layers. The EBs are washed in phosphate buffered saline and resuspended in HBSS.

Purified EBs are sequentially extracted with 0.1% OGP [high ionic strength] in HBSS to remove peripheral surface proteins and held on ice. The same EB preparation is then extracted with 1.0% OGP, 10 mM DTT, 1 mM PMSF, and 10 mM EDTA, in a 50 mM
10 Tris pH 7.4 buffer. The extracts are dialyzed (3500 molecular weight cut off) to remove detergent and other reagents and are concentrated by lyophilization. Eluents are dialyzed to remove excess detergent and then lyophilized. Envelope proteins are size fractionated by SDS-PAGE and visualized by silver staining or analyzed by Western blotting. Protein(s) of about 90-115 kDa present in moderate amounts are detected in the gel.

15

6.2 AMINO TERMINAL SEQUENCING OF PMP POLYPEPTIDE

To obtain the N-terminal amino acid sequence, sufficient quantities of the PMPE or PMPI protein ($\geq 5 \mu\text{g}$) are electroblotted onto a PVDF membrane (Applied Biosystems), and stained with Coomassie blue. Immobilized protein is released from the
20 membrane and treated *in situ* with low levels of endopeptidase Lys-C, endopeptidase Arg-C and/or endopeptidase Glu-C to fragment the native protein. The resulting peptide fragments are purified by HPLC and their N-terminal amino acid sequences are determined using an ABI 430 Protein Sequenator and standard protein sequencing methodologies.

25 6.3. DETERMINATION OF POST-TRANSLATIONAL MODIFICATIONS

Recently, several *C. trachomatis* membrane-associated proteins have been shown to be post-translationally modified. The 18 kDa and 32 kDa cysteine-rich EB proteins, which are lectin-binding proteins, have been shown to carry specific carbohydrate moieties (Swanson et al. 1990. Infect. Immun. 58:502-507). Incorporation of radiolabeled
30 palmitic acid has been used to demonstrate that the about 27 kDa *C. trachomatis* Mip-like protein is lipidated (Lundemose et al. 1993. J. Bacteriol. 175:3669-3671). Swanson et al. have discovered that the MOMP from the L2 serovar contains N-acetylglucosamine and/or N-acetylgalactosamine and these carbohydrate moieties mediate binding of MOMP to Hela cell membranes.

35

To ascertain whether the PMPE or PMPI protein is glycosylated, EBs are grown on McCoy cells in the presence of tritiated galactose or glucosamine and analyzed by SDS-PAGE and autoradiography. Briefly, McCoy cells are grown in T225 flasks under standard conditions (DMEM + 10% FCS, 35 ml per flask, 10% CO₂) to about 90% confluency and inoculated with sufficient EBs to achieve 90%-100% infectivity. Following a 3 hour infection period at 37°C cycloheximide is added (1 µg/ml) to inhibit host cell protein synthesis and the cultures reincubated for an additional 4-6 hours. Approximately 0.5 mCi of tritiated galactose (D-[4,5-³H(N)]galactose, NEN) or glucosamine (D- [1,6-³H(N)]glucosamine, NEN) is then be added to each flask and the cultures allowed to incubate for an additional 30-40 hours. Cells are harvested by scraping, and EBs purified by gradient centrifugation. PMPE or PMPI protein is isolated from 1.0% OGP surface extracts, eluted with NaCl and analyzed by SDS-PAGE using ¹⁴C-labeled molecular weight markers (BRL). The resulting gel is dried and subjected to autoradiography by exposure for 1-4 weeks to Kodak X-AR film at -70°C.

To determine post synthesis lipid modification, *C. trachomatis* is cultivated on monolayers of McCoy cells according to standard procedures. Approximately 24 hours postinfection, conventional culture media (DMEM + 10% FCS) is removed and replaced with a serum-free medium containing cycloheximide (1 µg/ml) and [U-¹⁴C]palmitic acid (0.5 mCi/T225 flask, NEN) and incubated for a further 16-24 hours to allow protein lipidation to occur. Surface EB extracts are prepared and analyzed by autoradiography as described above.

6.4 ANTI-PMPE or Anti-PMPI ANTISERUM

Antisera to PMPE or PMPI polypeptides are prepared by injecting the PMPE or PMPI polypeptide into an animal, such as a rabbit, mouse or guinea pig, with or without an adjuvant by any method generally known to those skilled in the art. For instance, PMPE is injected with Freund's complete adjuvant followed by injections of PMPE with Freund's incomplete adjuvant. Normally, a semi-purified or purified form of the protein is injected. For instance, the PMPE polypeptide is resolved from other proteins using SDS-PAGE according to standard techniques well known to those skilled in the art, as previously described (Laemmli, 1970, Nature 227:680-685), and cutting the PMPE-containing band out of the gel. The excised band containing PMPE is macerated and injected into an animal to generate antiserum to the PMPE polypeptide. The antisera is examined using well known and generally accepted methods of ELISA to determine titer, Western blots to

determine binding to proteins, and for immunofluorescent staining and for complement-mediated cytotoxic activity against *Chlamydia*.

To aid in the characterization of the PMPE or PMPI protein, hyperimmune rabbit antisera is raised against whole EBs from *C. trachomatis*. Each animal is given a total of three immunizations of about 250 µg *Chlamydia* EBs per injection (beginning with the EBs mixed with complete Freund's adjuvant and followed with EBs mixed with incomplete Freund's adjuvant) at approximately 21 day intervals. At each immunization, approximately half of the material is administered intramuscularly (i.m.) and half is injected intranodally. Fourteen days after the third vaccination, a fourth booster of about 100 µg of EBs is given i.m. and the animals exsanguinated 7-10 days later.

6.5 ELISA

Anti-PMPE or anti-PMPI antibody titers are measured by ELISA using purified PMPE or PMPI protein (~1 µg/well) or *C. trachomatis* EBs (whole or crude protein extracts) or cells infected with *Chlamydia* as capture ligands by any method known by those skilled in the art. Serial dilutions of antisera are made in PBS and tested by ELISA in duplicate. HRP-conjugated antibody is diluted and used as the second reporter antibody in these assays. Titers are expressed as the greatest dilution showing positive ELISA reaction, i.e., an O.D. 450 value >2SD above the mean negative control value (pre-bleed rabbit sera).

6.6 WESTERN BLOTS

Chlamydia trachomatis is grown in McCoy cells and *Chlamydia* cell lysates are prepared as described in section 6.1, *supra*. The solubilized cells are resolved on 12% polyacrylamide gels and the separated proteins were electrophoretically transferred to PVDF membranes at 100 V for 1.5 hours as previously described (Thebaine et al. 1979, Proc. Natl. Acad. Sci. USA 76:4350-4354). The PVDF membranes are then pretreated with 25 ml of Dulbecco's phosphate buffered saline containing 0.5% sodium casein, 0.5% bovine serum albumin and 1% goat serum. All subsequent incubations are carried out using this pretreatment buffer.

PVDF membranes are incubated with 25 ml of a dilution of preimmune rabbit serum or serum from a rabbit immunized with PMPE or PMPI polypeptide (as described above) for 1 hour at room temperature or with monoclonal antibodies to PMPE or PMPI. PVDF membranes are then washed twice with wash buffer (20 mM Tris buffer [pH 7.5.] containing 150 mM sodium chloride and 0.05% Tween-20). PVDF membranes are

incubated with 25 ml peroxidase-labeled goat anti-rabbit (or anti-mouse for monoclonals) IgG (Jackson ImmunoResearch Laboratories, West Grove, PA.) for 30 minutes at room temperature. PVDF membranes are then washed 4 times with wash buffer, and are developed with 3,3'diaminobenzidine tetra-hydrochloride and urea peroxide as supplied by Sigma Chemical Co. (St. Louis, Mo.; catalog number D-4418) for 4 minutes each.

Hyperimmune antisera or monoclonal antibody is used to probe Western blots of crude EB or RB extracts as well as 1.0% OGP EB extract preparations to identify PMPE or PMPI polypeptides from other *C. trachomatis* serovars and *Chlamydia* species. Lysates from *C. trachomatis* A, B, Ba, C, D, Da, E, F, G, H, I, Ia, J, K, L1, L2, L3, or MoPn serovars or *Chlamydia pneumoniae* are electrophoresed to identify proteins reactive with antisera generated against PMPE or PMPI protein.

6.7 CELLULAR ENVELOPE LOCATION OF PMPE AND PMPI

Surface localization of the PMPE or PMPI protein on different *Chlamydia* strains and derivatives is examined by indirect fluorescence antibody (IFA). IFA is performed using the procedures generally known by those skilled in the art using hyperimmune anti-PMPE or PMPI protein as the primary antibody. Hak cells infected with whole EBs from *C. trachomatis* are achieved by the following method.

McCoy or Hak cells are grown to confluence in D-MEM media on 12 mm plain coverslips inside 24 well tissue culture plates then centrifugally inoculated with $\sim 5 \times 10^4$ inclusion forming units (IFU) of the *C. trachomatis*. After ~ 24 hours incubation, the culture media is removed and infected cells fixed in methanol for 10 min. The fixed monolayer is then washed with PBS (1X) to remove fixative and overlaid with $>300 \mu\text{l}$ of anti-PMPE or PMPI rabbit antibody that has been diluted in PBS. After 1 hour incubation with the primary antibody, the cells are washed gently with PBS then incubated for ~ 30 minutes with mouse anti-rabbit IgG antibody conjugated with FITC. The second antibody is diluted using a PBS solution containing 0.0091% Evans Blue as a counter stain to visualize the monolayer. Cells are washed 2X in PBS to remove the secondary antibody, the coverslips are removed from the culture plates, and mounted onto microscope slides using a fluorescent mounting medium.

Identical cell samples are stained with pre-bleed rabbit antibody or FITC-conjugated second antibody alone are processed in parallel and served as antibody specificity (negative) controls. Counterstained samples are examined at a 1000-X magnification with a Zeiss Axioskop photomicroscope equipped with plan-neofluar objectives.

6.8 PROPERTIES OF PMPE and PMPI POLYPEPTIDES

PMPE polypeptide exists as a protein of approximately 90-115 KDa in its native state as determined via Western blots of crude EB or RB extracts of *Chlamydia*, as described in Section 6.1. PMPI polypeptide exists as a protein of approximately 90-115 KDa in its native state as determined via Western blots of crude EB or RB extracts of *Chlamydia*.

The isoelectric point of the PMPE protein is about 7.17. The isoelectric point of the PMPI protein is about 6.36.

6.9 VACCINE EFFICACY

An *in vitro* neutralization model using methods generally known to those skilled in the art is used to show that protective antiserum inhibits Chlamydial infection (neutralization) of various tissue culture cell lines. Animal models are also essential for testing vaccine efficacy with both small animal (non-primate) and primate models necessary for preclinical evaluation. The guinea-pig is used for studying experimental ocular and genital infection by the Guinea-pig inclusion conjunctivitis agent (GPIC), *C. psittaci*.

The mouse offers a consistent and reproducible model of genital tract infection using human genital tract isolates. This mouse model is a generally accepted pre-clinical assay and was used to evaluate MOMP as a subunit vaccine. Another model is known as the primate model of trachoma infection wherein the induction of secretory IgA was shown to be a prime component of protection. Vaccinogenic ability of new subunit antigen candidates is determined using the above-mentioned generally accepted *in vitro* neutralization and animal model systems.

6.9.1 IN VITRO NEUTRALIZATION MODEL

As a preliminary exercise to the animal protection studies, hyperimmune anti-PMPE or PMPI antibody is evaluated for its ability to block the infectivity of various *C. trachomatis* serovars (e.g., L2, B, F) *in vitro*. Although McCoy cells are used to propagate *Chlamydia*, these cells also allow antibody-mediated uptake via Fc receptors. Therefore, to evaluate anti-PMPE or anti-PMPI antibody inhibition of infectivity, Hak cells, which do not display Fc receptors, are used in these analyses.

Cells are grown on coverslips in 24-well plates to a subconfluent monolayer (about 90% confluency = 1×10^5 cells/ml) at 37°C in 5% CO₂. Anti-PMPE or PMPI antibody is diluted to about 100 µg/ml (total protein) in sucrose-phosphate-glutamate (SPG)

buffer and then serially diluted in SPG buffer. Frozen aliquots of pretitered *Chlamydia* EBs are diluted in SPG buffer to about 2×10^4 IFU (inclusion forming units)/ml. EBs are premixed with the diluted anti-PMPE or PMPI antibody and incubated 30 minutes at 37°C on a rocking platform.

- 5 Prepared Hak cells are washed in HBSS and then incubated with the anti-PMPE or PMPI antibody/*Chlamydia* EB mixture in triplicate for each antibody using ~500 IFU/ml. Plates are centrifuged at ~500 rpm at room temperature for 1 hour then incubated for 2 hours at 37°C or are incubated for 2 hours at 37°C without prior centrifugation to allow EB infection of the monolayer. Then the inoculum is removed and plates washed 3
10 times with HBSS. Tissue culture media containing 1 µg/ml of cycloheximide is added and plates incubated for about 24-48 hours at 37°C in 5% CO₂ to allow inclusion bodies to develop. After incubation, the media is removed and cell monolayers washed 3X in PBS. Plates are fixed in methanol for 20 minutes and re-washed in PBS.

- Cells are stained to visualize inclusions by incubating with anti-*Chlamydia*
15 LPS antibody (diluted about 1:500), washed 3 times in PBS, followed by incubation with FITC-conjugated goat secondary antibody for 30 minutes at 37°C. Coverslips are washed, air dried, and mounted in glycerol on glass slides. Inclusions are counted in five fields through the midline of the coverslip on a Zeiss fluorescence photomicroscope. Results are reported as the percent reduction of inclusion-containing cells with respect to a
20 heterogenous antibody control (rabbit pre-bleed sera).

6.9.2 VACCINE EFFICACY (MOUSE MODEL OF SALPINGITIS AND FERTILITY)

IMMUNIZATION AND CHALLENGE

- 25 The Tuffrey murine infertility model is employed to evaluate the efficacy of rPMPE or rPMPI to protect animals against *Chlamydia trachomatis*-induced salpingitis and infertility. Three groups of female C3HeOuJ mice (6 weeks of age, Jackson Labs) are employed for this evaluation. The test group is immunized (*e.g.*, intradermally, intraperitoneal, subcutaneously, intramuscularly, or mucosally) by administration of a
30 vaccine formulation containing approximately 10-100 µg of purified rPMPE or rPMPI and adjuvant. For instance, mice that are immunized intranasally are sedated using an anesthesia cocktail consisting of 16% Ketaject and 16% Xlaject in 68% pyrogen-free PBS (100 µl) i.p./animal. Sedated animals are placed on their backs and using a standard laboratory pipette administered the vaccine formulations; approximately 10 µl of the
35 vaccine solution per nostril with a 5-10 minute wait period between applications.

Two groups of female mice are immunized similarly but with a preparation containing adjuvant only, no antigen. One of these groups is subsequently challenged with *C. trachomatis* (sham immunized, infected) and serves as the negative fertility control while the other group is not challenged (sham immunized, sham infected) and serves as the positive fertility control.

At week 4, all animals are administered a single i.p. dose of progesterone (2.5 mg in pyrogen-free PBS, Depo-Provera, Upjohn) to stabilize the uterine epithelium. At week 5, animals immunized with rPMPE or rPMPI and animals in the negative control group are infected by bilateral intrauterine inoculation with approximately 5×10^5 IFU of *C. trachomatis* (including but not limited to, from serovar F, strain NI1) in 100 μ l of sucrose phosphate glutamate buffer (SPG). To mimic the manipulations to the reproductive tract experienced by the other groups, animals in the positive control are bilaterally inoculated with 100 μ l of a McCoy cell extract that contains no *C. trachomatis*. At week 7, animals from each group are sacrificed by CO₂ asphyxiation and the complete genital tract (both upper and lower reproductive tracts) are removed for histopathological analysis. At week 9, the remaining females from each group are caged with 8-10 week old male C3H mice for a 2 month breeding period to assess fertility (1 male for every 2 females per cage with weekly rotation of the males within each group, animals from different experimental groups were not mixed). Palpation and periodic weighing are used to determine when animals in each pair become pregnant. The parameters used to estimate group fertility are: F, the number of mice which littered at least once during the mating period divided by the total number of mice in that study group; M, the number of newborn mice (born dead or alive) divided by the number of litters produced in that group during the mating period; and N, the number of newborn mice (born dead or alive) divided by the total number of mice in that group.

HISTOPATHOLOGY

Genital tracts are treated for > 24 hours in Bouin's fixative, progressively dehydrated in 50%, 70% and 100% methanol, soaked in toluol, and either paraffin embedded or directly embedded in OCT compound (Tissue-TEK, Miles) and subsequently snap frozen in liquid nitrogen. Tissue sections (approximately 6 μ m) are stained with hematoxylin and eosin (after deparaffinization of the Bouin fixed samples). Inflammatory changes in the oviducts and ovaries are graded as follows: 0, no apparent inflammatory reaction; 1, a few mononuclear cells infiltrating the periovarial space or the submucosa of the oviduct; 2, same as 1 but to a greater extent; 3, same as 2 but with a thickened oviductal submucosa and the presence of inflammatory cells in the oviductal lumen; 4, same as 3 but

to a greater extent. Inflammation in the cervix/vagina is scored based on the level of the intraepithelial infiltrate observed.

DETERMINATION OF rPMPE or rPMPI SPECIFIC HUMORAL RESPONSES

Blood samples are collected periodically during the immunization and challenge phases by retroorbital bleeding and serum prepared by centrifugation. Vaginal secretions are collected by repeated injection of 50-100 µl of sterile PBS into the vagina with a standard laboratory pipetter and immediately withdrawing the solution. Two to three injection/withdrawal cycles are performed.

Quantitation of antibody (Ab) responses by ELISA are performed as described in Section 6.5. Microwell ELISA plates (Maxisorb, NUNC) for determining antibody levels are coated overnight at 4°C with ~0.5-1.0 µg of purified rPMPE or rPMPI per well in 10 mM carbonate/bicarbonate buffer (pH 9.6), washed with PBS containing 0.1% Tween-20 (washing buffer) and blocked for ~1 hr at 37°C with a PBS solution containing 3% BSA. For the determination of antigen-specific serum IgG levels, test sera or vaginal secretions are serially diluted in washing buffer containing 0.5% BSA and aliquots (100 µl) incubated in the antigen-coated wells for ~2 hr at 37°C. The plates are then washed and incubated for ~1 hr at 37°C with a horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG second antibody (Sigma). A HRP-conjugated goat anti-mouse IgA secondary antibody is used to detect the presence of rPMPE or rPMPI specific IgA in serum or vaginal secretions. After incubation with the appropriate secondary Ab, the plates are washed and incubated for ~20-30 minutes at room temperature with TMB substrate (Sigma). Reactions are stopped by the addition of 2M H₂SO₄ and the absorbance determined at 450 nm on a Molecular Devices SpectroMax microplate reader. Titers are determined as the reciprocal of the sample dilution corresponding to an optical density of 1.0 at 450 nm.

DETERMINATION OF rPMPE or rPMPI SPECIFIC CELLULAR RESPONSES

Groups of mice are immunized with rPMPE or rPMPI plus adjuvant vaccine as described above. At week 5, animals from each group are sacrificed by CO₂ asphyxiation, spleens removed and single cell suspensions prepared using conventional methodologies. For cellular assessment, animals are not treated with hormone. For both the positive control group (sham immunized and sham infected) and the negative control group (sham immunized, infected), spleen cells are pooled and tested for restimulation.

For the measurement of spleen cell proliferation, spleens are ground (5 to 10 rounds) in 5 ml RPMI 1640 Glutamax I supplemented with 10% fetal calf serum, 25 mM

HEPES, 50 U/ml penicillin, 50 µg/ml streptomycin, 1 mM sodium pyruvate, nonessential amino acids, and 50 mM 2-mercaptoethanol (Gibco-BRL). Live cells are counted by Trypan Blue staining and diluted in the same media to reach a density of $1.0 - 2.0 \times 10^6$ cells/ml (Falcon 2063 polypropylene tubes). Triplicate cultures are set-up in round bottom
5 96-well culture plates (Nunc, Nunc) using $\sim 5 \times 10^5$ responder cells per well in 200 µl of media. Cells are stimulated with rPMPE or rPMPI (antigen-specific proliferation) or with concanavalin A (Boehringer Mannheim) as a positive stimulation control; unstimulated cell cultures are used as a negative control of cellular activation. After 72-96 hours of incubation at 37°C in 5% CO₂, cells are pulsed labeled for ~18 hrs with 1.0 Ci ³H-
10 thymidine (Amersham) per well. Pulsed cells are harvested onto glass-fiber sheets using a Tomtec Cell Harvester (Mk III) and counted for beta-emission in a 3-channel Wallac 1450 Trilux Liquid Scintillation Counter. The stimulation index (SI) for a sample (individual or pooled) is defined as the mean of the antigen or ConA-stimulated T-cell uptake of ³H-thymidine for triplicate wells divided by the mean of the unstimulated uptake for triplicate
15 wells. SIs for both antigen-specific (rPMPE or rPMPI-specific) and ConA-specific proliferation are determined.

Results presented in Figure 7 demonstrate that animals immunized with recombinant PMPE protein develop a strong and uniform antigen-specific T-cell proliferative response. These data also show that T-cells from animals immunized with
20 recombinant PMPE recognize and are strongly stimulated by the infectious EB form of *C. trachomatis*.

6.10 ISOLATION OF *C. TRACHOMATIS* CHROMOSOMAL DNA

Chlamydia trachomatis were grown as described supra in Section 6.1. Gradient
25 purified EBs were suspended in ~5.0 ml of sterile water. An equal volume of lysis buffer (200 mM NaCl, 20 mM EDTA, 40 mM Tris-HCl pH 8.0, 0.5% (w/v) SDS, 0.5% (v/v) 2-mercaptoethanol, and 250 µg/ml of proteinase K) was added and the cells suspended by gentle agitation and trituration. The cell suspension was then incubated ~12 hours at 50°C to lyse the EBs and liberate chromosomal DNA. Proteinaceous material was precipitated by
30 the addition of 5.0 ml of saturated NaCl (~6.0 M, in sterile water) and centrifugation at ~5,500 X g in a Sorval SS34 rotor at room temperature. Chromosomal DNA was precipitated from the cleared supernatant by the addition of two volumes of 100% ethanol. Aggregated DNA was collected and washed using gentle agitation in a small volume of a 70% ethanol solution. Purified chromosomal DNA was suspended in sterile water and
35 allowed to dissolve/disburse overnight at 4°C by gentle rocking. The concentration of

dissolved DNA was determined spectrophotometrically at 260nm using an extinction coefficient of 1.0 O.D. unit ~50 µg/ml.

6.11 PCR CLONING OF THE PMPE ORF

- 5 To produce high levels of recombinant PMPE protein for immunogenicity and protective efficacy studies, the PMPE ORF was PCR cloned into an *E. coli* high expression vector, pQE-30 (QiaGen). Genes cloned into the pQE-30 vector are expressed from a T5 promoter which is under the control of the lac operator. Genes cloned into pQE-30 are expressed as a fusion protein containing a Met-Arg-Gly-Ser-(His)₆ (SEQ ID NO.:71) N terminus. An additional 15 amino acid segment encoded by vector sequences residing between the (His)₆ domain and the SalI site are also part of the N terminus. Oligonucleotide PCR primers complementary to the DNA sequences encoding the first 10 amino acid residues of the N-terminus of the mature protein and the last 9 C-terminal amino acid residues of the *C. trachomatis* serovar L2 PMPE ORF present in the UC Berkeley genomic database (<http://chlamydia-www.berkeley.edu>) were synthesized. In addition to the PMPE specific sequences, these PCR primers were designed to contain flanking SalI restriction sites to allow cloning of the ORF into the pQE-30 expression vector. The oligonucleotides (SEQ ID NOs.:66 and 67) were used to amplify PMPE-specific PCR products from *C. trachomatis* L2 serovar, genomic DNA.
- 15
- 20 The sequence of the amplification primers for SEQ ID NO.:66 (forward primer) and SEQ ID NO.:67 (reverse primer) used for these PCR reactions are shown below.

Forward primer for PMPE

- 25 5'- ATC CAG CAG AG GGT CGA CGG GTT CCA GAT CCT ACG AAA GAG TCG CTA TC- 3' (SEQ ID NO.:66.)

Reverse primer for PMPE

- 5'- ATC CAG CAG AGG GTC GAC GGC C TTA GAA TCG CAG AGC AAT TTC CCC ATT GA - 3' (SEQ ID NO.:67)
- 30

In addition to the PMPE coding sequences, a TAA (TAA in reverse complement) stop codon was engineered into the reverse primer immediately after the last PMPE codon to end protein synthesis. A SalI restriction site was engineered into the

35

reverse primer downstream and adjacent to the TAA stop codon to facilitate cloning into pQE-30.

Standard PCR amplification reactions (2 mM Mg²⁺, 200 µmol dNTPs, 0.75 units AmpliTaq, 50 µl final volume) were programmed using ~0.1 µg of *C. trachomatis* L2 chromosomal DNA. Amplification of the PMPE target sequence was achieved using a standard 32-cycle, three-step thermal profile, *i.e.*, 95°C, 30 sec; 55°C, 45 sec; 72°C, 3 min. Amplification was carried out in 0.2 ml polypropylene thin-walled PCR tubes (Perkin-Elmer) in a Perkin-Elmer model 2400 thermal cycler. PCR amplification reactions produced the expected PMPE-specific ~3.0 Kbp amplicon.

The ~3.0 Kbp PMPE amplicon was purified from unincorporated primers using hydroxyapatite spin columns (QiaGen) and digested to completion with an excess of Sall (BRL, ~10 units per 1 µg DNA) according to the manufacturers recommendations. The purified and digested PMPE ORF was then purified *via* QiaGen columns as described above and cloned into plasmid pQE-30 that had been previously digested to completion with Sall and treated with calf intestinal alkaline phosphatase (BRL, ~0.05 units / pmole of 5' ends) to prevent vector religation (~5:1, insert:vector ratio).

Digestion of the pQE-30 vector with Sall produces a single restriction fragment of ~3.4 kbp.

Aliquots from the ligation reaction were then used to electrotransform a suitable *E. coli* host (*e.g.*, M15 (pREP)). Transformed cells were plated on 2X-YT agar containing 100 µg/ml ampicillin (for pQE-30) and 40 µg/ml kanamycin (for pREP) grown at 37°C for ~12-16 hours. Mini-prep DNA from ampicillin/kanamycin-resistant transformants picked at random were prepared using commercially available reagents (QiaGen Mini Prep Kit) and examined for the presence of recombinant plasmids larger than the pQE-30 plasmid (*i.e.*, insert-carrying plasmids). Putative PMPE-insert carrying recombinant plasmids were then digested to completion with Sall and examined for the presence of the PMP-specific fragment by standard agarose gel electrophoresis (0.8% agarose, TAE buffer). All plasmids tested were found to contain the PMPE insert. Plasmid M15 pREP (pQE-pmpE-CT)#37 was one recombinant derivative isolated by these procedures.

6.12 PCR CLONING OF THE PMPI ORF

To produce high levels of recombinant PMPI protein for immunogenicity and protective efficacy studies, the PMPI ORF was PCR cloned into an *E. coli* high expression vector pBAD/Thio-E (Invitrogen) under the control of the *araBAD* promoter.

Oligonucleotide PCR primers complementary to the DNA sequences encoding the first 10 amino acid residues of the N-terminus and the last 8 C-terminal amino acid residues of the *C. trachomatis* L2 PMPI ORF present in the UC Berkeley genomic database (<http://chlamydia-www.berkeley.edu>) were synthesized. In addition to the PMPI specific sequences, the 5' forward PCR primer contained the sequence 5' AGG CAG AGG CAT-3' (SEQ ID NO.:68) immediately upstream of the PMPI ATG start codon while the 3' reverse primer contained the sequence 5'-AGG CAG AGG GTC GAC'3' (SEQ ID NO.:70) immediately downstream of the C-terminal GAA codon. The oligonucleotides (SEQ ID NO.:69 and 70) were used to amplify PMPI-specific PCR products from *C. trachomatis* L2 genomic DNA. The sequence of the amplification primers for SEQ ID NO.:69 (forward primer) and SEQ ID NO.:70 (reverse primer) used for these PCR reactions are shown below.

Forward primer PMPI

15 5'- AGG CAG AGG CAT ATG CGA CCT GAT CAC ATG AAC TTC TGT TG- 3'
(SEQ ID NO.:69)

Reverse primer PMPI

20 5'-AGG CAG AGG GTC GAC GAA CCT GTA AGT GGT CCC CAG ATC -3' (SEQ ID
NO.:70)

Standard PCR amplification reactions (2 mM Mg²⁺, 200 μmol dNTPs, 0.75 units AmpliTaq, 50 μl final volume) were programmed using ~0.1 μg of *C. trachomatis* L2 chromosomal DNA. Amplification of the PMPI target sequence was achieved using a standard 32-cycle, three-step thermal profile, *i.e.*, 95°C, 30 sec.; 55°C, 45 sec.; 72°C, 3 min. Amplification was carried out in 0.2ml polypropylene thin-walled PCR tubes (Perkin-Elmer) in a Perkin-Elmer model 2400 thermal cycler. PCR amplification reactions produced the expected PMPI-specific ~3.0 Kbp amplicon.

The ~3.0 Kbp PMPI amplicon was purified from unincorporated primers using hydroxyapatite spin columns (QiaGen). The purified PMPI ORF was then cloned into the T/A PCR product cloning vector pUni/V5-HIS-TOPO plasmid (Invitrogen) using standard TOPO cloning methods described by the manufacturer. The plasmid pUni/V5-His-TOPO carries a loxP site upstream of the T/A cloning site that can be used to recombine insert carrying plasmids with other loxP-containing plasmids for subsequent controlled expression of recombinant protein.

Aliquots from the PMPI amplimer and pUni/V5-His-TOPO ligation reaction were then used to transform a suitable *E. coli* host (e.g., PIR1). Transformed cells were plated on 2X-YT agar containing 40 µg/ml kanamycin and grown at 37°C for ~12-16 hours. Mini-prep DNA from kanamycin-resistant transformants picked at random were prepared using commercially available reagents (QiaGen Mini Prep Kit) and examined for the presence of recombinant plasmids larger than the ~2.2 Kbp vector plasmid Uni/V5-His-TOPO (i.e., insert-carrying plasmids). pUni/V5-His-TOPO plasmids carrying the cloned PMPI ORF were mixed (~100 ng) with the plasmid pBAD/Thio-E (~100 ng) in the presence of a recombination buffer supplied by the manufacturer and the two were recombined into a single molecule by homologous recombination at the lox sites on both the pUni/V5-His-TOPO-PMPI plasmid and pBAD/Thio-E vector catalyzed by the Cre recombinase. pBAD/Thio-E carries a segment of the *E. coli* thioredoxin protein (~12 Kda) that has been mutated to encode an N-terminal (His) affinity chromatography domain. A single loxP recombination site is also encoded by pBAD/Thio-E immediately downstream of the His-Thio redoxin coding sequence. The His-Thioredoxin coding sequence and the loxP site are themselves downstream of the *araBAD* promoter. Recombining pBAD/Thio-E with PMPI derivatives of pUni/V5-His-TOPO through the loxP sites using the loxP-specific Cre recombinase results in the formation of a chimeric protein with the His-thioredoxin domain at the N-terminus which is fused in frame to the PMPI ORF. Following recombination the chimeric plasmids were transformed into *E. coli* TOP10 cells. Transformed cells were selected on plates containing 40 µg/ml kanamycin. All ~9.5 kbp plasmids tested were found to contain the PMPI insert. Plasmid TOP10 (pBAD-PmpI-Ct-Uni)#7 was one recombinant derivative isolated by these procedures.

6.13 EXPRESSION OF RECOMBINANT PMPE

One milliliter of a frozen stock of *E. coli* strain M15 pREP containing plasmid (pQE-pmpE-CT)#37 was used to inoculate ~100 ml of 2X-YT broth containing 40 µg/ml kanamycin and 100 µg/ml ampicillin and grown overnight at 30°C to prepare a fermentor seed culture. Approximately 20 ml of the overnight seed culture was then used to inoculate a New Brunswick Bioflow 3000 fermentor loaded with ~2.0 L of 2X-YT broth containing 40 µg/ml kanamycin and 100 µg/ml ampicillin. The culture was grown at 37°C with vigorous aeration until an O.D.₆₀₀ value of ~1.0 was attained. Expression of rPMPE was induced by adding IPTG to a 1.0 mM final concentration and continuing fermentation. Incubation in the presence of IPTG was continued for approximately 4-5 hours.

At the end of the induction period, the *E. coli* culture, with some cells displaying classic recombinant protein inclusion bodies, was harvested by continuous flow centrifugation using an Heraeus Contifuge 28RS centrifuge. Following centrifugation, cell mass was scraped from the centrifuge bowl and stored at -70°C until processed.

- 5 Approximately 15 gm of the M15 pREP (pQE-pmpE-CT)#37 frozen cell paste was resuspended by vortexing and trituration in ~40 ml of ice cold 10 mM sodium phosphate buffer, pH 7.3. Once suspended, lysozyme (Chicken egg white, Sigma) and DNase I (Bovine pancreas, Sigma) were added to final concentrations of 1.0 mg/ml and 0.01 mg/ml, respectively, and the mixture incubated on ice for 30-45 minutes. Cells were
- 10 disrupted by 2 sequential passes through a pre-cooled (~4°C) SLM Aminco French Pressure Cell (~14 Kpsi, 1" diameter bore). The cell lysate was then centrifuged for 5 min at ~500 X g (4°C) in a Sorvall SS34 rotor to remove unbroken cells. Insoluble material containing the rPMPE was isolated (pelleted) by centrifugation for 45 minutes at ~20,000 X g (4°C) in a Sorvall SS34 rotor. The supernatant from this centrifugation was discarded and the
- 15 insoluble fraction stored at -20°C in pellet form.

- To selectively extract contaminating proteins and remove endotoxin, the rPMPE-containing insoluble pellet was thawed on ice and washed twice with 10 ml of PBS buffer containing 2.0% Triton X-100. Washing was performed at room temperature and suspension of the gelatinous rPMPE-containing pellet was accomplished by vortexing and
- 20 homogenization in a conventional glass tissue grinder. Insoluble material containing the rPMPE was recovered after washing by centrifugation at ~10,000 X g for 20 minutes (room temperature) in a Sorvall SS34 rotor. Insoluble material was then washed (again by vortexing and homogenization) 2 times with 10 ml of a 4.0 M urea solution containing 2.0 M NaCl. Washed rPMPE material was recovered by centrifugation as above. The insoluble
- 25 rPMPE fraction was further washed 2 times with 10 ml of a PBS solution containing 1.0% Zwittergent 3-14 (Sigma).

- The rPMPE pellet recovered after centrifugation of the final wash solution was then solubilized for 2 hours at room temperature in standard Laemelli SDS-PAGE sample buffer containing 4 M urea. Solubilized rPMPE was size fractionated into a single
- 30 protein band of ~ 105 kDa by electrophoresis through a cylindrical ~37 mm X ~12 cm 6% polyacrylamide (36:1, acrylamide:bis-acrylamide) Tris/glycine/SDS preparative gel. A 4% polyacrylamide stacking gel was formed on top of the resolving gel (~37mm X ~3cm). Electrophoresis was carried out on a BioRad model 491 PrepCell unit for ~12 hours at ~22°C (12 watts constant wattage) using a conventional Tris/glycine/SDS running buffer
- 35 (BioRad). As electrophoresis proceeded, size fractionated proteins eluting from the bottom

of the PrepCell were pumped to an Amersham fraction collector where ~8.0 ml fractions were collected.

Aliquots (~20µl) from each fraction were mixed with an equal volume of 2X LSB heated to ~100°C for 3 minutes and electrophoresed on a 4-20% SDS PAG to identify fractions containing the PMPE protein. Prestained molecular weight standards were loaded into a parallel lane and were used as a size gauge. PMPE-containing factors were pooled and excess SDS detergent was removed by diluting the eluted sample with approximately 20 volumes of sterile, endotoxin-free 10 mM sodium phosphate buffer (pH 7.4) and concentrated to approximately 1.0 mg/ml by ultrafiltration in an Amicon stirred concentration cell using a YM30 ultrafiltration membrane

Residual endotoxin was removed from the concentrated rPMPE solution by polymyxin B Affi-Prep Polymyxin Matrix (BioRad) treatment. Affi-Prep treatment was performed overnight at 4°C in a batch mode according to the manufacturers recommendations.

The protein concentration of the concentrated, polymyxin B-treated rPMPE was determined using the Micro BCA method (Pierce Chem.) and BSA as a standard.

Purified rPMPE (~0.9-1.2 mg/ml protein concentration) was evaluated for purity, identity, and residual endotoxin burden by SDS-PAGE, Western blot, and a colorimetric endotoxin assay (BioWhittaker), respectively. The gel-purified rPMPE material displayed a purity of >95% as a single band of the expected molecular size by gel analysis. Residual endotoxin is calculated to be ≤ 0.05 EU/g.

6.14 EXPRESSION OF RECOMBINANT PMPI

One milliliter of a frozen stock of *E. coli* strain TOP10 containing plasmid (pBAD-pmpI-Ct-Uni)#7 was used to inoculate ~100 ml of 2X-YT broth containing 40 µg/ml kanamycin and grown overnight at 37°C to prepare a fermenter seed culture. Approximately 20 ml of the overnight seed culture was then used to inoculate a New Brunswick Bioflow 3000 fermenter loaded with ~2.0 L of 2X-YT broth containing 40 µg/ml kanamycin. The culture was grown at 37°C with vigorous aeration until an O.D.₆₀₀ value of ~1.0 was attained. Expression of rPMPI was induced by addition of arabinose to a final concentration of 1.0 mM and continuing cultivation for approximately 4-5 hours.

At the end of the induction period, the *E. coli* culture, with some cells displaying classic recombinant protein inclusion bodies, was harvested by continuous flow centrifugation using an Heraeus Contifuge 28RS centrifuge. Following centrifugation, cell mass was scraped from the centrifuge bowl and stored at -70°C until processed.

Approximately 15 gm of the TOP10 (pBAD-pmpI-Ct-Uni)#7 frozen cell paste was resuspended by vortexing and trituration in ~40 ml of ice cold 10mM sodium phosphate buffer, pH 7.3. Once suspended, lysozyme (Chicken egg white, Sigma) and DNAase I (Bovine pancreas, Sigma) were added to final concentrations of 1.0 mg/ml and 0.01 mg/ml, respectively, and the mixture incubated on ice for 30- 45 minutes. Cells were disrupted by 2 sequential passes through a pre-cooled (~4°C) SLM Aminco French Pressure Cell (~14 Kpsi, 1" diameter bore). The cell lysate was then centrifuged for 5 min at ~500 X g (4°C) in a Sorvall SS34 rotor to remove unbroken cells. Insoluble material containing the rPMPI was isolated (pelleted) by centrifugation for 45 min at ~20,000 X g (4°C) in a Sorvall SS34 rotor. The supernatant from this centrifugation was discarded and the insoluble fraction stored at -20°C in pellet form.

To selectively extract contaminating proteins and remove endotoxin, the rPMPI-containing insoluble pellet was thawed on ice and washed twice with 10 ml of PBS buffer containing 2.0% Triton X-100. Washing was performed at room temperature and suspension of the gelatinous rPMPI-containing pellet was accomplished by vortexing and homogenization in a conventional glass tissue grinder. Insoluble material containing the rPMPI was recovered after washing by centrifugation at ~10,000 X g for 20 minutes (room temperature) in a Sorvall SS34 rotor. Insoluble material was then washed (again by vortexing and homogenization) 2 times with 10 ml of a 4.0 M urea solution containing 2.0 M NaCl. Washed rPMPI material was recovered by centrifugation as above. The insoluble rPMPI fraction was further washed 2 times with 10 ml of a PBS solution containing 1.0% Zwittergent 3-14 (Sigma).

The rPMPI pellet recovered after centrifugation of the final wash solution was then solubilized for 2 hours at room temperature in standard Laemmli SDS-PAGE sample buffer containing 4 M urea. Solubilized rPMPI-thioredoxin-fusion protein was size fractionated into a single protein band of ~ 105 kDa using a model 491 PrepCell (BioRad) cylindrical gel as described above for PMPE above. PMPI was obtained from SDS PAGE and residual endotoxin removed as described for PMPE above.

The protein concentration of the concentrated, polymyxin B-treated rPMPI-thioredoxin fusion protein was determined using the Micro BCA method (Pierce Chem.) and BSA as a standard.

Purified rPMPI (~0.9-1.2 mg/ml protein concentration) was evaluated for purity, identity, and residual endotoxin burden by SDS-PAGE, Western blot, and a colorimetric endotoxin assay (BioWhittaker), respectively. The gel-purified rPMPI material

displayed a purity of >95% as a single band of the expected molecular size by gel analysis. Residual endotoxin is calculated to be ≤ 0.05 EU/g.

6.15 AFFINITY CHROMATOGRAPHY PURIFICATION OF RECOMBINANT PROTEIN

5

Recombinant PMPE or PMPI protein is purified to apparent homogeneity using standard preparative immobilized metal affinity chromatography (IMAC) procedures. Briefly, an *E. coli* strain harboring an expression plasmid containing PMPE or PMPI protein gene is grown in Luria broth in a 5L fermenter (New Brunswick) at 37°C with moderate
10 aeration until mid-log phase (~ 0.5 O.D.₆₀₀) and induced with IPTG or arabinose (1 mM final) for 4-5 hours. Cell paste is collected, washed in PBS and stored at -20°C. Aliquots of frozen cell paste (~ 9 -10 grams wet weight) are suspended in ~ 120 ml of D-PBS by mechanical agitation and lysed by passage through a French pressure cell (2X, 14,000 psi, 4°C). Soluble protein is then removed from rPMPE or rPMPI protein inclusion bodies by
15 high speed centrifugation ($\sim 20,000 \times g$, 4°C, 30 min).

The insoluble pellet containing rPMPE or rPMPI protein is suspended in ~ 20 ml of ice cold D-PBS by homogenization and centrifuged as above. Washed rPMPE or rPMPI protein inclusion bodies are then denatured by suspension in a sodium phosphate buffer (0.1 M, pH 7.0) containing 7.4 M guanidine hydrochloride, 5% 2-ME and 10%
20 glycerol and loaded onto a Ni²⁺-affinity column (1.5 cm X 25 cm, bed volume ~ 30 ml) prepared from Fast-Flow Chelating Sepharose (Pharmacia) and charged with Ni²⁺ or Zn²⁺ ions by standard procedures. Unbound material is removed by washing the column with ~ 5 -10 column volumes of a sodium phosphate buffer (0.1 M, pH 7.0) containing ~ 7.4 M guanidine HCl.

25 Recombinant PMPE or PMPI protein bound to the affinity resin by virtue of the (His)₆ affinity purification domain is eluted using sodium phosphate buffer (pH 7.4) containing 7.4 M guanidine HCl and 200 mM imidazole. Eluted material is dialyzed against TE buffer containing SDS (0.5%) to remove the guanidine. Dialyzed material is concentrated using a Amicon stirred cell concentrator using a YM30 membrane and mixed
30 with a 1/5 volume of 5X SDS gel sample buffer containing 1 mM 2-mercaptoethanol and boiled at 100°C for 5 minutes.

Samples are loaded onto Tris/glycine acrylamide gels (4% stacking gel, 4-20% resolving gel, 30:0.8 acrylamide:bis solution, 1 mm thickness). A prestained molecular weight standard (SeeBlue or Multimark, Novex) is run in parallel with the
35 rPMPE or rPMPI protein samples to identify size fractions on the gel. The purity of rPMPE

or rPMPI protein is determined using conventional SDS-PAGE and commercially available silver staining reagents (Silver Stain Plus, Novex).

6.16 GENERATION OF A RADIOLABELLED SCREENING PROBE

5 The sequence information shown above is used to design a pair of nondegenerate oligonucleotide primers. PCR amplification of DNA fragments is performed under the same conditions as described above with the exception that the annealing temperature is lowered to 50°C. The DNA fragment is isolated from an agarose gel as before and radiolabeled using [³²P]-gamma-ATP and T4 polynucleotide kinase according to
10 standard methods. Unincorporated radiolabel is separated from the probe on a G25 Sepharose spin column. Before use, the probe is denatured for 2 min. at 95°C and subsequently chilled on ice (4°C).

6.17 HYBRIDIZATION OF PLAQUE-LIFT FILTERS AND SOUTHERN BLOTS WITH RADIOLABELLED PROBE

15 Phage plaques from library platings are immobilized on nylon filters using standard transfer protocols well known to those skilled in the art. Digested bacterial genomic DNA, phage or plasmid DNA is electrophoresed on 0.8% TAE-agarose gels and transferred onto nylon filters using a pressure blotter (Stratagene) according to the
20 manufacturer's recommendations. Hybridizations with selected probes are performed at 37°C (for example, to detect PMP homologs of other species). Hybridizations with specific probes are generally carried out at 50-60°C (*e.g.*, to detect the identical sequence or the analogous protein in another serovar). Washes of increasing stringency are done at the respective hybridization temperatures until nonspecific background is minimized.

6.18 CONSTRUCTION OF A *Chlamydia* GENOMIC DNA LIBRARY

25 A genomic library was constructed in the λZAPII replacement vector obtained from Stratgene. The vector arms were digested with EcoR1. Digests of *Chlamydia* DNA by EcoR1 were performed to yield fragment sizes between 1 kb and 5 kb.
30 Ligations of vector arms and insert DNA were carried out according to standard protocols. Ligation reactions were packaged *in vitro* using the Stratagene GigaPack Gold III extract. The packaged phage were plated on *E. coli* X1 Blue MRA (P2) (Stratagene). An initial library titer was determined and expressed as number of pfu.

35 The library is screened using 4×10^4 pfu that are plated at a density of 8×10^3 pfu/130 mm plate with a PMPE or PMPI specific, probe. Several putative positive phage

plagues are located and the strongest hybridizing phage are eluted from cored agarose plugs, titered and replated for secondary screening. The selected phages are replated at low density (approximately 100 pfu/plate) and plaques are analyzed by PCR using primer pairs. Inserts carrying plasmids (phagemids) are rescued from the selected phage by co-infecting
5 *E. coli* cells with an appropriate helper virus.

6.19 DETERMINATION OF INSERT SIZE AND MAPPING OF DNA FRAGMENTS

In order to estimate the size of inserts, phagemid DNA is digested with
10 appropriate restriction enzymes (*e.g.*, NotI) and the digests are analyzed on a 0.5% TAE-agarose gel side by side with suitable DNA markers. In order to map restriction fragments that would hybridize to the probe, DNA from phagemid isolates is digested with a number of common restriction enzymes either alone or in combination with NotI. The rationale of this approach is to discriminate between fragments that span the insert/phagemid vector
15 junction and those that map on the NotI insert. The series of single and double digests are run side-by-side for each phage isolate and analyzed by Southern analysis with radiolabeled probe.

6.20 SEQUENCING OF THE PMPE and PMPI GENE

20 Sequencing of the PMPE and PMPI gene is performed using the Dye Terminator Cycle Sequencing Kit from Perkin-Elmer according to the manufacturer's specifications. The sequencing reactions are read using an ABI Prism 310 Genetic Analyzer. The sequences are aligned using the AutoAssembler software (Perkin-Elmer) provided with the ABI Prism 310 sequencer.

25

The present invention is not to be limited in scope by the microorganism deposited or the specific embodiments described herein. It will be understood that variations which are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention, in addition to those shown and described herein, will
30 become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

35

WHAT IS CLAIMED IS:

1. An isolated PMPE or PMPI polypeptide of a *Chlamydia spp.*, having a molecular weight between 90 and 115 kDa as determined by SDS polyacrylamide gel electrophoresis.
2. The PMPE or PMPI polypeptide of claim 1, wherein the *Chlamydia spp.* is *Chlamydia trachomatis*, *Chlamydia pneumonia*, *Chlamydia psittaci* or *Chlamydia pecorum*.
3. The PMPE or PMPI polypeptide of claim 2, wherein the *Chlamydia spp.* is *C. trachomatis*.
4. The PMPE or PMPI polypeptide of claim 1, which comprises an amino acid sequence of SEQ ID NO.:2 or 4, a sequence substantially homologous thereto, or an at least 8 amino acid fragment thereof.
5. The PMPE or PMPI polypeptide of claim 1, or a peptide fragment thereof, which specifically binds an antibody that specifically binds to a protein having the amino acid sequence of SEQ ID NO.:2 or 4.
6. A peptide fragment of the PMPE or PMPI polypeptide of claim 1, which fragment is at least 8 amino acids in length.
7. The peptide fragment of claim 6 wherein said peptide fragment comprises the amino acid sequence of one of SEQ ID NO.:5-34.
8. An isolated fusion polypeptide comprising at least two peptides, said at least two peptides each consisting of an amino acid sequence of one of SEQ ID NO.:5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34, with the proviso that the peptides are arranged in a configuration that is different from the configuration of a naturally occurring PMPE or PMPI polypeptide.

9. The isolated fusion polypeptide of claim 8 wherein the fusion polypeptide comprises peptides consisting of the amino acid sequences of SEQ ID NO.:5, 6, 7, 8, 9, 10 and 11.

5 10. The isolated fusion polypeptide of claim 8 wherein the fusion polypeptide comprises peptides consisting of the amino acid sequences of SEQ ID NO.:23, 24, 25, 26, 27, 28, and 29.

11. An antibody or an antigen-binding fragment thereof that specifically
10 binds the PMPE or PMPI polypeptide of claim 1.

12. An antibody or an antigen-binding fragment thereof that specifically binds the peptide fragment of claim 6.

15 13. An antibody or an antigen-binding fragment thereof that specifically binds a peptide fragment consisting of an amino acid sequence of SEQ ID NO.:5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34.

20 14. The antibody of claim 11, 12 or 13 which is a cytotoxic, cytostatic, or neutralizing antibody.

15. A vaccine comprising the PMPE or PMPI polypeptide of claim 1 and a pharmaceutically acceptable carrier or diluent.
25

16. The vaccine of claim 15 further comprising one or more adjuvants or immunostimulatory compounds.

17. The vaccine of claim 16 wherein the adjuvants or immunostimulatory
30 compounds are one or more of alum, MLT, QS21, MF59, CpG DNA, PML, calcium phosphate and PLG.

18. The vaccine of claim 16 comprising one adjuvant or immunostimulatory compound.
35

19. The vaccine of claim 16 comprising two different adjuvants or immunostimulatory compounds.

20. A vaccine comprising the polypeptide fragment of claim 6 and a pharmaceutically acceptable carrier or diluent.

21. The vaccine of claim 20 further comprising one or more adjuvants or immunostimulatory compounds.

22. The vaccine of claim 21 wherein the one or more adjuvants or immunostimulatory compounds are selected from the group consisting of alum, MLT, QS21, MF59, CpG DNA, PML, calcium phosphate and PLG.

23. The vaccine of claim 21 comprising one adjuvant or immunostimulatory compound.

24. The vaccine of claim 21 comprising two different adjuvants or immunostimulatory compounds.

25. A vaccine comprising the isolated fusion polypeptide of claim 8 and a pharmaceutically acceptable carrier or diluent.

26. The vaccine of claim 25 further comprising one or more adjuvants or immunostimulatory compounds.

27. The vaccine of claim 26 wherein the one or more adjuvants or immunostimulatory compounds are selected from the group consisting of alum, MLT, QS21, MF59, CpG DNA, PML, calcium phosphate and PLG.

28. The vaccine of claim 26 comprising one adjuvant or immunostimulatory compound.

29. The vaccine of claim 26 comprising two different adjuvants or immunostimulatory compounds.

30. A vaccine comprising the antibody of claim 11 and a pharmaceutically acceptable carrier or diluent.

31. The vaccine of any one of claims 15, 20 or 25 additionally comprising one or more immunogens selected from the group consisting of a lipid, lipoprotein, phospholipid, lipooligosaccharide, protein, attenuated organism and inactivated whole cell.

32. The vaccine of claim 31 wherein the one or more immunogens are a DPT vaccine, a HMWP of *C. trachomatis*, a MOMP of *C. trachomatis*, or an entire organism, or subunit therefrom, of *Chlamydia*, *Neisseria gonorrhea*, HIV, *Haemophilus influenzae*, *Moraxella catarrhalis*, *Human papilloma virus*, *Herpes simplex virus*, *Haemophilus ducreyi*, *Treponema pallidum*, *Candida albicans* or *Streptococcus pneumoniae*.

33. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a PMPE or PMPI polypeptide, or an at least 8 amino acid fragment thereof, of a *Chlamydia spp.*, said PMPE or PMPI polypeptide having a molecular weight between 90 and 115 kDa as determined by SDS polyacrylamide gel electrophoresis.

34. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO.:1 or 3, an at least 15 nucleotide fragment thereof, or the complement thereof.

35. A pharmaceutical composition comprising the isolated nucleic acid molecule of claim 33.

36. A vaccine comprising the isolated nucleic acid molecule of claim 33.

37. A vaccine comprising an isolated nucleic acid comprising a nucleotide sequence encoding the PMPE or PMPI polypeptide of claim 1, or an at least 15 nucleotide fragment thereof, and further comprising one or more adjuvants or immunostimulatory compounds.

38. The vaccine of claim 37 wherein the one or more adjuvants or immunostimulatory compounds are alum, MLT, QS21, MF59, CpG DNA, PML, calcium phosphate or PLG.

5 39. The vaccine of claim 37 comprising one adjuvant or immunostimulatory compound.

40. The vaccine of claim 37 comprising two different adjuvants or immunostimulatory compounds.

10

41. A vaccine comprising one or more of an isolated PMPE or PMPI polypeptide of a *Chlamydia spp.*, having a molecular weight between 90 and 115 kDa as determined in SDS polyacrylamide gel electrophoresis; or an isolated nucleic acid comprising a nucleotide sequence encoding an PMPE or PMPI polypeptide of a *Chlamydia*
15 *spp.*, said PMPE or PMPI polypeptide having a molecular weight between 90 and 115 kDa as determined by SDS polyacrylamide gel electrophoresis; said vaccine further comprising one or more adjuvants or immunostimulatory compounds selected from the group consisting of alum, MLT, QS21, MF59, CpG DNA, PML, calcium phosphate and PLG.

20 42. A method of producing an immune response in an animal comprising administering to the animal an immunogenic amount of the PMPE or PMPI polypeptide of claim 1.

43. A method of producing an immune response in an animal comprising
25 administering to the animal an immunogenic amount of the peptide fragment of claim 6.

44. A method of producing an immune response in an animal comprising administering to the animal an immunogenic amount of the isolated fusion polypeptide of claim 8.

30

45. A method of producing an immune response in an animal comprising administering to the animal an immunogenic amount of the nucleic acid molecule of claims 33 or 34.

35

46. A method of producing an immune response in an animal comprising administering to the animal an immunogenic amount of the vaccine of claim 41.

47. A method of producing an immune response in an animal comprising administering to the animal an immunogenic amount of one or more of the vaccines of claims 15, 20, 25, 30, 36, or 37, wherein said vaccines are administered simultaneously or sequentially.

48. Plasmid M15 pREP (pQE-pmpE-Ct-Uni)#37 obtainable from *E. coli*, as deposited with the ATCC and assigned accession number PTA-2462.

49. Plasmid TOP10 (pBAD-pmpI-Ct-Uni)#7 obtainable from *E. coli*, as deposited with the ATCC and assigned accession number PTA-2461.

50. A recombinant expression vector adapted for transformation of a host cell comprising the nucleic acid molecule of claim 33 or 34.

51. The recombinant expression vector of claim 50 further comprising an expression means operatively coupled to the nucleic acid molecule for expression by the host of the PMPE or PMPI protein, or a fragment thereof.

52. The expression vector of claim 51, wherein the expression means includes a nucleotide sequence encoding an amino acid sequence that can be used for the purification of the PMPE or PMPI protein.

53. The expression vector of claim 51 wherein the expression means further includes a nucleotide sequence encoding an amino acid sequence that directs secretion from the host of the PMPE or PMPI polypeptide.

54. A transformed host cell containing the expression vector of claim 50.

55. A transformed host cell containing the plasmid of claim 48 or 49.

56. A host cell containing the nucleic acid molecule of claim 33 or 34 operatively linked to a heterologous promoter.

57. An isolated recombinant PMPE or PMPI polypeptide produced by a method comprising culturing the transformed host cell of claim 54 under conditions suitable for expression of said PMPE or PMPI polypeptide and recovering said PMPE or PMPI polypeptide.

5

58. An isolated recombinant PMPE or PMPI polypeptide produced by a method comprising culturing the transformed host of claim 55 under conditions suitable for expression of said PMPE or PMPI polypeptide and recovering said PMPE or PMPI polypeptide.

10

59. An isolated PMPE or PMPI polypeptide produced by a method comprising culturing the host cell of claim 56 under conditions suitable for the expression of a PMPE or PMPI polypeptide and recovering said PMPE or PMPI polypeptide.

15

60. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the polypeptide of claim 1.

20

61. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the polypeptide fragment of claim 6.

25

62. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the isolated fusion polypeptide of claim 8.

30

63. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the vaccine of claim

30.

35

64. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the vaccine of claim 31.

5

65. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the vaccine of claim 32.

10

66. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the vaccine of claim 37.

15

67. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount of the vaccine of claim 41.

20

68. A method of preventing, treating or ameliorating a disorder or disease associated with infection of an animal with *Chlamydia* by administering to a subject in need of such prevention, treatment or amelioration an effective amount more than one of the vaccines of claims 15, 20, 25, 30, 31, 35, 37 or 41, each optionally comprising one or more immunogens selected from the group consisting of a lipid, lipoprotein, phospholipid, lipooligosaccharide, protein, attenuated organism and inactivated whole cell, wherein said vaccines are administered simultaneously or sequentially

25

69. An antagonist which inhibits the activity of the polypeptide of claim 1.

30

70. An antagonist which inhibits the expression of the nucleic acid of claim 33.

35

71. A method for identifying compounds that interact with the polypeptide of claim 1, said method comprising contacting a composition comprising the polypeptide with the compound to be screened under conditions that permit interaction between the compound and the polypeptide; and detecting the interaction of the compound
5 with the polypeptide.

72. A method for identifying compounds which interact with the nucleic acid molecule of claim 33, said method comprising contacting a composition comprising the nucleic acid molecule with the compound to be screened under conditions that permit
10 interaction between the compound and the nucleic acid molecule; and detecting the interaction of the nucleic acid with the compound.

15

20

25

30

35

ABSTRACT OF THE DISCLOSURE

The invention discloses the *Chlamydia* PMPE and PMPI polypeptide, polypeptides derived thereof (PMP-derived polypeptides), nucleotide sequences encoding
5 said polypeptides, antibodies that specifically bind the PMP polypeptides and PMP-derived polypeptides and T-cells specific for PMP polypeptides and PMP-derived polypeptides. Also disclosed are prophylactic and therapeutic compositions, including immunogenic compositions, *e.g.*, vaccines, comprising PMP polypeptides or PMP-derived polypeptides or antibodies thereto. The invention additionally discloses methods of inducing in animals an
10 immune response to *Chlamydia* cells, *Chlamydia* elementary bodies, and/or cells expressing *Chlamydial* proteins, *e.g.*, cell infected with *Chlamydia*.

15

20

25

30

35




FIG. 1




FIG. 2




FIG. 3




FIG. 4

atg	aaa	aaa	gcg	ttt	ttc	ttt	ttc	ott	att	gga	aac	tcc	cta	tca	gga	48
Met	Lys	Lys	Ala	Phe	Phe	Phe	Phe	Leu	Ile	Gly	Asn	Ser	Leu	Ser	Gly	
1				5					10					15		
cta	gct	aga	gag	gtt	cct	tct	aga	atc	ttt	ctt	atg	ccc	aac	tca	gtt	96
Leu	Ala	Arg	Glu	Val	Pro	Ser	Arg	Ile	Phe	Leu	Met	Pro	Asn	Ser	Val	
			20					25					30			
cca	gat	cct	acg	aaa	gag	tcg	cta	tca	aat	aaa	att	agt	ttg	aca	gga	144
Pro	Asp	Pro	Thr	Lys	Glu	Ser	Leu	Ser	Asn	Lys	Ile	Ser	Leu	Thr	Gly	
		35					40					45				
gac	act	cac	aat	ctc	act	aac	tgc	tat	ctc	gat	aac	cta	cgc	tac	ata	192
Asp	Thr	His	Asn	Leu	Thr	Asn	Cys	Tyr	Leu	Asp	Asn	Leu	Arg	Tyr	Ile	
	50					55				60						
ctg	gct	att	cta	caa	aaa	act	ccc	aat	gaa	gga	gct	gct	gtc	aca	ata	240
Leu	Ala	Ile	Leu	Gln	Lys	Thr	Pro	Asn	Glu	Gly	Ala	Ala	Val	Thr	Ile	
65				70					75				80			
aca	gat	tac	cta	agc	ttt	ttt	gat	aca	caa	aaa	gaa	ggt	att	tat	ttt	288
Thr	Asp	Tyr	Leu	Ser	Phe	Phe	Asp	Thr	Gln	Lys	Glu	Gly	Ile	Tyr	Phe	
			85					90					95			
gca	aaa	aat	ctc	acc	cct	gaa	agt	ggt	ggt	gcg	att	ggt	tat	gcg	agt	336
Ala	Lys	Asn	Leu	Thr	Pro	Glu	Ser	Gly	Gly	Ala	Ile	Gly	Tyr	Ala	Ser	
			100					105				110				
ccc	aat	tct	cct	acc	gtg	gag	att	cgt	gat	aca	ata	ggt	cct	gta	atc	384
Pro	Asn	Ser	Pro	Thr	Val	Glu	Ile	Arg	Asp	Thr	Ile	Gly	Pro	Val	Ile	
		115					120					125				
ttt	gaa	aat	aat	act	tgt	tgc	aga	cca	ttt	aca	tcg	agt	aat	cct	aat	432
Phe	Glu	Asn	Asn	Thr	Cys	Cys	Arg	Pro	Phe	Thr	Ser	Ser	Asn	Pro	Asn	
	130					135					140					
gca	gct	gtt	aat	aaa	ata	aga	gaa	ggc	gga	gcc	att	cat	gct	caa	aat	480
Ala	Ala	Val	Asn	Lys	Ile	Arg	Glu	Gly	Gly	Ala	Ile	His	Ala	Gln	Asn	
145				150				155					160			
ctt	tac	ata	aat	cat	aat	cat	gat	gtg	gtc	gga	ttt	atg	aag	aac	ttt	528
Leu	Tyr	Ile	Asn	His	Asn	His	Asp	Val	Val	Gly	Phe	Met	Lys	Asn	Phe	
			165					170					175			
tct	tat	gtc	cga	gga	gga	gcc	att	agt	acc	gct	aat	acc	ttt	gtt	gtg	576
Ser	Tyr	Val	Arg	Gly	Gly	Ala	Ile	Ser	Thr	Ala	Asn	Thr	Phe	Val	Val	
			180					185					190			
agc	gag	aat	cag	tct	tgt	ttt	ctc	ttt	atg	gac	aac	atc	tgt	att	caa	624
Ser	Glu	Asn	Gln	Ser	Cys	Phe	Leu	Phe	Met	Asp	Asn	Ile	Cys	Ile	Gln	
		195					200					205				
act	aat	aca	gca	gga	aaa	ggt	ggc	gct	atc	tat	gct	gga	acg	agc	aat	672
Thr	Asn	Thr	Ala	Gly	Lys	Gly	Gly	Ala	Ile	Tyr	Ala	Gly	Thr	Ser	Asn	
	210					215					220					

FIG. 5A

tct ttt gag agt aat aac tgc gat ctc ttc ttt atc aat aac gcc tgt	720
Ser Phe Glu Ser Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys	
225 230 235 240	
tgt gca gga gga gcg atc ttc tcc cct atc tgt tct cta aca gga aat	768
Cys Ala Gly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn	
245 250 255	
cgt ggt aac atc gtt ttc tat aac aat cgc tgc ttt aaa aat gta gaa	816
Arg Gly Asn Ile Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu	
260 265 270	
aca gct tct tca gaa gct tct gat gga gga gca att aaa gta act act	864
Thr Ala Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr	
275 280 285	
cgc cta gat gtt aca ggc aat cgt ggt agg atc ttt ttt agt gac aat	912
Arg Leu Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn	
290 295 300	
atc aca aaa aat tat ggc gga gct att tac gct cct gta gtt acc cta	960
Ile Thr Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu	
305 310 315 320	
gtg gat aat ggc cct acc tac ttt ata aac aat atc gcc aat aat aag	1008
Val Asp Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys	
325 330 335	
ggg ggc gct atc tat ata gac gga acc agc aac tcc aaa att tct gcc	1056
Gly Gly Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala	
340 345 350	
gac cgc cat gct att att ttt aat gaa aat att gtg act aat gta act	1104
Asp Arg His Ala Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr	
355 360 365	
aat gca aat ggt acc agt acg tca gct aat cct cct aga aga aat gca	1152
Asn Ala Asn Gly Thr Ser Thr Ser Ala Asn Pro Arg Arg Asn Ala	
370 375 380	
ata aca gta gca agc tcc tct ggt gaa att cta tta gga gca ggg agt	1200
Ile Thr Val Ala Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser	
385 390 395 400	
agc caa aat tta att ttt tat gat cct att gaa gtt agc aat gca ggg	1248
Ser Gln Asn Leu Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly	
405 410 415	
gtc tct gtg tcc ttc aat aag gaa gct gat caa aca ggc tct gta gta	1296
Val Ser Val Ser Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val	
420 425 430	
ttt tca gga gct act gtt aat tct gca gat ttt cat caa cgc aat tta	1344
Phe Ser Gly Ala Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu	
435 440 445	

FIG. 5B

caa	aca	aaa	aca	cct	gca	ccc	ctt	act	ctc	agt	aat	ggt	ttt	cta	tgt	1392
Gln	Thr	Lys	Thr	Pro	Ala	Pro	Leu	Thr	Leu	Ser	Asn	Gly	Phe	Leu	Cys	
450						455					460					
atc	gaa	gat	cat	gct	cag	ctt	aca	gtg	aat	cga	ttc	aca	caa	act	ggg	1440
Ile	Glu	Asp	His	Ala	Gln	Leu	Thr	Val	Asn	Arg	Phe	Thr	Gln	Thr	Gly	
465					470				475						480	
ggt	gtt	gtt	tct	ctt	ggg	aat	gga	gca	gtt	ctg	agt	tgc	tat	aaa	aat	1488
Gly	Val	Val	Ser	Leu	Gly	Asn	Gly	Ala	Val	Leu	Ser	Cys	Tyr	Lys	Asn	
				485				490						495		
ggt	gca	gga	aat	tct	gct	agc	aat	gcc	tct	ata	aca	ctg	aag	cat	att	1536
Gly	Ala	Gly	Asn	Ser	Ala	Ser	Asn	Ala	Ser	Ile	Thr	Leu	Lys	His	Ile	
			500					505					510			
gga	ttg	aat	ctt	tct	tcc	att	ctg	aaa	agt	ggt	gct	gag	att	cct	tta	1584
Gly	Leu	Asn	Leu	Ser	Ser	Ile	Leu	Lys	Ser	Gly	Ala	Glu	Ile	Pro	Leu	
	515						520					525				
ttg	tgg	gta	gag	cct	aca	aat	aac	agc	aat	aac	tat	aca	gca	gat	act	1632
Leu	Trp	Val	Glu	Pro	Thr	Asn	Asn	Ser	Asn	Asn	Tyr	Thr	Ala	Asp	Thr	
530						535					540					
gca	gct	acc	ttt	tca	tta	agt	gat	gta	aaa	ctc	tca	ctc	att	gat	gac	1680
Ala	Ala	Thr	Phe	Ser	Leu	Ser	Asp	Val	Lys	Leu	Ser	Leu	Ile	Asp	Asp	
545					550					555					560	
tat	ggg	aat	tct	cct	tat	gaa	tcc	aca	gat	cta	acc	cat	gct	ctg	tca	1728
Tyr	Gly	Asn	Ser	Pro	Tyr	Glu	Ser	Thr	Asp	Leu	Thr	His	Ala	Leu	Ser	
				565					570					575		
tca	cag	cct	atg	cta	tct	att	tct	gag	gct	agt	gat	aac	cag	cta	aga	1776
Ser	Gln	Pro	Met	Leu	Ser	Ile	Ser	Glu	Ala	Ser	Asp	Asn	Gln	Leu	Arg	
			580					585					590			
tct	gat	gat	atg	gat	ttt	tcg	gga	cta	aat	gtc	cct	cat	tat	gga	tgg	1824
Ser	Asp	Asp	Met	Asp	Phe	Ser	Gly	Leu	Asn	Val	Pro	His	Tyr	Gly	Trp	
	595						600					605				
caa	gga	ctt	tgg	act	tgg	ggc	tgg	gca	aaa	act	caa	gat	cca	gaa	cca	1872
Gln	Gly	Leu	Trp	Thr	Trp	Gly	Trp	Ala	Lys	Thr	Gln	Asp	Pro	Glu	Pro	
610						615					620					
gca	tct	tca	gca	aca	atc	aca	gat	cca	caa	aaa	gcc	aat	aga	ttc	cat	1920
Ala	Ser	Ser	Ala	Thr	Ile	Thr	Asp	Pro	Gln	Lys	Ala	Asn	Arg	Phe	His	
625					630					635					640	
aga	acc	tta	tta	ctg	act	tgg	ctt	cct	gct	ggg	tat	gtt	cct	agc	ccg	1968
Arg	Thr	Leu	Leu	Leu	Thr	Trp	Leu	Pro	Ala	Gly	Tyr	Val	Pro	Ser	Pro	
				645				650						655		
aaa	cac	aga	agt	ccc	ctc	ata	gcg	aat	acc	tta	tgg	ggg	aat	atg	ctg	2016
Lys	His	Arg	Ser	Pro	Leu	Ile	Ala	Asn	Thr	Leu	Trp	Gly	Asn	Met	Leu	
			660					665					670			

FIG. 5C

ctt gca aca gaa agc tta aaa aat agt gca gaa ctg aca cct agt gat	2064
Leu Ala Thr Glu Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Asp	
675 680 685	
cat cct ttc tgg gga att aca gga gga gga cta ggc atg atg gtt tac	2112
His Pro Phe Trp Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr	
690 695 700	
caa gat cct cga gaa aat cat cct gga ttc cat atg cgc tct tcc gga	2160
Gln Asp Pro Arg Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly	
705 710 715 720	
tac tct gcg ggg atg ata gca ggg cag aca cac acc ttc tca ttg aaa	2208
Tyr Ser Ala Gly Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys	
725 730 735	
ttc agt cag acc tac acc aaa ctc aat gag cgt tac gca aaa aac aac	2256
Phe Ser Gln Thr Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn	
740 745 750	
gta tct tct aaa aat tac tca tgc caa gga gaa atg ctc ttc tca ttg	2304
Val Ser Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu	
755 760 765	
caa gaa ggt ttc ttg ctg act aaa tta gtt ggg ctt tac agc tat gga	2352
Gln Glu Gly Phe Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly	
770 775 780	
gac cat aac tgt cac cat ttc tat acc caa gga gaa aat cta aca tct	2400
Asp His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser	
785 790 795 800	
caa ggg acg ttc cgt agt caa acg atg gga ggt gct gtt ttt ttt gat	2448
Gln Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp	
805 810 815	
ctc cct atg aaa ccc ttt gga tca acg cat ata ctg aca gct ccc ttt	2496
Leu Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe	
820 825 830	
tta ggt gct ctt ggt att tat tct agc ctg tct cac ttt act gag gtg	2544
Leu Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser His Phe Thr Glu Val	
835 840 845	
gga gcc tat ccg cga agc ttt tct aca aag act cct ttg atc aat gtc	2592
Gly Ala Tyr Pro Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile Asn Val	
850 855 860	
cta gtc cct att gga gtt aaa ggt agc ttt atg aat gct acc caa aga	2640
Leu Val Pro Ile Gly Val Lys Gly Ser Phe Met Asn Ala Thr Gln Arg	
865 870 875 880	
cct caa gcc tgg act gta gaa ttg gca tac caa ccc gtt ctg tat aga	2688
Pro Gln Ala Trp Thr Val Glu Leu Ala Tyr Gln Pro Val Leu Tyr Arg	
885 890 895	

FIG. 5D

caa gaa cca ggg atc gcg acc cag ctc cta gcc agt aag ggt att tgg	2736
Gln Glu Pro Gly Ile Ala Thr Gln Leu Leu Ala Ser Lys Gly Ile Trp	
900 905 910	
ttt ggt agt gga agc ccc tca tgc cgt cat gcc atg tcc tat aaa atc	2784
Phe Gly Ser Gly Ser Pro Ser Ser Arg His Ala Met Ser Tyr Lys Ile	
915 920 925	
tca cag caa aca caa cct ttg agt tgg tta act ctc cat ttc cag tat	2832
Ser Gln Gln Thr Gln Pro Leu Ser Trp Leu Thr Leu His Phe Gln Tyr	
930 935 940	
cat gga ttc tac tcc tct tca acc ttc tgt aat tat ctc aat ggg gaa	2880
His Gly Phe Tyr Ser Ser Ser Thr Phe Cys Asn Tyr Leu Asn Gly Glu	
945 950 955 960	
att gct ctg cga ttc tag	2898
Ile Ala Leu Arg Phe	
965	

FIG. 5E

atg	cga	cct	gat	cat	atg	aac	ttc	tgt	tgt	cta	tgt	gct	gct	att	ttg	48
Met	Arg	Pro	Asp	His	Met	Asn	Phe	Cys	Cys	Leu	Cys	Ala	Ala	Ile	Leu	
1				5				10						15		
tca	tcc	aca	gcg	gtc	ctc	ttt	ggc	cag	gat	ccc	tta	ggt	gaa	acc	gcc	96
Ser	Ser	Thr	Ala	Val	Leu	Phe	Gly	Gln	Asp	Pro	Leu	Gly	Glu	Thr	Ala	
			20					25					30			
ctc	ctc	act	aaa	aat	cct	aat	cat	gtc	gtc	tgt	aca	ttt	ttt	gag	gac	144
Leu	Leu	Thr	Lys	Asn	Pro	Asn	His	Val	Val	Cys	Thr	Phe	Phe	Glu	Asp	
		35					40					45				
tgt	acc	atg	gag	agc	ctc	ttt	cct	gct	ctt	tgt	gct	cat	gca	tca	caa	192
Cys	Thr	Met	Glu	Ser	Leu	Phe	Pro	Ala	Leu	Cys	Ala	His	Ala	Ser	Gln	
	50					55				60						
gac	gat	cct	ttg	tat	gta	ctt	gga	aat	tcc	tac	tgt	tgg	ttc	gta	tct	240
Asp	Asp	Pro	Leu	Tyr	Val	Leu	Gly	Asn	Ser	Tyr	Cys	Trp	Phe	Val	Ser	
65					70					75					80	
aaa	ctc	cat	atc	acg	gac	ccc	aaa	gag	gct	ctt	ttt	aaa	gaa	aaa	gga	288
Lys	Leu	His	Ile	Thr	Asp	Pro	Lys	Glu	Ala	Leu	Phe	Lys	Glu	Lys	Gly	
			85					90					95			
gat	ctt	tcc	att	caa	aac	ttt	cgc	ttc	ctt	tcc	ttc	aca	gat	tgc	tct	336
Asp	Leu	Ser	Ile	Gln	Asn	Phe	Arg	Phe	Leu	Ser	Phe	Thr	Asp	Cys	Ser	
			100				105						110			
tcc	aag	gaa	agc	tct	cct	tct	att	att	cat	caa	aag	aat	ggt	cag	tta	384
Ser	Lys	Glu	Ser	Ser	Pro	Ser	Ile	Ile	His	Gln	Lys	Asn	Gly	Gln	Leu	
		115					120					125				
tcc	ttg	cgc	aat	aat	ggt	agc	atg	agt	ttc	tgt	cga	aat	cat	gct	gaa	432
Ser	Leu	Arg	Asn	Asn	Gly	Ser	Met	Ser	Phe	Cys	Arg	Asn	His	Ala	Glu	
	130					135					140					
ggc	tct	gga	gga	gcc	atc	tct	gcg	gat	gcc	ttt	tct	cta	cag	cac	aac	480
Gly	Ser	Gly	Gly	Ala	Ile	Ser	Ala	Asp	Ala	Phe	Ser	Leu	Gln	His	Asn	
145					150					155					160	
tat	ctt	ttc	aca	gct	ttt	gaa	gag	aat	tct	tct	aaa	gga	aat	ggc	gga	528
Tyr	Leu	Phe	Thr	Ala	Phe	Glu	Glu	Asn	Ser	Ser	Lys	Gly	Asn	Gly	Gly	
				165					170					175		
gcc	att	cag	gct	caa	acc	ttc	tct	tta	tct	aga	aat	gtg	tcg	cct	att	576
Ala	Ile	Gln	Ala	Gln	Thr	Phe	Ser	Leu	Ser	Arg	Asn	Val	Ser	Pro	Ile	
			180					185					190			
tct	ttc	gcc	cgt	aat	cgt	gcg	gat	tta	aat	ggc	ggc	gct	att	tgc	tgt	624
Ser	Phe	Ala	Arg	Asn	Arg	Ala	Asp	Leu	Asn	Gly	Gly	Ala	Ile	Cys	Cys	
		195					200					205				
agt	aat	ctt	att	tgt	tca	ggg	aat	gta	aac	cct	ctc	ttt	ttc	act	gga	672
Ser	Asn	Leu	Ile	Cys	Ser	Gly	Asn	Val	Asn	Pro	Leu	Phe	Phe	Thr	Gly	
	210					215					220					

FIG. 6A

aac tcc gcc acg aat gga ggc gct att tgt tgt atc agc gat cta aac	720
Asn Ser Ala Thr Asn Gly Gly Ala Ile Cys Cys Ile Ser Asp Leu Asn	
225 230 235 240	
acc tca gaa aaa ggc tct ctc tct ctt gct tgt aac caa gaa acg cta	768
Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn Gln Glu Thr Leu	
245 250 255	
ttt gca agc aat tct gct aaa gaa aaa ggc ggg gct att tat gcc aag	816
Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala Ile Tyr Ala Lys	
260 265 270	
cac atg gta ttg cgt tat aac ggt cct gtt tcc ttc att aac aac agc	864
His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe Ile Asn Asn Ser	
275 280 285	
gct aaa ata ggt gga gct atc gcc atc cag tcc gga ggg agt ctc tct	912
Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly Gly Ser Leu Ser	
290 295 300	
atc ctt gca ggt gaa gga tct gtt ctg ttc cag aat aac tcc caa cgc	960
Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn Asn Ser Gln Arg	
305 310 315 320	
acc tcc gac caa ggt cta gta aga aac gcc atc tac tta gag aaa gat	1008
Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr Leu Glu Lys Asp	
325 330 335	
gcg att ctt tct tcc tta gaa gct cgc aac gga gat att ctt ttc ttt	1056
Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp Ile Leu Phe Phe	
340 345 350	
gat cct att gta caa gaa agt agc agc aaa gaa tcg cct ctt ccc tcc	1104
Asp Pro Ile Val Gln Glu Ser Ser Ser Lys Glu Ser Pro Leu Pro Ser	
355 360 365	
tct ttg caa gcc agc gtg act tct ccc acc cca gcc acc gca tct cct	1152
Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala Thr Ala Ser Pro	
370 375 380	
tta gtt att cag aca agt gca aac cgt tca gtg att ttc tcg agc gaa	1200
Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile Phe Ser Ser Glu	
385 390 395 400	
cgt ctt tct gaa gaa gaa aaa act cct gat aac ctc act tcc caa cta	1248
Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser Gln Leu	
405 410 415	
cag cag cct atc gaa ctg aaa tcc gga cgc tta gtt tta aaa gat cgc	1296
Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys Asp Arg	
420 425 430	
gct gtc ctt tcc gcg cct tct ctc tct cag gat cct caa gct ctc ctc	1344
Ala Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala Leu Leu	
435 440 445	

FIG. 6B

(SHEET 12 OF 14)

FIG. 6C

acg acc tcc tat ata gct act gta caa gcg caa ctc gct acc tct cta	2064
Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu Ala Thr Ser Leu	
675 680 685	
atg aaa atc tct gca cag gca tgc tac aat gaa agt atc cat gag cta	2112
Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser Ile His Glu Leu	
690 695 700	
aaa aca aaa tat cgc tcc ttc tct aaa gaa gga ttc gga tcc tgg cat	2160
Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe Gly Ser Trp His	
705 710 715 720	
agc gtt gca gta tcc gga gaa gtg tgc gca tcg att cct att gta tcc	2208
Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile Pro Ile Val Ser	
725 730 735	
aat ggt tcc gga ctg ttc agc tcc ttc tct att ttc tct aaa ctg caa	2256
Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe Ser Lys Leu Gln	
740 745 750	
gga ttt tca gga aca cag gac ggt ttt gag gag agt tcg gga gag att	2304
Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser Ser Gly Glu Ile	
755 760 765	
cgg tcc ttt tct gcc agc tct ttc aga aat att tca ctt cct ata gga	2352
Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser Leu Pro Ile Gly	
770 775 780	
ata aca ttt gaa aaa aaa tcc caa aaa aca cga acc tac tat tac ttt	2400
Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr Tyr Tyr Tyr Phe	
785 790 795 800	
cta gga gcc tac atc caa gac ctg aaa cgt gat gtg gaa tcg gga cct	2448
Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val Glu Ser Gly Pro	
805 810 815	
gta gtg tta ctc aaa aat gcc gtc tcc tgg gat gct cct atg gcg aac	2496
Val Val Leu Leu Lys Asn Ala Val Ser Trp Asp Ala Pro Met Ala Asn	
820 825 830	
ttg gat tca cga gcc tac atg ttc agg ctt acg aat caa aga gct cta	2544
Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn Gln Arg Ala Leu	
835 840 845	
cac aga ctt cag acg ctg tta aat gtg tct tgt gtg ctg cgt ggg caa	2592
His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val Leu Arg Gly Gln	
850 855 860	
agc cat agt tac tcc ctg gat ctg ggg acc act tac agg ttc	2634
Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr Arg Phe	
865 870 875	
tag	2637

FIG. 6D




FIG. 7

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

and for which a patent application:

☒ is attached hereto and includes amendment(s) filed on (if applicable)

☐ was filed in the United States on as Application No. (for declaration not accompanying application)

with amendment(s) filed on (if applicable)

☐ was filed as PCT international Application No. on and was amended under PCT Article 19 on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint S. Leslie Misrock (Reg. No. 18872), Berj A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28462), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Patik (Reg. No. 25510), Thomas E. Friebe (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Stimpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33885), Ann L. Gisolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Familant (Reg. No. 35514), Kelly D. Talcott (Reg. No. 39582), Francis D. Carrito (Reg. No. 38100), Anthony M. Insogna (Reg. No. 35203), Brian M. Kothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.


SEND CORRESPONDENCE TO:

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, N.Y. 10036-2711

DIRECT TELEPHONE CALLS TO:
PENNIE & EDMONDS LLP DOCKETING
(212) 790-2803

201	FULL NAME OF INVENTOR	LAST NAME Jackson	FIRST NAME W.	MIDDLE NAME James
	RESIDENCE & CITIZENSHIP	CITY Marriottsville	STATE OR FOREIGN COUNTRY Maryland	COUNTRY OF CITIZENSHIP U.S.A.
	POST OFFICE ADDRESS	STREET 1687 Armistice Way	CITY Marriottsville	STATE OR COUNTRY Maryland ZIP CODE 21104
202	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY ZIP CODE
203	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY ZIP CODE
204	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY ZIP CODE
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	STREET	CITY	STATE OR COUNTRY ZIP CODE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201  W. James Jackson	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
DATE 10/2/00	DATE	DATE
SIGNATURE OF INVENTOR 204	SIGNATURE OF INVENTOR 205	SIGNATURE OF INVENTOR 206
DATE	DATE	DATE

EXPRESS MAIL NO.: EL 501 634 175 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: W. James Jackson

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: Concurrently herewith

Examiner: To be assigned

For: CHLAMYDIA PROTEIN, GENE
SEQUENCE AND USES THEREOF

Attorney Docket No.: 7969-087

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicant, in connection with the above-identified patent application, submits herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date October 2, 2000

Geraldine F. Baldwin 31,232
Geraldine F. Baldwin (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosure

by Margaret B. Baldwin
Reg No. 40,922

SEQUENCE LISTING

<110> W. James Jackson

<120> CHLAMYDIA PROTEIN, GENE SEQUENCE AND USES THEREOF

<130> 7969-087

<160> 71

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2898

<212> DNA

<213> Chlamydia sp

<220>

<221> CDS

<222> (1)...(2895)

<400> 1

atg	aaa	aaa	gcg	ttt	ttc	ttt	ttc	ctt	att	gga	aac	tcc	cta	tca	gga	48
Met	Lys	Lys	Ala	Phe	Phe	Phe	Phe	Leu	Ile	Gly	Asn	Ser	Leu	Ser	Gly	
1				5					10					15		
cta	gct	aga	gag	gtt	cct	tct	aga	atc	ttt	ctt	atg	ccc	aac	tca	gtt	96
Leu	Ala	Arg	Glu	Val	Pro	Ser	Arg	Ile	Phe	Leu	Met	Pro	Asn	Ser	Val	
			20					25					30			
cca	gat	cct	acg	aaa	gag	tcg	cta	tca	aat	aaa	att	agt	ttg	aca	gga	144
Pro	Asp	Pro	Thr	Lys	Glu	Ser	Leu	Ser	Asn	Lys	Ile	Ser	Leu	Thr	Gly	
		35					40					45				
gac	act	cac	aat	ctc	act	aac	tgc	tat	ctc	gat	aac	cta	cgc	tac	ata	192
Asp	Thr	His	Asn	Leu	Thr	Asn	Cys	Tyr	Leu	Asp	Asn	Leu	Arg	Tyr	Ile	
	50					55					60					
ctg	gct	att	cta	caa	aaa	act	ccc	aat	gaa	gga	gct	gct	gtc	aca	ata	240
Leu	Ala	Ile	Leu	Gln	Lys	Thr	Pro	Asn	Glu	Gly	Ala	Ala	Val	Thr	Ile	
65				70					75				80			
aca	gat	tac	cta	agc	ttt	ttt	gat	aca	caa	aaa	gaa	ggg	att	tat	ttt	288
Thr	Asp	Tyr	Leu	Ser	Phe	Phe	Asp	Thr	Gln	Lys	Glu	Gly	Ile	Tyr	Phe	
			85					90					95			
gca	aaa	aat	ctc	acc	cct	gaa	agt	ggg	ggg	gcg	att	ggg	tat	gcg	agt	336
Ala	Lys	Asn	Leu	Thr	Pro	Glu	Ser	Gly	Gly	Ala	Ile	Gly	Tyr	Ala	Ser	
		100						105					110			
ccc	aat	tct	cct	acc	gtg	gag	att	cgt	gat	aca	ata	ggg	cct	gta	atc	384
Pro	Asn	Ser	Pro	Thr	Val	Glu	Ile	Arg	Asp	Thr	Ile	Gly	Pro	Val	Ile	
		115					120					125				
ttt	gaa	aat	aat	act	tgt	tgc	aga	cca	ttt	aca	tcg	agt	aat	cct	aat	432
Phe	Glu	Asn	Asn	Thr	Cys	Cys	Arg	Pro	Phe	Thr	Ser	Ser	Asn	Pro	Asn	
130						135					140					

gca gct gtt aat aaa ata aga gaa ggc gga gcc att cat gct caa aat	480
Ala Ala Val Asn Lys Ile Arg Glu Gly Gly Ala Ile His Ala Gln Asn	
145 150 155 160	
ctt tac ata aat cat aat cat gat gtg gtc gga ttt atg aag aac ttt	528
Leu Tyr Ile Asn His Asn His Asp Val Val Gly Phe Met Lys Asn Phe	
165 170 175	
tct tat gtc cga gga gga gcc att agt acc gct aat acc ttt gtt gtg	576
Ser Tyr Val Arg Gly Gly Ala Ile Ser Thr Ala Asn Thr Phe Val Val	
180 185 190	
agc gag aat cag tct tgt ttt ctc ttt atg gac aac atc tgt att caa	624
Ser Glu Asn Gln Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln	
195 200 205	
act aat aca gca gga aaa ggt ggc gct atc tat gct gga acg agc aat	672
Thr Asn Thr Ala Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn	
210 215 220	
tct ttt gag agt aat aac tgc gat ctc ttc ttt atc aat aac gcc tgt	720
Ser Phe Glu Ser Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys	
225 230 235 240	
tgt gca gga gga gcg atc ttc tcc cct atc tgt tct cta aca gga aat	768
Cys Ala Gly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn	
245 250 255	
cgt ggt aac atc gtt ttc tat aac aat cgc tgc ttt aaa aat gta gaa	816
Arg Gly Asn Ile Val Phe Tyr Asn Asn Arg Cys Phe Lys Asn Val Glu	
260 265 270	
aca gct tct tca gaa gct tct gat gga gga gca att aaa gta act act	864
Thr Ala Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr	
275 280 285	
cgc cta gat gtt aca ggc aat cgt ggt agg atc ttt ttt agt gac aat	912
Arg Leu Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn	
290 295 300	
atc aca aaa aat tat ggc gga gct att tac gct cct gta gtt acc cta	960
Ile Thr Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu	
305 310 315 320	
gtg gat aat ggc cct acc tac ttt ata aac aat atc gcc aat aat aag	1008
Val Asp Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys	
325 330 335	
ggg ggc gct atc tat ata gac gga acc agc aac tcc aaa att tct gcc	1056
Gly Gly Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala	
340 345 350	
gac cgc cat gct att att ttt aat gaa aat att gtg act aat gta act	1104
Asp Arg His Ala Ile Ile Phe Asn Glu Asn Ile Val Thr Asn Val Thr	
355 360 365	

aat gca aat ggt acc agt acg tca gct aat cct cct aga aga aat gca	1152
Asn Ala Asn Gly Thr Ser Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala	
370 375 380	
ata aca gta gca agc tcc tct ggt gaa att cta tta gga gca ggg agt	1200
Ile Thr Val Ala Ser Ser Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser	
385 390 395 400	
agc caa aat tta att ttt tat gat cct att gaa gtt agc aat gca ggg	1248
Ser Gln Asn Leu Ile Phe Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly	
405 410 415	
gtc tct gtg tcc ttc aat aag gaa gct gat caa aca ggc tct gta gta	1296
Val Ser Val Ser Phe Asn Lys Glu Ala Asp Gln Thr Gly Ser Val Val	
420 425 430	
ttt tca gga gct act gtt aat tct gca gat ttt cat caa cgc aat tta	1344
Phe Ser Gly Ala Thr Val Asn Ser Ala Asp Phe His Gln Arg Asn Leu	
435 440 445	
caa aca aaa aca cct gca ccc ctt act ctc agt aat ggt ttt cta tgt	1392
Gln Thr Lys Thr Pro Ala Pro Leu Thr Leu Ser Asn Gly Phe Leu Cys	
450 455 460	
atc gaa gat cat gct cag ctt aca gtg aat cga ttc aca caa act ggg	1440
Ile Glu Asp His Ala Gln Leu Thr Val Asn Arg Phe Thr Gln Thr Gly	
465 470 475 480	
ggg gtt gtt tct ctt ggg aat gga gca gtt ctg agt tgc tat aaa aat	1488
Gly Val Val Ser Leu Gly Asn Gly Ala Val Leu Ser Cys Tyr Lys Asn	
485 490 495	
ggg gca gga aat tct gct agc aat gcc tct ata aca ctg aag cat att	1536
Gly Ala Gly Asn Ser Ala Ser Asn Ala Ser Ile Thr Leu Lys His Ile	
500 505 510	
gga ttg aat ctt tct tcc att ctg aaa agt ggt gct gag att cct tta	1584
Gly Leu Asn Leu Ser Ser Ile Leu Lys Ser Gly Ala Glu Ile Pro Leu	
515 520 525	
ttg tgg gta gag cct aca aat aac agc aat aac tat aca gca gat act	1632
Leu Trp Val Glu Pro Thr Asn Asn Ser Asn Asn Tyr Thr Ala Asp Thr	
530 535 540	
gca gct acc ttt tca tta agt gat gta aaa ctc tca ctc att gat gac	1680
Ala Ala Thr Phe Ser Leu Ser Asp Val Lys Leu Ser Leu Ile Asp Asp	
545 550 555 560	
tat ggg aat tct cct tat gaa tcc aca gat cta acc cat gct ctg tca	1728
Tyr Gly Asn Ser Pro Tyr Glu Ser Thr Asp Leu Thr His Ala Leu Ser	
565 570 575	
tca cag cct atg cta tct att tct gag gct agt gat aac cag cta aga	1776
Ser Gln Pro Met Leu Ser Ile Ser Glu Ala Ser Asp Asn Gln Leu Arg	
580 585 590	

tct gat gat atg gat ttt tcg gga cta aat gtc cct cat tat gga tgg	1824
Ser Asp Asp Met Asp Phe Ser Gly Leu Asn Val Pro His Tyr Gly Trp	
595 600 605	
caa gga ctt tgg act tgg ggc tgg gca aaa act caa gat cca gaa cca	1872
Gln Gly Leu Trp Thr Trp Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro	
610 615 620	
gca tct tca gca aca atc aca gat cca caa aaa gcc aat aga ttc cat	1920
Ala Ser Ser Ala Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His	
625 630 635 640	
aga acc tta tta ctg act tgg ctt cct gct ggg tat gtt cct agc ccg	1968
Arg Thr Leu Leu Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro	
645 650 655	
aaa cac aga agt ccc ctc ata gcg aat acc tta tgg ggg aat atg ctg	2016
Lys His Arg Ser Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu	
660 665 670	
ctt gca aca gaa agc tta aaa aat agt gca gaa ctg aca cct agt gat	2064
Leu Ala Thr Glu Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Asp	
675 680 685	
cat cct ttc tgg gga att aca gga gga gga cta ggc atg atg gtt tac	2112
His Pro Phe Trp Gly Ile Thr Gly Gly Gly Leu Gly Met Met Val Tyr	
690 695 700	
caa gat cct cga gaa aat cat cct gga ttc cat atg cgc tct tcc gga	2160
Gln Asp Pro Arg Glu Asn His Pro Gly Phe His Met Arg Ser Ser Gly	
705 710 715 720	
tac tct gcg ggg atg ata gca ggg cag aca cac acc ttc tca ttg aaa	2208
Tyr Ser Ala Gly Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys	
725 730 735	
ttc agt cag acc tac acc aaa ctc aat gag cgt tac gca aaa aac aac	2256
Phe Ser Gln Thr Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn	
740 745 750	
gta tct tct aaa aat tac tca tgc caa gga gaa atg ctc ttc tca ttg	2304
Val Ser Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu	
755 760 765	
caa gaa ggt ttc ttg ctg act aaa tta gtt ggg ctt tac agc tat gga	2352
Gln Glu Gly Phe Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly	
770 775 780	
gac cat aac tgt cac cat ttc tat acc caa gga gaa aat cta aca tct	2400
Asp His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser	
785 790 795 800	
caa ggg acg ttc cgt agt caa acg atg gga ggt gct gtt ttt ttt gat	2448
Gln Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp	
805 810 815	

Thr	Asp	Tyr	Leu	Ser	Phe	Phe	Asp	Thr	Gln	Lys	Glu	Gly	Ile	Tyr	Phe	
				85					90					95		
Ala	Lys	Asn	Leu	Thr	Pro	Glu	Ser	Gly	Gly	Ala	Ile	Gly	Tyr	Ala	Ser	
			100					105					110			
Pro	Asn	Ser	Pro	Thr	Val	Glu	Ile	Arg	Asp	Thr	Ile	Gly	Pro	Val	Ile	
		115					120					125				
Phe	Glu	Asn	Asn	Thr	Cys	Cys	Arg	Pro	Phe	Thr	Ser	Ser	Asn	Pro	Asn	
	130					135					140					
Ala	Ala	Val	Asn	Lys	Ile	Arg	Glu	Gly	Gly	Ala	Ile	His	Ala	Gln	Asn	
145					150					155					160	
Leu	Tyr	Ile	Asn	His	Asn	His	Asp	Val	Val	Gly	Phe	Met	Lys	Asn	Phe	
			165						170					175		
Ser	Tyr	Val	Arg	Gly	Gly	Ala	Ile	Ser	Thr	Ala	Asn	Thr	Phe	Val	Val	
		180						185					190			
Ser	Glu	Asn	Gln	Ser	Cys	Phe	Leu	Phe	Met	Asp	Asn	Ile	Cys	Ile	Gln	
	195						200					205				
Thr	Asn	Thr	Ala	Gly	Lys	Gly	Gly	Ala	Ile	Tyr	Ala	Gly	Thr	Ser	Asn	
	210					215					220					
Ser	Phe	Glu	Ser	Asn	Asn	Cys	Asp	Leu	Phe	Phe	Ile	Asn	Asn	Ala	Cys	
225				230						235					240	
Cys	Ala	Gly	Gly	Ala	Ile	Phe	Ser	Pro	Ile	Cys	Ser	Leu	Thr	Gly	Asn	
			245					250						255		
Arg	Gly	Asn	Ile	Val	Phe	Tyr	Asn	Asn	Arg	Cys	Phe	Lys	Asn	Val	Glu	
		260						265					270			
Thr	Ala	Ser	Ser	Glu	Ala	Ser	Asp	Gly	Gly	Ala	Ile	Lys	Val	Thr	Thr	
	275						280					285				
Arg	Leu	Asp	Val	Thr	Gly	Asn	Arg	Gly	Arg	Ile	Phe	Phe	Ser	Asp	Asn	
	290					295					300					
Ile	Thr	Lys	Asn	Tyr	Gly	Gly	Ala	Ile	Tyr	Ala	Pro	Val	Val	Thr	Leu	
305				310					315						320	
Val	Asp	Asn	Gly	Pro	Thr	Tyr	Phe	Ile	Asn	Asn	Ile	Ala	Asn	Asn	Lys	
			325					330					335			
Gly	Gly	Ala	Ile	Tyr	Ile	Asp	Gly	Thr	Ser	Asn	Ser	Lys	Ile	Ser	Ala	
		340					345					350				
Asp	Arg	His	Ala	Ile	Ile	Phe	Asn	Glu	Asn	Ile	Val	Thr	Asn	Val	Thr	
	355						360					365				
Asn	Ala	Asn	Gly	Thr	Ser	Thr	Ser	Ala	Asn	Pro	Pro	Arg	Arg	Asn	Ala	
	370					375				380						
Ile	Thr	Val	Ala	Ser	Ser	Ser	Gly	Glu	Ile	Leu	Leu	Gly	Ala	Gly	Ser	
385				390					395					400		
Ser	Gln	Asn	Leu	Ile	Phe	Tyr	Asp	Pro	Ile	Glu	Val	Ser	Asn	Ala	Gly	
			405					410					415			
Val	Ser	Val	Ser	Phe	Asn	Lys	Glu	Ala	Asp	Gln	Thr	Gly	Ser	Val	Val	
		420					425					430				
Phe	Ser	Gly	Ala	Thr	Val	Asn	Ser	Ala	Asp	Phe	His	Gln	Arg	Asn	Leu	
	435					440					445					
Gln	Thr	Lys	Thr	Pro	Ala	Pro	Leu	Thr	Leu	Ser	Asn	Gly	Phe	Leu	Cys	
	450				455						460					
Ile	Glu	Asp	His	Ala	Gln	Leu	Thr	Val	Asn	Arg	Phe	Thr	Gln	Thr	Gly	
465				470					475					480		
Gly	Val	Val	Ser	Leu	Gly	Asn	Gly	Ala	Val	Leu	Ser	Cys	Tyr	Lys	Asn	
			485					490					495			
Gly	Ala	Gly	Asn	Ser	Ala	Ser	Asn	Ala	Ser	Ile	Thr	Leu	Lys	His	Ile	
		500					505					510				
Gly	Leu	Asn	Leu	Ser	Ser	Ile	Leu	Lys	Ser	Gly	Ala	Glu	Ile	Pro	Leu	
	515					520						525				
Leu	Trp	Val	Glu	Pro	Thr	Asn	Asn	Ser	Asn	Asn	Tyr	Thr	Ala	Asp	Thr	
	530					535					540					

Ala	Ala	Thr	Phe	Ser	Leu	Ser	Asp	Val	Lys	Leu	Ser	Leu	Ile	Asp	Asp
545					550					555					560
Tyr	Gly	Asn	Ser	Pro	Tyr	Glu	Ser	Thr	Asp	Leu	Thr	His	Ala	Leu	Ser
				565					570					575	
Ser	Gln	Pro	Met	Leu	Ser	Ile	Ser	Glu	Ala	Ser	Asp	Asn	Gln	Leu	Arg
			580					585					590		
Ser	Asp	Asp	Met	Asp	Phe	Ser	Gly	Leu	Asn	Val	Pro	His	Tyr	Gly	Trp
		595					600					605			
Gln	Gly	Leu	Trp	Thr	Trp	Gly	Trp	Ala	Lys	Thr	Gln	Asp	Pro	Glu	Pro
	610					615					620				
Ala	Ser	Ser	Ala	Thr	Ile	Thr	Asp	Pro	Gln	Lys	Ala	Asn	Arg	Phe	His
625					630					635					640
Arg	Thr	Leu	Leu	Leu	Thr	Trp	Leu	Pro	Ala	Gly	Tyr	Val	Pro	Ser	Pro
				645					650					655	
Lys	His	Arg	Ser	Pro	Leu	Ile	Ala	Asn	Thr	Leu	Trp	Gly	Asn	Met	Leu
			660					665					670		
Leu	Ala	Thr	Glu	Ser	Leu	Lys	Asn	Ser	Ala	Glu	Leu	Thr	Pro	Ser	Asp
		675					680					685			
His	Pro	Phe	Trp	Gly	Ile	Thr	Gly	Gly	Gly	Leu	Gly	Met	Met	Val	Tyr
	690					695					700				
Gln	Asp	Pro	Arg	Glu	Asn	His	Pro	Gly	Phe	His	Met	Arg	Ser	Ser	Gly
705					710					715					720
Tyr	Ser	Ala	Gly	Met	Ile	Ala	Gly	Gln	Thr	His	Thr	Phe	Ser	Leu	Lys
				725					730					735	
Phe	Ser	Gln	Thr	Tyr	Thr	Lys	Leu	Asn	Glu	Arg	Tyr	Ala	Lys	Asn	Asn
			740					745					750		
Val	Ser	Ser	Lys	Asn	Tyr	Ser	Cys	Gln	Gly	Glu	Met	Leu	Phe	Ser	Leu
		755					760					765			
Gln	Glu	Gly	Phe	Leu	Leu	Thr	Lys	Leu	Val	Gly	Leu	Tyr	Ser	Tyr	Gly
	770					775					780				
Asp	His	Asn	Cys	His	His	Phe	Tyr	Thr	Gln	Gly	Glu	Asn	Leu	Thr	Ser
785					790					795					800
Gln	Gly	Thr	Phe	Arg	Ser	Gln	Thr	Met	Gly	Gly	Ala	Val	Phe	Phe	Asp
				805					810					815	
Leu	Pro	Met	Lys	Pro	Phe	Gly	Ser	Thr	His	Ile	Leu	Thr	Ala	Pro	Phe
			820					825					830		
Leu	Gly	Ala	Leu	Gly	Ile	Tyr	Ser	Ser	Leu	Ser	His	Phe	Thr	Glu	Val
		835					840					845			
Gly	Ala	Tyr	Pro	Arg	Ser	Phe	Ser	Thr	Lys	Thr	Pro	Leu	Ile	Asn	Val
	850					855					860				
Leu	Val	Pro	Ile	Gly	Val	Lys	Gly	Ser	Phe	Met	Asn	Ala	Thr	Gln	Arg
865					870					875					880
Pro	Gln	Ala	Trp	Thr	Val	Glu	Leu	Ala	Tyr	Gln	Pro	Val	Leu	Tyr	Arg
				885					890					895	
Gln	Glu														

<210> 3
<211> 2637
<212> DNA

<213> Chlamydia sp

<220>

<221> CDS

<222> (1) ... (2634)

<400> 3

atg cga cct gat cat atg aac ttc tgt tgt cta tgt gct gct att ttg	48
Met Arg Pro Asp His Met Asn Phe Cys Cys Leu Cys Ala Ala Ile Leu	
1 5 10 15	
tca tcc aca gcg gtc ctc ttt ggc cag gat ccc tta ggt gaa acc gcc	96
Ser Ser Thr Ala Val Leu Phe Gly Gln Asp Pro Leu Gly Glu Thr Ala	
20 25 30	
ctc ctc act aaa aat cct aat cat gtc gtc tgt aca ttt ttt gag gac	144
Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr Phe Phe Glu Asp	
35 40 45	
tgt acc atg gag agc ctc ttt cct gct ctt tgt gct cat gca tca caa	192
Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala His Ala Ser Gln	
50 55 60	
gac gat cct ttg tat gta ctt gga aat tcc tac tgt tgg ttc gta tct	240
Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys Trp Phe Val Ser	
65 70 75 80	
aaa ctc cat atc acg gac ccc aaa gag gct ctt ttt aaa gaa aaa gga	288
Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe Lys Glu Lys Gly	
85 90 95	
gat ctt tcc att caa aac ttt cgc ttc ctt tcc ttc aca gat tgc tct	336
Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe Thr Asp Cys Ser	
100 105 110	
tcc aag gaa agc tct cct tct att att cat caa aag aat ggt cag tta	384
Ser Lys Glu Ser Ser Pro Ser Ile Ile His Gln Lys Asn Gly Gln Leu	
115 120 125	
tcc ttg cgc aat aat ggt agc atg agt ttc tgt cga aat cat gct gaa	432
Ser Leu Arg Asn Asn Gly Ser Met Ser Phe Cys Arg Asn His Ala Glu	
130 135 140	
ggc tct gga gga gcc atc tct gcg gat gcc ttt tct cta cag cac aac	480
Gly Ser Gly Gly Ala Ile Ser Ala Asp Ala Phe Ser Leu Gln His Asn	
145 150 155 160	
tat ctt ttc aca gct ttt gaa gag aat tct tct aaa gga aat ggc gga	528
Tyr Leu Phe Thr Ala Phe Glu Glu Asn Ser Ser Lys Gly Asn Gly Gly	
165 170 175	
gcc att cag gct caa acc ttc tct tta tct aga aat gtg tcg cct att	576
Ala Ile Gln Ala Gln Thr Phe Ser Leu Ser Arg Asn Val Ser Pro Ile	
180 185 190	
tct ttc gcc cgt aat cgt gcg gat tta aat ggc ggc gct att tgc tgt	624
Ser Phe Ala Arg Asn Arg Ala Asp Leu Asn Gly Gly Ala Ile Cys Cys	
195 200 205	

agt aat ctt att tgt tca ggg aat gta aac cct ctc ttt ttc act gga Ser Asn Leu Ile Cys Ser Gly Asn Val Asn Pro Leu Phe Phe Thr Gly 210 215 220	672
aac tcc gcc acg aat gga ggc gct att tgt tgt atc agc gat cta aac Asn Ser Ala Thr Asn Gly Gly Ala Ile Cys Cys Ile Ser Asp Leu Asn 225 230 235 240	720
acc tca gaa aaa ggc tct ctc tct ctt gct tgt aac caa gaa acg cta Thr Ser Glu Lys Gly Ser Leu Ser Leu Ala Cys Asn Gln Glu Thr Leu 245 250 255	768
ttt gca agc aat tct gct aaa gaa aaa ggc ggg gct att tat gcc aag Phe Ala Ser Asn Ser Ala Lys Glu Lys Gly Gly Ala Ile Tyr Ala Lys 260 265 270	816
cac atg gta ttg cgt tat aac ggt cct gtt tcc ttc att aac aac agc His Met Val Leu Arg Tyr Asn Gly Pro Val Ser Phe Ile Asn Asn Ser 275 280 285	864
gct aaa ata ggt gga gct atc gcc atc cag tcc gga ggg agt ctc tct Ala Lys Ile Gly Gly Ala Ile Ala Ile Gln Ser Gly Gly Ser Leu Ser 290 295 300	912
atc ctt gca ggt gaa gga tct gtt ctg ttc cag aat aac tcc caa cgc Ile Leu Ala Gly Glu Gly Ser Val Leu Phe Gln Asn Asn Ser Gln Arg 305 310 315 320	960
acc tcc gac caa ggt cta gta aga aac gcc atc tac tta gag aaa gat Thr Ser Asp Gln Gly Leu Val Arg Asn Ala Ile Tyr Leu Glu Lys Asp 325 330 335	1008
gcg att ctt tct tcc tta gaa gct cgc aac gga gat att ctt ttc ttt Ala Ile Leu Ser Ser Leu Glu Ala Arg Asn Gly Asp Ile Leu Phe Phe 340 345 350	1056
gat cct att gta caa gaa agt agc agc aaa gaa tcg cct ctt ccc tcc Asp Pro Ile Val Gln Glu Ser Ser Ser Lys Glu Ser Pro Leu Pro Ser 355 360 365	1104
tct ttg caa gcc agc gtg act tct ccc acc cca gcc acc gca tct cct Ser Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala Thr Ala Ser Pro 370 375 380	1152
tta gtt att cag aca agt gca aac cgt tca gtg att ttc tcg agc gaa Leu Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile Phe Ser Ser Glu 385 390 395 400	1200
cgt ctt tct gaa gaa gaa aaa act cct gat aac ctc act tcc caa cta Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser Gln Leu 405 410 415	1248
cag cag cct atc gaa ctg aaa tcc gga cgc tta gtt tta aaa gat cgc Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys Asp Arg 420 425 430	1296

gct gtc ctt tcc gcg cct tct ctc tct cag gat cct caa gct ctc ctc	1344
Ala Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala Leu Leu	
435 440 445	
att atg gaa gcg gga act tct tta aaa act tcc tct gat ttg aag tta	1392
Ile Met Glu Ala Gly Thr Ser Leu Lys Thr Ser Ser Asp Leu Lys Leu	
450 455 460	
gct acg cta agt att ccc ctt cat tcc tta gat act gaa aaa agc gta	1440
Ala Thr Leu Ser Ile Pro Leu His Ser Leu Asp Thr Glu Lys Ser Val	
465 470 475 480	
act atc cac gcc cct aac ctt tct atc caa aag atc ttc ctc tct aat	1488
Thr Ile His Ala Pro Asn Leu Ser Ile Gln Lys Ile Phe Leu Ser Asn	
485 490 495	
tct gga gat gag aat ttt tat gaa aat gta gag ctt ctc agt aaa gag	1536
Ser Gly Asp Glu Asn Phe Tyr Glu Asn Val Glu Leu Leu Ser Lys Glu	
500 505 510	
caa aac aat att cct ctc ctt act ctc tct aaa gag caa tct cat tta	1584
Gln Asn Asn Ile Pro Leu Leu Thr Leu Ser Lys Glu Gln Ser His Leu	
515 520 525	
cat ctt cct gat ggg aac ctc tct tct cac ttt gga tat caa gga gat	1632
His Leu Pro Asp Gly Asn Leu Ser Ser His Phe Gly Tyr Gln Gly Asp	
530 535 540	
tgg act ttt tct tgg aaa gat tct gat gaa ggg cat tct ctg att gct	1680
Trp Thr Phe Ser Trp Lys Asp Ser Asp Glu Gly His Ser Leu Ile Ala	
545 550 555 560	
aat tgg acg cct aaa aac tat gtg cct cat cca gaa cgt caa tct aca	1728
Asn Trp Thr Pro Lys Asn Tyr Val Pro His Pro Glu Arg Gln Ser Thr	
565 570 575	
ctc gtt gcg aac act ctt tgg aac acc tat tcc gat atg caa gct gtg	1776
Leu Val Ala Asn Thr Leu Trp Asn Thr Tyr Ser Asp Met Gln Ala Val	
580 585 590	
cag tcg atg att aat aca ata gcg cac gga gga gcc tat cta ttt gga	1824
Gln Ser Met Ile Asn Thr Ile Ala His Gly Gly Ala Tyr Leu Phe Gly	
595 600 605	
acg tgg gga tct gct gtt tct aat tta ttc tat gct cac gac agc tct	1872
Thr Trp Gly Ser Ala Val Ser Asn Leu Phe Tyr Ala His Asp Ser Ser	
610 615 620	
ggg aaa cct atc gat aat tgg cat cat aga agc ctt ggc tac cta ttc	1920
Gly Lys Pro Ile Asp Asn Trp His His Arg Ser Leu Gly Tyr Leu Phe	
625 630 635 640	
ggt atc agt act cac agt tta gat gac cat tct ttc tgc ttg gct gca	1968
Gly Ile Ser Thr His Ser Leu Asp Asp His Ser Phe Cys Leu Ala Ala	
645 650 655	

gga caa tta ctc ggg aaa tcg tcc gat tcc ttt att acg tct aca gaa Gly Gln Leu Leu Gly Lys Ser Ser Asp Ser Phe Ile Thr Ser Thr Glu 660 665 670	2016
acg acc tcc tat ata gct act gta caa gcg caa ctc gct acc tct cta Thr Thr Ser Tyr Ile Ala Thr Val Gln Ala Gln Leu Ala Thr Ser Leu 675 680 685	2064
atg aaa atc tct gca cag gca tgc tac aat gaa agt atc cat gag cta Met Lys Ile Ser Ala Gln Ala Cys Tyr Asn Glu Ser Ile His Glu Leu 690 695 700	2112
aaa aca aaa tat cgc tcc ttc tct aaa gaa gga ttc gga tcc tgg cat Lys Thr Lys Tyr Arg Ser Phe Ser Lys Glu Gly Phe Gly Ser Trp His 705 710 715 720	2160
agc gtt gca gta tcc gga gaa gtg tgc gca tcg att cct att gta tcc Ser Val Ala Val Ser Gly Glu Val Cys Ala Ser Ile Pro Ile Val Ser 725 730 735	2208
aat ggt tcc gga ctg ttc agc tcc ttc tct att ttc tct aaa ctg caa Asn Gly Ser Gly Leu Phe Ser Ser Phe Ser Ile Phe Ser Lys Leu Gln 740 745 750	2256
gga ttt tca gga aca cag gac ggt ttt gag gag agt tcg gga gag att Gly Phe Ser Gly Thr Gln Asp Gly Phe Glu Glu Ser Ser Gly Glu Ile 755 760 765	2304
cgg tcc ttt tct gcc agc tct ttc aga aat att tca ctt cct ata gga Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser Leu Pro Ile Gly 770 775 780	2352
ata aca ttt gaa aaa aaa tcc caa aaa aca cga acc tac tat tac ttt Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr Tyr Tyr Tyr Phe 785 790 795 800	2400
cta gga gcc tac atc caa gac ctg aaa cgt gat gtg gaa tcg gga cct Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val Glu Ser Gly Pro 805 810 815	2448
gta gtg tta ctc aaa aat gcc gtc tcc tgg gat gct cct atg gcg aac Val Val Leu Leu Lys Asn Ala Val Ser Trp Asp Ala Pro Met Ala Asn 820 825 830	2496
ttg gat tca cga gcc tac atg ttc agg ctt acg aat caa aga gct cta Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn Gln Arg Ala Leu 835 840 845	2544
cac aga ctt cag acg ctg tta aat gtg tct tgt gtg ctg cgt ggg caa His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val Leu Arg Gly Gln 850 855 860	2592
agc cat agt tac tcc ctg gat ctg ggg acc act tac agg ttc Ser His Ser Tyr Ser Leu Asp Leu Gly Thr Thr Tyr Arg Phe 865 870 875	2634
tag	2637

<210> 4
 <211> 878
 <212> PRT
 <213> Chlamydia sp

<400> 4

Met	Arg	Pro	Asp	His	Met	Asn	Phe	Cys	Cys	Leu	Cys	Ala	Ala	Ile	Leu
1				5					10					15	
Ser	Ser	Thr	Ala	Val	Leu	Phe	Gly	Gln	Asp	Pro	Leu	Gly	Glu	Thr	Ala
			20					25					30		
Leu	Leu	Thr	Lys	Asn	Pro	Asn	His	Val	Val	Cys	Thr	Phe	Phe	Glu	Asp
		35				40						45			
Cys	Thr	Met	Glu	Ser	Leu	Phe	Pro	Ala	Leu	Cys	Ala	His	Ala	Ser	Gln
	50				55					60					
Asp	Asp	Pro	Leu	Tyr	Val	Leu	Gly	Asn	Ser	Tyr	Cys	Trp	Phe	Val	Ser
65				70					75					80	
Lys	Leu	His	Ile	Thr	Asp	Pro	Lys	Glu	Ala	Leu	Phe	Lys	Glu	Lys	Gly
			85					90						95	
Asp	Leu	Ser	Ile	Gln	Asn	Phe	Arg	Phe	Leu	Ser	Phe	Thr	Asp	Cys	Ser
		100					105						110		
Ser	Lys	Glu	Ser	Ser	Pro	Ser	Ile	Ile	His	Gln	Lys	Asn	Gly	Gln	Leu
	115					120						125			
Ser	Leu	Arg	Asn	Asn	Gly	Ser	Met	Ser	Phe	Cys	Arg	Asn	His	Ala	Glu
	130				135					140					
Gly	Ser	Gly	Gly	Ala	Ile	Ser	Ala	Asp	Ala	Phe	Ser	Leu	Gln	His	Asn
145				150					155					160	
Tyr	Leu	Phe	Thr	Ala	Phe	Glu	Glu	Asn	Ser	Ser	Lys	Gly	Asn	Gly	Gly
			165					170						175	
Ala	Ile	Gln	Ala	Gln	Thr	Phe	Ser	Leu	Ser	Arg	Asn	Val	Ser	Pro	Ile
	180						185					190			
Ser	Phe	Ala	Arg	Asn	Arg	Ala	Asp	Leu	Asn	Gly	Gly	Ala	Ile	Cys	Cys
	195					200					205				
Ser	Asn	Leu	Ile	Cys	Ser	Gly	Asn	Val	Asn	Pro	Leu	Phe	Phe	Thr	Gly
	210				215					220					
Asn	Ser	Ala	Thr	Asn	Gly	Gly	Ala	Ile	Cys	Cys	Ile	Ser	Asp	Leu	Asn
225				230					235					240	
Thr	Ser	Glu	Lys	Gly	Ser	Leu	Ser	Leu	Ala	Cys	Asn	Gln	Glu	Thr	Leu
			245					250					255		
Phe	Ala	Ser	Asn	Ser	Ala	Lys	Glu	Lys	Gly	Gly	Ala	Ile	Tyr	Ala	Lys
		260				265						270			
His	Met	Val	Leu	Arg	Tyr	Asn	Gly	Pro	Val	Ser	Phe	Ile	Asn	Asn	Ser
	275					280					285				
Ala	Lys	Ile	Gly	Gly	Ala	Ile	Ala	Ile	Gln	Ser	Gly	Gly	Ser	Leu	Ser
	290				295					300					
Ile	Leu	Ala	Gly	Glu	Gly	Ser	Val	Leu	Phe	Gln	Asn	Asn	Ser	Gln	Arg
305				310					315					320	
Thr	Ser	Asp	Gln	Gly	Leu	Val	Arg	Asn	Ala	Ile	Tyr	Leu	Glu	Lys	Asp
			325					330					335		
Ala	Ile	Leu	Ser	Ser	Leu	Glu	Ala	Arg	Asn	Gly	Asp	Ile	Leu	Phe	Phe
		340					345					350			
Asp	Pro	Ile	Val	Gln	Glu	Ser	Ser	Ser	Lys	Glu	Ser	Pro	Leu	Pro	Ser
	355					360						365			
Ser	Leu	Gln	Ala	Ser	Val	Thr	Ser	Pro	Thr	Pro	Ala	Thr	Ala	Ser	Pro
	370				375					380					
Leu	Val	Ile	Gln	Thr	Ser	Ala	Asn	Arg	Ser	Val	Ile	Phe	Ser	Ser	Glu
385				390					395					400	
Arg	Leu	Ser	Glu	Glu	Glu	Lys	Thr	Pro	Asp	Asn	Leu	Thr	Ser	Gln	Leu
			405					410						415	

Gln	Gln	Pro	Ile	Glu	Leu	Lys	Ser	Gly	Arg	Leu	Val	Leu	Lys	Asp	Arg
			420					425					430		
Ala	Val	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Gln	Asp	Pro	Gln	Ala	Leu	Leu
		435					440					445			
Ile	Met	Glu	Ala	Gly	Thr	Ser	Leu	Lys	Thr	Ser	Ser	Asp	Leu	Lys	Leu
	450					455					460				
Ala	Thr	Leu	Ser	Ile	Pro	Leu	His	Ser	Leu	Asp	Thr	Glu	Lys	Ser	Val
465				470					475						480
Thr	Ile	His	Ala	Pro	Asn	Leu	Ser	Ile	Gln	Lys	Ile	Phe	Leu	Ser	Asn
			485						490					495	
Ser	Gly	Asp	Glu	Asn	Phe	Tyr	Glu	Asn	Val	Glu	Leu	Leu	Ser	Lys	Glu
			500					505					510		
Gln	Asn	Asn	Ile	Pro	Leu	Leu	Thr	Leu	Ser	Lys	Glu	Gln	Ser	His	Leu
		515					520					525			
His	Leu	Pro	Asp	Gly	Asn	Leu	Ser	Ser	His	Phe	Gly	Tyr	Gln	Gly	Asp
	530					535					540				
Trp	Thr	Phe	Ser	Trp	Lys	Asp	Ser	Asp	Glu	Gly	His	Ser	Leu	Ile	Ala
545				550					555						560
Asn	Trp	Thr	Pro	Lys	Asn	Tyr	Val	Pro	His	Pro	Glu	Arg	Gln	Ser	Thr
			565					570					575		
Leu	Val	Ala	Asn	Thr	Leu	Trp	Asn	Thr	Tyr	Ser	Asp	Met	Gln	Ala	Val
			580					585					590		
Gln	Ser	Met	Ile	Asn	Thr	Ile	Ala	His	Gly	Gly	Ala	Tyr	Leu	Phe	Gly
		595					600					605			
Thr	Trp	Gly	Ser	Ala	Val	Ser	Asn	Leu	Phe	Tyr	Ala	His	Asp	Ser	Ser
	610					615					620				
Gly	Lys	Pro	Ile	Asp	Asn	Trp	His	His	Arg	Ser	Leu	Gly	Tyr	Leu	Phe
625				630					635						640
Gly	Ile	Ser	Thr	His	Ser	Leu	Asp	Asp	His	Ser	Phe	Cys	Leu	Ala	Ala
			645						650				655		
Gly	Gln	Leu	Leu	Gly	Lys	Ser	Ser	Asp	Ser	Phe	Ile	Thr	Ser	Thr	Glu
			660					665					670		
Thr	Thr	Ser	Tyr	Ile	Ala	Thr	Val	Gln	Ala	Gln	Leu	Ala	Thr	Ser	Leu
		675					680					685			
Met	Lys	Ile	Ser	Ala	Gln	Ala	Cys	Tyr	Asn	Glu	Ser	Ile	His	Glu	Leu
	690					695					700				
Lys	Thr	Lys	Tyr	Arg	Ser	Phe	Ser	Lys	Glu	Gly	Phe	Gly	Ser	Trp	His
705				710					715						720
Ser	Val	Ala	Val	Ser	Gly	Glu	Val	Cys	Ala	Ser	Ile	Pro	Ile	Val	Ser
			725						730				735		
Asn	Gly	Ser	Gly	Leu	Phe	Ser	Ser	Phe	Ser	Ile	Phe	Ser	Lys	Leu	Gln
			740					745					750		
Gly	Phe	Ser	Gly	Thr	Gln	Asp	Gly	Phe	Glu	Glu	Ser	Ser	Gly	Glu	Ile
	755					760						765			
Arg	Ser	Phe</													

<210> 5
 <211> 42
 <212> PRT
 <213> Chlamydia sp

<400> 5
 Ser Gly Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn
 1 5 10 15
 Ser Val Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu
 20 25 30
 Thr Gly Asp Thr His Asn Leu Thr Asn Cys
 35 40

<210> 6
 <211> 107
 <212> PRT
 <213> Chlamydia sp

<400> 6
 Ser Gly Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn
 1 5 10 15
 Ser Val Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu
 20 25 30
 Thr Gly Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg
 35 40 45
 Tyr Ile Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val
 50 55 60
 Thr Ile Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile
 65 70 75 80
 Tyr Phe Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr
 85 90 95
 Ala Ser Pro Asn Ser Pro Thr Val Glu Ile Arg
 100 105

<210> 7
 <211> 81
 <212> PRT
 <213> Chlamydia sp

<400> 7
 Ser Leu Thr Gly Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn
 1 5 10 15
 Leu Arg Tyr Ile Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala
 20 25 30
 Ala Val Thr Ile Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys Glu
 35 40 45
 Gly Ile Tyr Phe Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala Ile
 50 55 60
 Gly Tyr Ala Ser Pro Asn Ser Pro Thr Val Glu Ile Arg Asp Thr Ile
 65 70 75 80
 Gly

<210> 8
 <211> 66
 <212> PRT
 <213> Chlamydia sp

<400> 8
 Gly Pro Val Ile Phe Glu Asn Asn Thr Cys Cys Arg Pro Phe Thr Ser
 1 5 10 15
 Ser Asn Pro Asn Ala Ala Val Asn Lys Ile Arg Glu Gly Gly Ala Ile
 20 25 30
 His Ala Gln Asn Leu Tyr Ile Asn His Asn His Asp Val Val Gly Phe
 35 40 45
 Met Lys Asn Phe Ser Tyr Val Arg Gly Gly Ala Ile Ser Thr Ala Asn
 50 55 60
 Thr Phe
 65

<210> 9
 <211> 67
 <212> PRT
 <213> Chlamydia sp

<400> 9
 Asn Gln Ser Cys Phe Leu Phe Met Asp Asn Ile Cys Ile Gln Thr Asn
 1 5 10 15
 Thr Ala Gly Lys Gly Gly Ala Ile Tyr Ala Gly Thr Ser Asn Ser Phe
 20 25 30
 Glu Ser Asn Asn Cys Asp Leu Phe Phe Ile Asn Asn Ala Cys Cys Ala
 35 40 45
 Gly Gly Ala Ile Phe Ser Pro Ile Cys Ser Leu Thr Gly Asn Arg Gly
 50 55 60
 Asn Ile Val
 65

<210> 10
 <211> 92
 <212> PRT
 <213> Chlamydia sp

<400> 10
 Ser Ser Glu Ala Ser Asp Gly Gly Ala Ile Lys Val Thr Thr Arg Leu
 1 5 10 15
 Asp Val Thr Gly Asn Arg Gly Arg Ile Phe Phe Ser Asp Asn Ile Thr
 20 25 30
 Lys Asn Tyr Gly Gly Ala Ile Tyr Ala Pro Val Val Thr Leu Val Asp
 35 40 45
 Asn Gly Pro Thr Tyr Phe Ile Asn Asn Ile Ala Asn Asn Lys Gly Gly
 50 55 60
 Ala Ile Tyr Ile Asp Gly Thr Ser Asn Ser Lys Ile Ser Ala Asp Arg
 65 70 75 80
 His Ala Ile Ile Phe Asn Glu Asn Ile Val Thr Asn
 85 90

<210> 11
 <211> 66
 <212> PRT
 <213> Chlamydia sp

<400> 11
 Thr Ser Ala Asn Pro Pro Arg Arg Asn Ala Ile Thr Val Ala Ser Ser
 1 5 10 15
 Ser Gly Glu Ile Leu Leu Gly Ala Gly Ser Ser Gln Asn Leu Ile Phe
 20 25 30

Tyr Asp Pro Ile Glu Val Ser Asn Ala Gly Val Ser Val Ser Phe Asn
 35 40 45
 Lys Glu Ala Asp Gln Thr Gly Ser Val Val Phe Ser Gly Ala Thr Val
 50 55 60
 Asn Ser
 65

<210> 12
 <211> 51
 <212> PRT
 <213> Chlamydia sp

<400> 12
 Ser Ala Asp Phe His Gln Arg Asn Leu Gln Thr Lys Thr Pro Ala Pro
 1 5 10 15
 Leu Thr Leu Ser Asn Gly Phe Leu Cys Ile Glu Asp His Ala Gln Leu
 20 25 30
 Thr Val Asn Arg Phe Thr Gln Thr Gly Gly Val Val Ser Leu Gly Asn
 35 40 45
 Gly Ala Val
 50

<210> 13
 <211> 66
 <212> PRT
 <213> Chlamydia sp

<400> 13
 Glu Ile Pro Leu Leu Trp Val Glu Pro Thr Asn Asn Ser Asn Asn Tyr
 1 5 10 15
 Thr Ala Asp Thr Ala Ala Thr Phe Ser Leu Ser Asp Val Lys Leu Ser
 20 25 30
 Leu Ile Asp Asp Tyr Gly Asn Ser Pro Tyr Glu Ser Thr Asp Leu Thr
 35 40 45
 His Ala Leu Ser Ser Gln Pro Met Leu Ser Ile Ser Glu Ala Ser Asp
 50 55 60
 Asn Gln
 65

<210> 14
 <211> 36
 <212> PRT
 <213> Chlamydia sp

<400> 14
 Gln Leu Arg Ser Asp Asp Met Asp Phe Ser Gly Leu Asn Val Pro His
 1 5 10 15
 Tyr Gly Trp Gln Gly Leu Trp Thr Trp Gly Trp Ala Lys Thr Gln Asp
 20 25 30
 Pro Glu Pro Ala
 35

<210> 15
 <211> 36
 <212> PRT
 <213> Chlamydia sp

<400> 15

Gly Trp Ala Lys Thr Gln Asp Pro Glu Pro Ala Ser Ser Ala Thr Ile
 1 5 10 15
 Thr Asp Pro Gln Lys Ala Asn Arg Phe His Arg Thr Leu Leu Leu Thr
 20 25 30
 Trp Leu Pro Ala
 35

<210> 16
 <211> 76
 <212> PRT
 <213> Chlamydia sp

<400> 16
 Ala Ser Ser Ala Thr Ile Thr Asp Pro Gln Lys Ala Asn Arg Phe His
 1 5 10 15
 Arg Thr Leu Leu Leu Thr Trp Leu Pro Ala Gly Tyr Val Pro Ser Pro
 20 25 30
 Lys His Arg Ser Pro Leu Ile Ala Asn Thr Leu Trp Gly Asn Met Leu
 35 40 45
 Leu Ala Thr Glu Ser Leu Lys Asn Ser Ala Glu Leu Thr Pro Ser Asp
 50 55 60
 His Pro Phe Trp Gly Ile Thr Gly Gly Gly Leu Gly
 65 70 75

<210> 17
 <211> 76
 <212> PRT
 <213> Chlamydia sp

<400> 17
 Met Ile Ala Gly Gln Thr His Thr Phe Ser Leu Lys Phe Ser Gln Thr
 1 5 10 15
 Tyr Thr Lys Leu Asn Glu Arg Tyr Ala Lys Asn Asn Val Ser Ser Lys
 20 25 30
 Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln Glu Gly Phe
 35 40 45
 Leu Leu Thr Lys Leu Val Gly Leu Tyr Ser Tyr Gly Asp His Asn Cys
 50 55 60
 His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser
 65 70 75

<210> 18
 <211> 21
 <212> PRT
 <213> Chlamydia sp

<400> 18
 Ser Lys Asn Tyr Ser Cys Gln Gly Glu Met Leu Phe Ser Leu Gln Glu
 1 5 10 15
 Gly Phe Leu Leu Thr
 20

<210> 19
 <211> 61
 <212> PRT
 <213> Chlamydia sp

<400> 19

Asp His Asn Cys His His Phe Tyr Thr Gln Gly Glu Asn Leu Thr Ser
 1 5 10 15
 Gln Gly Thr Phe Arg Ser Gln Thr Met Gly Gly Ala Val Phe Phe Asp
 20 25 30
 Leu Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu Thr Ala Pro Phe
 35 40 45
 Leu Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser His Phe
 50 55 60

<210> 20
 <211> 51
 <212> PRT
 <213> Chlamydia sp

<400> 20
 Phe Asp Leu Pro Met Lys Pro Phe Gly Ser Thr His Ile Leu Thr Ala
 1 5 10 15
 Pro Phe Leu Gly Ala Leu Gly Ile Tyr Ser Ser Leu Ser His Phe Thr
 20 25 30
 Glu Val Gly Ala Tyr Pro Arg Ser Phe Ser Thr Lys Thr Pro Leu Ile
 35 40 45
 Asn Val Leu
 50

<210> 21
 <211> 31
 <212> PRT
 <213> Chlamydia sp

<400> 21
 Met Lys Lys Ala Phe Phe Phe Phe Leu Ile Gly Asn Ser Leu Ser Gly
 1 5 10 15
 Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser
 20 25 30

<210> 22
 <211> 500
 <212> PRT
 <213> Chlamydia sp

<400> 22
 Met Lys Lys Ala Phe Phe Phe Phe Leu Ile Gly Asn Ser Leu Ser Gly
 1 5 10 15
 Leu Ala Arg Glu Val Pro Ser Arg Ile Phe Leu Met Pro Asn Ser Val
 20 25 30
 Pro Asp Pro Thr Lys Glu Ser Leu Ser Asn Lys Ile Ser Leu Thr Gly
 35 40 45
 Asp Thr His Asn Leu Thr Asn Cys Tyr Leu Asp Asn Leu Arg Tyr Ile
 50 55 60
 Leu Ala Ile Leu Gln Lys Thr Pro Asn Glu Gly Ala Ala Val Thr Ile
 65 70 75 80
 Thr Asp Tyr Leu Ser Phe Phe Asp Thr Gln Lys Glu Gly Ile Tyr Phe
 85 90 95
 Ala Lys Asn Leu Thr Pro Glu Ser Gly Gly Ala Ile Gly Tyr Ala Ser
 100 105 110
 Pro Asn Ser Pro Thr Val Glu Ile Arg Asp Thr Ile Gly Pro Val Ile
 115 120 125

Phe	Glu	Asn	Asn	Thr	Cys	Cys	Arg	Pro	Phe	Thr	Ser	Ser	Asn	Pro	Asn
130						135					140				
Ala	Ala	Val	Asn	Lys	Ile	Arg	Glu	Gly	Gly	Ala	Ile	His	Ala	Gln	Asn
145					150					155					160
Leu	Tyr	Ile	Asn	His	Asn	His	Asp	Val	Val	Gly	Phe	Met	Lys	Asn	Phe
				165						170				175	
Ser	Tyr	Val	Arg	Gly	Gly	Ala	Ile	Ser	Thr	Ala	Asn	Thr	Phe	Val	Val
			180					185					190		
Ser	Glu	Asn	Gln	Ser	Cys	Phe	Leu	Phe	Met	Asp	Asn	Ile	Cys	Ile	Gln
		195					200					205			
Thr	Asn	Thr	Ala	Gly	Lys	Gly	Gly	Ala	Ile	Tyr	Ala	Gly	Thr	Ser	Asn
		210					215					220			
Ser	Phe	Glu	Ser	Asn	Asn	Cys	Asp	Leu	Phe	Phe	Ile	Asn	Asn	Ala	Cys
225					230					235					240
Cys	Ala	Gly	Gly	Ala	Ile	Phe	Ser	Pro	Ile	Cys	Ser	Leu	Thr	Gly	Asn
				245						250				255	
Arg	Gly	Asn	Ile	Val	Phe	Tyr	Asn	Asn	Arg	Cys	Phe	Lys	Asn	Val	Glu
				260				265					270		
Thr	Ala	Ser	Ser	Glu	Ala	Ser	Asp	Gly	Gly	Ala	Ile	Lys	Val	Thr	Thr
		275					280					285			
Arg	Leu	Asp	Val	Thr	Gly	Asn	Arg	Gly	Arg	Ile	Phe	Phe	Ser	Asp	Asn
		290				295					300				
Ile	Thr	Lys	Asn	Tyr	Gly	Gly	Ala	Ile	Tyr	Ala	Pro	Val	Val	Thr	Leu
305					310					315					320
Val	Asp	Asn	Gly	Pro	Thr	Tyr	Phe	Ile	Asn	Asn	Ile	Ala	Asn	Asn	Lys
				325						330				335	
Gly	Gly	Ala	Ile	Tyr	Ile	Asp	Gly	Thr	Ser	Asn	Ser	Lys	Ile	Ser	Ala
			340					345					350		
Asp	Arg	His	Ala	Ile	Ile	Phe	Asn	Glu	Asn	Ile	Val	Thr	Asn	Val	Thr
		355					360					365			
Asn	Ala	Asn	Gly	Thr	Ser	Thr	Ser	Ala	Asn	Pro	Pro	Arg	Arg	Asn	Ala
		370					375				380				
Ile	Thr	Val	Ala	Ser	Ser	Ser	Gly	Glu	Ile	Leu	Leu	Gly	Ala	Gly	Ser
385					390					395					400
Ser	Gln	Asn	Leu	Ile	Phe	Tyr	Asp	Pro	Ile	Glu	Val	Ser	Asn	Ala	Gly
				405						410				415	
Val	Ser	Val	Ser	Phe	Asn	Lys	Glu	Ala	Asp	Gln	Thr	Gly	Ser	Val	Val
			420					425					430		
Phe	Ser	Gly	Ala	Thr	Val	Asn	Ser	Ala	Asp	Phe	His	Gln	Arg	Asn	Leu
		435					440					445			
Gln	Thr	Lys	Thr	Pro	Ala	Pro	Leu	Thr	Leu	Ser	Asn	Gly	Phe	Leu	Cys
		450				455					460				
Ile	Glu	Asp	His	Ala	Gln	Leu	Thr	Val	Asn	Arg	Phe	Thr	Gln	Thr	Gly
465					470					475					480
Gly	Val	Val	Ser	Leu	Gly	Asn	Gly	Ala	Val	Leu	Ser	Cys	Tyr	Lys	Asn
				485					490					495	
Gly	Ala	Gly	Asn												
			500												

<210> 23
 <211> 28
 <212> PRT
 <213> Chlamydia sp

<400> 23
 Ala Ala Ile Leu Ser Ser Thr Ala Val Leu Phe Gly Gln Asp Pro Leu
 1 5 10 15

Gly Glu Thr Ala Leu Leu Thr Lys Asn Pro Asn His
 20 25

<210> 24
 <211> 41
 <212> PRT
 <213> Chlamydia sp

<400> 24
 Val Leu Gly Asn Ser Tyr Cys Trp Phe Val Ser Lys Leu His Ile Thr
 1 5 10 15
 Asp Pro Lys Glu Ala Leu Phe Lys Glu Lys Gly Asp Leu Ser Ile Gln
 20 25 30
 Asn Phe Arg Phe Leu Ser Phe Thr Asp
 35 40

<210> 25
 <211> 76
 <212> PRT
 <213> Chlamydia sp

<400> 25
 Ile Ser Ala Asp Ala Phe Ser Leu Gln His Asn Tyr Leu Phe Thr Ala
 1 5 10 15
 Phe Glu Glu Asn Ser Ser Lys Gly Asn Gly Gly Ala Ile Gln Ala Gln
 20 25 30
 Thr Phe Ser Leu Ser Arg Asn Val Ser Pro Ile Ser Phe Ala Arg Asn
 35 40 45
 Arg Ala Asp Leu Asn Gly Gly Ala Ile Cys Cys Ser Asn Leu Ile Cys
 50 55 60
 Ser Gly Asn Val Asn Pro Leu Phe Phe Thr Gly Asn
 65 70 75

<210> 26
 <211> 41
 <212> PRT
 <213> Chlamydia sp

<400> 26
 Ala Cys Asn Gln Glu Thr Leu Phe Ala Ser Asn Ser Ala Lys Glu Lys
 1 5 10 15
 Gly Gly Ala Ile Tyr Ala Lys His Met Val Leu Arg Tyr Asn Gly Pro
 20 25 30
 Val Ser Phe Ile Asn Asn Ser Ala Lys
 35 40

<210> 27
 <211> 86
 <212> PRT
 <213> Chlamydia sp

<400> 27
 Leu Gln Ala Ser Val Thr Ser Pro Thr Pro Ala Thr Ala Ser Pro Leu
 1 5 10 15
 Val Ile Gln Thr Ser Ala Asn Arg Ser Val Ile Phe Ser Ser Glu Arg
 20 25 30
 Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser Gln Leu Gln
 35 40 45

Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys Asp Arg Ala
 50 55 60
 Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala Leu Leu Ile
 65 70 75 80
 Met Glu Ala Gly Thr Ser
 85

<210> 28
 <211> 56
 <212> PRT
 <213> Chlamydia sp

<400> 28
 Glu Arg Leu Ser Glu Glu Glu Lys Thr Pro Asp Asn Leu Thr Ser Gln
 1 5 10 15
 Leu Gln Gln Pro Ile Glu Leu Lys Ser Gly Arg Leu Val Leu Lys Asp
 20 25 30
 Arg Ala Val Leu Ser Ala Pro Ser Leu Ser Gln Asp Pro Gln Ala Leu
 35 40 45
 Leu Ile Met Glu Ala Gly Thr Ser
 50 55

<210> 29
 <211> 51
 <212> PRT
 <213> Chlamydia sp

<400> 29
 Pro Leu His Ser Leu Asp Thr Glu Lys Ser Val Thr Ile His Ala Pro
 1 5 10 15
 Asn Leu Ser Ile Gln Lys Ile Phe Leu Ser Asn Ser Gly Asp Glu Asn
 20 25 30
 Phe Tyr Glu Asn Val Glu Leu Leu Ser Lys Glu Gln Asn Asn Ile Pro
 35 40 45
 Leu Leu Thr
 50

<210> 30
 <211> 56
 <212> PRT
 <213> Chlamydia sp

<400> 30
 Ser Asn Leu Phe Tyr Ala His Asp Ser Ser Gly Lys Pro Ile Asp Asn
 1 5 10 15
 Trp His His Arg Ser Leu Gly Tyr Leu Phe Gly Ile Ser Thr His Ser
 20 25 30
 Leu Asp Asp His Ser Phe Cys Leu Ala Ala Gly Gln Leu Leu Gly Lys
 35 40 45
 Ser Ser Asp Ser Phe Ile Thr Ser
 50 55

<210> 31
 <211> 66
 <212> PRT
 <213> Chlamydia sp

<400> 31

Ser Phe Ser Lys Glu Gly Phe Gly Ser Trp His Ser Val Ala Val Ser
 1 5 10 15
 Gly Glu Val Cys Ala Ser Ile Pro Ile Val Ser Asn Gly Ser Gly Leu
 20 25 30
 Phe Ser Ser Phe Ser Ile Phe Ser Lys Leu Gln Gly Phe Ser Gly Thr
 35 40 45
 Gln Asp Gly Phe Glu Glu Ser Ser Gly Glu Ile Arg Ser Phe Ser Ala
 50 55 60
 Ser Ser
 65

<210> 32
 <211> 61
 <212> PRT
 <213> Chlamydia sp

<400> 32
 Ser Gly Glu Ile Arg Ser Phe Ser Ala Ser Ser Phe Arg Asn Ile Ser
 1 5 10 15
 Leu Pro Ile Gly Ile Thr Phe Glu Lys Lys Ser Gln Lys Thr Arg Thr
 20 25 30
 Tyr Tyr Tyr Phe Leu Gly Ala Tyr Ile Gln Asp Leu Lys Arg Asp Val
 35 40 45
 Glu Ser Gly Pro Val Val Leu Leu Lys Asn Ala Val Ser
 50 55 60

<210> 33
 <211> 31
 <212> PRT
 <213> Chlamydia sp

<400> 33
 Met Ala Asn Leu Asp Ser Arg Ala Tyr Met Phe Arg Leu Thr Asn Gln
 1 5 10 15
 Arg Ala Leu His Arg Leu Gln Thr Leu Leu Asn Val Ser Cys Val
 20 25 30

<210> 34
 <211> 500
 <212> PRT
 <213> Chlamydia sp

<400> 34
 Met Arg Pro Asp His Met Asn Phe Cys Cys Leu Cys Ala Ala Ile Leu
 1 5 10 15
 Ser Ser Thr Ala Val Leu Phe Gly Gln Asp Pro Leu Gly Glu Thr Ala
 20 25 30
 Leu Leu Thr Lys Asn Pro Asn His Val Val Cys Thr Phe Phe Glu Asp
 35 40 45
 Cys Thr Met Glu Ser Leu Phe Pro Ala Leu Cys Ala His Ala Ser Gln
 50 55 60
 Asp Asp Pro Leu Tyr Val Leu Gly Asn Ser Tyr Cys Trp Phe Val Ser
 65 70 75 80
 Lys Leu His Ile Thr Asp Pro Lys Glu Ala Leu Phe Lys Glu Lys Gly
 85 90 95
 Asp Leu Ser Ile Gln Asn Phe Arg Phe Leu Ser Phe Thr Asp Cys Ser
 100 105 110

Ser	Lys	Glu	Ser	Ser	Pro	Ser	Ile	His	Gln	Lys	Asn	Gly	Gln	Leu
	115						120				125			
Ser	Leu	Arg	Asn	Asn	Gly	Ser	Met	Ser	Phe	Cys	Arg	Asn	His	Glu
	130					135					140			
Gly	Ser	Gly	Gly	Ala	Ile	Ser	Ala	Asp	Ala	Phe	Ser	Leu	Gln	His
145					150					155				Asn
Tyr	Leu	Phe	Thr	Ala	Phe	Glu	Glu	Asn	Ser	Ser	Lys	Gly	Asn	Gly
				165					170					160
Ala	Ile	Gln	Ala	Gln	Thr	Phe	Ser	Leu	Ser	Arg	Asn	Val	Ser	Pro
			180					185					175	Ile
Ser	Phe	Ala	Arg	Asn	Arg	Ala	Asp	Leu	Asn	Gly	Gly	Ala	Ile	Cys
	195						200					205		Cys
Ser	Asn	Leu	Ile	Cys	Ser	Gly	Asn	Val	Asn	Pro	Leu	Phe	Thr	Gly
	210					215					220			
Asn	Ser	Ala	Thr	Asn	Gly	Gly	Ala	Ile	Cys	Cys	Ile	Ser	Asp	Leu
225					230					235				Asn
Thr	Ser	Glu	Lys	Gly	Ser	Leu	Ser	Leu	Ala	Cys	Asn	Gln	Glu	Thr
				245						250				Leu
Phe	Ala	Ser	Asn	Ser	Ala	Lys	Glu	Lys	Gly	Gly	Ala	Ile	Tyr	Ala
			260					265					255	Lys
His	Met	Val	Leu	Arg	Tyr	Asn	Gly	Pro	Val	Ser	Phe	Ile	Asn	Asn
	275						280					285		Ser
Ala	Lys	Ile	Gly	Gly	Ala	Ile	Ala	Ile	Gln	Ser	Gly	Gly	Ser	Leu
	290					295					300			Ser
Ile	Leu	Ala	Gly	Glu	Gly	Ser	Val	Leu	Phe	Gln	Asn	Asn	Ser	Gln
305					310					315				Arg
Thr	Ser	Asp	Gln	Gly	Leu	Val	Arg	Asn	Ala	Ile	Tyr	Leu	Glu	Lys
				325					330					Asp
Ala	Ile	Leu	Ser	Ser	Leu	Glu	Ala	Arg	Asn	Gly	Asp	Ile	Leu	Phe
			340					345					335	Phe
Asp	Pro	Ile	Val	Gln	Glu	Ser	Ser	Ser	Lys	Glu	Ser	Pro	Leu	Pro
		355					360					365		Ser
Ser	Leu	Gln	Ala	Ser	Val	Thr	Ser	Pro	Thr	Pro	Ala	Thr	Ala	Ser
	370					375					380			Pro
Leu	Val	Ile	Gln	Thr	Ser	Ala	Asn	Arg	Ser	Val	Ile	Phe	Ser	Ser
385					390					395				Glu
Arg	Leu	Ser	Glu	Glu	Glu	Lys	Thr	Pro	Asp	Asn	Leu	Thr	Ser	Gln
				405					410					Leu
Gln	Gln	Pro	Ile	Glu	Leu	Lys	Ser	Gly	Arg	Leu	Val	Leu	Lys	Asp
			420					425					415	Arg
Ala	Val	Leu	Ser	Ala	Pro	Ser	Leu	Ser	Gln	Asp	Pro	Gln	Ala	Leu
		435					440					445		Leu
Ile	Met	Glu	Ala	Gly	Thr	Ser	Leu	Lys	Thr	Ser	Ser	Asp	Leu	Lys
	450					455					460			Leu
Ala	Thr	Leu	Ser	Ile	Pro	Leu	His	Ser	Leu	Asp	Thr	Glu	Lys	Ser
465					470					475				Val
Thr	Ile	His	Ala	Pro	Asn	Leu								

```
<210> 35
<211> 10
<212> PRT
<213> Chlamydia sp
<400> 35
```

Val Pro Asp Pro Thr Lys Glu Ser Leu Ser
1 5 10

<210> 36
<211> 126
<212> DNA
<213> Chlamydia sp

<400> 36
tcaggactag ctagagaggt tcctttctaga atcttttctta tgcccaactc agttccagat 60
cctacgaaag agtcgctatc aaataaaaatt agtttgacag gagacactca caatctcact 120
aactgc 126

<210> 37
<211> 321
<212> DNA
<213> Chlamydia sp

<400> 37
tcaggactag ctagagaggt tcctttctaga atcttttctta tgcccaactc agttccagat 60
cctacgaaag agtcgctatc aaataaaaatt agtttgacag gagacactca caatctcact 120
aactgctatc tcgataacct acgctacata ctggctattc tacaaaaaac tccaatgaa 180
ggagctgctg tcacaataac agattaccta agcttttttg atacacaaaa agaagggtatt 240
tattttgcaa aaaatctcac ccctgaaagt ggtggtgcga ttggttatgc gagtccaat 300
tctcctaccg tggagattcg t 321

<210> 38
<211> 243
<212> DNA
<213> Chlamydia sp

<400> 38
agtttgacag gagacactca caatctcact aactgctatc tcgataacct acgctacata 60
ctggctattc tacaaaaaac tccaatgaa ggagctgctg tcacaataac agattaccta 120
agcttttttg atacacaaaa agaagggtatt tattttgcaa aaaatctcac ccctgaaagt 180
ggtggtgcga ttggttatgc gagtccaat tctcctaccg tggagattcg tgatacaata 240
ggt 243

<210> 39
<211> 198
<212> DNA
<213> Chlamydia sp

<400> 39
ggtcctgtaa tctttgaaaa taatacttgt tgcagaccat ttacatcgag taatcctaata 60
gcagctgtta ataaaaataag agaaggcgga gccattcatg ctcaaaatct ttacataaat 120
cataatcatg atgtggtcgg atttatgaag aacttttctt atgtccgagg aggagccatt 180
agtaccgcta ataccttt 198

<210> 40
<211> 201
<212> DNA
<213> Chlamydia sp

<400> 40
aatcagtctt gttttctctt tatggacaac atctgtattc aaactaatac agcaggaaaa 60
ggtggcgcta tctatgctgg aacgagcaat tcttttgaga gtaataactg cgatctcttc 120
tttatcaata acgcctgttg tgcaggagga gcgatcttct cccctatctg ttctctaaca 180

ggaaatcgtg gtaacatcgt t

201

<210> 41
<211> 276
<212> DNA
<213> Chlamydia sp

<400> 41
tcttcagaag ctctctgatgg aggagcaatt aaagtaacta ctgcgcctaga tggttacaggc 60
aatcgtggta ggatcttttt tagtgacaat atcacaaaaa attatggcgg agctattttac 120
gctcctgtag ttaccctagt ggataatggc cctacctact ttataaacia tatcgccaat 180
aataaggggg gcgctatcta tatagacgga accagcaact ccaaaatttc tgccgaccgc 240
catgctatta tttttaatga aaatattgtg actaat 276

<210> 42
<211> 198
<212> DNA
<213> Chlamydia sp

<400> 42
acgtcagcta atcctcctag aagaaatgca ataacagtag caagctcctc tggtgaaatt 60
ctattaggag cagggagtag ccaaaattta attttttatg atcctattga agttagcaat 120
gcaggggtct ctgtgtcctt caataaggaa gctgatcaaa caggctctgt agtattttca 180
ggagctactg ttaattct 198

<210> 43
<211> 153
<212> DNA
<213> Chlamydia sp

<400> 43
tctgcagatt ttcattcaacg caattttacaa acaaaaacac ctgcacccct tactctcagt 60
aatgggttttc tatgtatcga agatcatgct cagcttacag tgaatcgatt cacacaaact 120
gggggtgttg tttctcttgg gaatggagca gtt 153

<210> 44
<211> 198
<212> DNA
<213> Chlamydia sp

<400> 44
gagattcctt tattgtgggt agagcctaca aataacagca ataactatac agcagatact 60
gcagctacct tttcattaag tgatgtaaaa ctctcactca ttgatgacta tgggaattct 120
ccttatgaat ccacagatct aacccatgct ctgtcatcac agcctatgct atctattttct 180
gaggctagtg ataaccag 198

<210> 45
<211> 108
<212> DNA
<213> Chlamydia sp

<400> 45
cagctaagat ctgatgatat ggattttttcg ggactaaatg tccctcatta tggatggcaa 60
ggactttgga cttggggctg ggcaaaaact caagatccag aaccagca 108

<210> 46
<211> 108
<212> DNA

<213> Chlamydia sp

<400> 46

ggctgggcaa aaactcaaga tccagaacca gcatcttcag caacaatcac agatccacaa	60
aaagccaata gattccatag aaccttatta ctgacttggc ttcctgct	108

<210> 47

<211> 228

<212> DNA

<213> Chlamydia sp

<400> 47

gcatcttcag caacaatcac agatccacaa aaagccaata gattccatag aaccttatta	60
ctgacttggc ttcctgctgg gtatgttcct agcccgaac acagaagtcc cctcatagcg	120
aataccttat gggggaatat gctgcttgca acagaaagct taaaaaatag tgcagaactg	180
acacctagtg atcatccttt ctggggaatt acaggaggag gactaggc	228

<210> 48

<211> 228

<212> DNA

<213> Chlamydia sp

<400> 48

atgatagcag ggcagacaca caccttctca ttgaaattca gtcagaccta caccaaactc	60
aatgagcgtt acgcaaaaaa caacgtatct tctaaaaatt actcatgccca aggagaaatg	120
ctcttctcat tgcaagaagg tttcttgctg actaaattag ttgggcttta cagctatgga	180
gaccataact gtcaccattt ctatacccaa ggagaaaatc taacatct	228

<210> 49

<211> 63

<212> DNA

<213> Chlamydia sp

<400> 49

tctaaaaatt actcatgccca aggagaaatg ctcttctcat tgcaagaagg tttcttgctg	60
act	63

<210> 50

<211> 183

<212> DNA

<213> Chlamydia sp

<400> 50

gaccataact gtcaccattt ctatacccaa ggagaaaatc taacatctca agggacgttc	60
cgtagtcaaa cgatgggagg tgctgttttt tttgatctcc ctatgaaacc ctttggatca	120
acgcatatac tgacagctcc ctttttaggt gctcttggtta tttattctag cctgtctcac	180
ttt	183

<210> 51

<211> 153

<212> DNA

<213> Chlamydia sp

<400> 51

tttgatctcc ctatgaaacc ctttggatca acgcatatac tgacagctcc ctttttaggt	60
gctcttggtta tttattctag cctgtctcac tttactgagg tgggagccta tccgcaagc	120
ttttctacaa agactccttt gatcaatgtc cta	153

<210> 52
 <211> 93
 <212> DNA
 <213> Chlamydia sp

<400> 52
 atgaaaaaag cgttttttctt tttccttatt ggaaactccc tatcaggact agctagagag 60
 gttccttcta gaatctttct tatgcccac tca 93

<210> 53
 <211> 1500
 <212> DNA
 <213> Chlamydia sp

<400> 53
 atgaaaaaag cgttttttctt tttccttatt ggaaactccc tatcaggact agctagagag 60
 gttccttcta gaatctttct tatgcccac tcagttccag atcctacgaa agagtcgcta 120
 tcaataaaaa ttagtttgac aggagacact cacaatctca ctaactgcta tctcgataac 180
 ctacgctaca tactggctat tctacaaaaa actcccaatg aaggagctgc tgtcacaata 240
 acagattacc taagcttttt tgatacacia aaagaaggta tttattttgc aaaaaatctc 300
 acccctgaaa gtgggtggtgc gattggttat gcgagtccca attctctac cgtggagatt 360
 cgtgatacaa taggtcctgt aatctttgaa aataatactt gttgcagacc atttacatcg 420
 agtaatccta atgcagctgt taataaaata agagaaggcg gagccattca tgcacaaaat 480
 ctttacataa atcataatca tgatgtggtc ggatttatga agaacttttc ttatgtccga 540
 ggaggagcca ttagtacgcg taataccttt gttgtgagcg agaatcagtc ttgttttctc 600
 tttatggaca acatctgtat tcaaactaat acagcaggaa aagggtggcg tatctatgct 660
 ggaacgagca attccttttga gagtaataac tgcgatctct tctttatcaa taacgcctgt 720
 tgtgcaggag gagcgatctt ctcccctatc tgttctctaa caggaaatcg tggtaacatc 780
 gttttctata acaatcgctg ctttaaaaaat gtagaaacag cttcttcaga agcttctgat 840
 ggaggagcaa ttaaagtaac tactcgcta gatgttacag gcaatcgtgg taggatcttt 900
 tttagtgaac atatcacaaa aaattatggc ggagctatct acgctcctgt agttacccta 960
 gtggataatg gccctaccta ctttataaac aatatcgcca ataataaggg gggcgctatc 1020
 tatatagacg gaaccagcaa ctccaaaatt tctgccgacc gccatgctat tatttttaat 1080
 gaaaatattg tgactaatgt aactaatgca aatggtacca gtacgtcagc taatcctcct 1140
 agaagaaatg caataacagt agcaagctcc tctggtgaaa ttctattagg agcaggaggat 1200
 agccaaaatt taatttttta tgatcctatt gaagttagca atgcaggggt ctctgtgtcc 1260
 ttcaataagg aagctgatca aacaggctct gtagtatttt caggagctac tgttaattct 1320
 gcagattttc atcaacgcaa tttacaaaac aaaacacctg cacccttac tctcagtaat 1380
 ggttttctat gtatcgaaga tcatgctcag cttacagtga atcgattcac aaaaactggg 1440
 ggtgttgttt ctcttgggaa tggagcagtt ctgagttgct ataaaaatgg tgcaggaaat 1500

<210> 54
 <211> 84
 <212> DNA
 <213> Chlamydia sp

<400> 54
 gctgctatct tgtcatccac agcggctctc tttggccagg atcccttagg tgaaaccgcc 60
 ctctcacta aaaatcctaa tcat 84

<210> 55
 <211> 123
 <212> DNA
 <213> Chlamydia sp

<400> 55
 gtacttggaa attcctactg ttggttcgta tctaaactcc atatcacgga ccccaaagag 60
 gctcttttta aagaaaaagg agatctttcc attcaaaact ttcgcttcct ttccttcaca 120

gat

123

<210> 56
<211> 228
<212> DNA
<213> Chlamydia sp

<400> 56
atctctgctg atgccttttc tctacagcac aactatcttt tcacagcttt tgaagagaat 60
tctttctaaag gaaatggcgg agccattcag gctcaaacct tctctttatc tagaaatgtg 120
tcgcctatctt ctttcgcccc taatcgtgcg gattttaaag gcggcgctat ttgctgtagt 180
aatcttattt gttcagggaa tgtaaaccct ctctttttca ctggaaac 228

<210> 57
<211> 123
<212> DNA
<213> Chlamydia sp

<400> 57
gcttgtaacc aagaaacgct atttgcaagc aattctgcta aagaaaaagg cggggctatt 60
tatgccaaag acatgggtatt gcgttataac ggtcctgttt ccttcattaa caacagcgct 120
aaa 123

<210> 58
<211> 258
<212> DNA
<213> Chlamydia sp

<400> 58
ttgcaagcca gcgtgacttc tcccacccca gccacgcgat ctcttttagt tattcagaca 60
agtgcacacc gttcagtgat tttctcgagc gaacgtcttt ctgaagaaga aaaaactcct 120
gataacctca cttcccaact acagcagcct atcgaactga aatccggacg cttagtttta 180
aaagatcgcg ctgtcctttc cgcgccttct ctctctcagg atcctcaagc tctcctcatt 240
atggaagcgg gaacttct 258

<210> 59
<211> 168
<212> DNA
<213> Chlamydia sp

<400> 59
gaacgtcttt ctgaagaaga aaaaactcct gataacctca cttcccaact acagcagcct 60
atcgaactga aatccggacg cttagtttta aaagatcgcg ctgtcctttc cgcgccttct 120
ctctctcagg atcctcaagc tctcctcatt atggaagcgg gaacttct 168

<210> 60
<211> 153
<212> DNA
<213> Chlamydia sp

<400> 60
ccccttcatt ccttagatac tgaaaaaagc gtaactatcc acgcccctaa cctttctatc 60
caaaagatct tctctcttaa ttctggagat gagaattttt atgaaaatgt agagcttctc 120
agtaaagagc aaaacaatat tctctcctt act 153

<210> 61
<211> 168
<212> DNA

<213> Chlamydia sp

<400> 61

tctaatttat	tctatgctca	cgacagctct	gggaaaccta	tcgataattg	gcacataga	60
agccttggt	acctattcgg	tatcagtact	cacagtttag	atgaccattc	tttctgcttg	120
gctgcaggac	aattactcgg	gaaatcgtcc	gattccttta	ttacgtct		168

<210> 62

<211> 198

<212> DNA

<213> Chlamydia sp

<400> 62

tccttctcta	agaaggatt	cggatcctgg	catagcgttg	cagtatccgg	agaagtgtgc	60
gcacgatctc	ctattgtatc	caatgggtcc	ggactgttca	gctccttctc	tattttctct	120
aaactgcaag	gattttcagg	aacacaggac	ggttttgagg	agagttcggg	agagattcgg	180
tccttttctg	ccagctct					198

<210> 63

<211> 183

<212> DNA

<213> Chlamydia sp

<400> 63

tcgggagaga	ttcgggtcctt	ttctgccagc	tctttcagaa	atattttcact	tcctatagga	60
ataacatttg	aaaaaaaaatc	caaaaaaaca	cgaacctact	attactttct	aggagcctac	120
atccaagacc	tgaaacgtga	tgtggaatcg	ggacctgtag	tgttactcaa	aaatgccgtc	180
tcc						183

<210> 64

<211> 93

<212> DNA

<213> Chlamydia sp

<400> 64

atggcgaaact	tggattcacg	agcctacatg	ttcaggctta	cgaatcaaag	agctctacac	60
agacttcaga	cgctgttaaa	tgtgtcttgt	gtg			93

<210> 65

<211> 1500

<212> DNA

<213> Chlamydia sp

<400> 65

atgcgacctg	atcatatgaa	cttctgttgt	ctatgtgctg	ctattttgtc	atccacagcg	60
gtcctctttg	gccaggatcc	cttaggtgaa	accgccctcc	tcactaaaaa	tcctaatacat	120
gtcgtctgta	cattttttga	ggactgtacc	atggagagcc	tctttcctgc	tctttgtgct	180
catgcatcac	aagacgatcc	tttgtatgta	cttggaatt	cctactgttg	gttcgtatct	240
aaactccata	tcacggaccc	caaagaggct	ctttttaaag	aaaaaggaga	tctttccatt	300
caaaactttc	gcttcctttc	cttcacagat	tgctcttcca	aggaaagctc	tccttctatt	360
attcatcaaa	agaatgggtca	gttatccttg	cgcaataatg	gtagcatgag	tttctgtcga	420
aatcatgctg	aaggctctgg	aggagccatc	tctgcggatg	ccttttctct	acagcacaaac	480
tatctttttc	cagctttttga	agagaattct	tctaaaggaa	atggcggagc	cattcaggct	540
caaaccttct	ctttatctag	aaatgtgtcg	cctatttctt	tcgcccgtaa	tcgtgcggat	600
ttaaatggcg	gcgctatttg	ctgtagtaat	cttatttgtt	cagggaatgt	aaaccctctc	660
tttttcaactg	gaaactccgc	cacgaatgga	ggcgctatct	gttgatcag	cgatctaaac	720
acctcagaaa	aaggctctct	ctctcttgc	tgtaaccaag	aaacgctatt	tgcaagcaat	780
tctgctaaag	aaaaaggcgg	ggctatttat	gccaagcaca	tggtattgctg	ttataacggt	840

cctgttttct	tcattaacaa	cagcgctaaa	atagggtggag	ctatcgccat	ccagtccgga	900
gggagtctct	ctatccttgc	aggtgaagga	tctgttctgt	tccagaataa	ctcccaacgc	960
acctccgacc	aaggtctagt	aagaaacgcc	atctacttag	agaaagatgc	gattctttct	1020
tccttagaag	ctcgcaacgg	agatattctt	ttctttgatc	ctattgtaca	agaaagtagc	1080
agcaaagaat	cgctctttcc	ctcctctttg	caagccagcg	tgacttctcc	caccccagcc	1140
accgcatctc	ctttagttat	tcagacaagt	gcaaaccggt	cagtgatttt	ctcgagcgaa	1200
cgtcttttctg	aagaagaaaa	aactcctgat	aacctcactt	cccaactaca	gcagcctatc	1260
gaactgaaat	ccggacgctt	agtttttaaaa	gatcgcgctg	tcctttccgc	gccttctctc	1320
tctcaggatc	ctcaagctct	cctcattatg	gaagcgggaa	cttcttttaa	aacttctctc	1380
gatttgaagt	tagctacgct	aagtattccc	cttcattcct	tagatactga	aaaaagcgta	1440
actatccacg	cccctaacct	ttctatccaa	aagatcttcc	tctctaattc	tggagatgag	1500

<210> 66
 <211> 49
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 66	
atccagcaga gggtcgacgg gttccagatc ctacgaaaga gtcgctatc	49

<210> 67
 <211> 51
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 67	
atccagcaga gggtcgacgg ccttagaatc gcagagcaat ttccccattg a	51

<210> 68
 <211> 12
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 68	
aggcagaggc at	12

<210> 69
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> primer

<400> 69	
aggcagaggc atatcgaccc tgatcacatg aacttctgtt g	41

<210> 70
 <211> 39

<212> DNA
<213> Artificial Sequence

<220>
<223> primer

<400> 70
aggcagaggg tcgacgaacc tgtaagtggc cccagatc

39

<210> 71
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> fusion protein terminus

<400> 71
Met Arg Gly Ser His His His His His His
1 5 10